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Aos “Vs da minha Vida” dedico, com amor, o poema “O Aprendiz” da 
autoria de Carolina Represas.  
Ao Vítor, por todos os dias me fazer acreditar nesta mensagem e, à 
Victória, para que a leia durante toda a sua Vida e acredite nas suas palavras.  
 
 
Quantos pores-do-sol fizeram uma alma cantar 
Quantos sorrisos criaram outros em redor 
Quantos corações falaram sem se controlar 
Não contei 
 
Quantas crianças gritaram o que é melhor 
Quantas caras que eram frias ganharam sabor 
Quantas mãos se deram, e quantos lábios se tocaram 
Só porque sim 
 
Oiço o que o céu não diz 
Sinto o que vento não toca 
Aprendo com o aprendiz 
E aceito com peito a derrota 
Lembro o que eu não fiz mas vou 
Ainda vou fazer por mim 
 
Tanta gente que quer, tanta história pela frente 
Tanta luta no desejo e o agir indiferente 
Tenta marcar o teu passo e amanhã estar presente 
Eu nunca falto 
Entre dias mais cinzentos e outros de cor 
Há que procurar as tintas e pintar calor 
E se o hoje se confunde lembra-te do ontem 
E sorri 
 
Podes ter a lua e o sol 
Pegadas no teu caminho 
Só não rasgues páginas em branco 
O livro não se escreve sozinho 
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NOTA PRELIMINAR 
 
Declara-se, para informação do papel do candidato na execução desta 
Tese, que o autor participou da conceção e execução do trabalho 
experimental que deu origem aos resultados, bem como na análise, 
interpretação e elaboração dos artigos científicos integrantes desta 
dissertação. O autor escreveu ainda a introdução, a discussão e as 
conclusões, salvaguardando as correções e recomendações providenciadas 
pelos seus orientadores. 
Este trabalho foi financiado pela Fundação para a Ciência e a Tecnologia 
do Ministério da Educação e Ciência, através da atribuição de uma bolsa 
individual de doutoramento, com a referência SFRH/BD/64441/2009. 
O trabalho de investigação foi realizado no Grupo de Oncologia 
Molecular do Instituto Português de Oncologia do Porto Francisco Gentil, 
Entidade Pública Empresarial, em colaboração com o Instituto Superior de 
Ciências da Saúde - Norte e o Centro Hospitalar de São João, Entidade Pública 
Empresarial. 
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IX 
 
PREFÁCIO DO AUTOR 
 
Sempre acreditei que, “ser Farmacêutico é bem mais do que ser o 
técnico do medicamento… e que tal implicava encarar a profissão com garra 
e sentimento”. Hoje, fruto dos conhecimentos apreendidos e das 
experiências vividas, percebo que o Farmacêutico está para o medicamento 
como o Médico está para a doença, o que me apazigua mas também me 
inquieta, pois não sei quem está realmente para o doente?. No meio desta 
inquietude, percebo que da integração do medicamento na doença resulta a 
dimensão holística do doente e que, nesta se enquadra a razão de existir da 
Farmacogenómica.  
A perceção de que cada um de nós é diferente dos demais é 
assustadora mas igualmente motivante. E pensar que a individualidade 
começa tão precocemente, teoricamente desde logo após o melhor 
espermatozóide fecundar o melhor óvulo. E, desde então, há uma série de 
múltiplos fatores que influenciam o património genético, aquilo que somos, 
em fases tão peculiares da Vida e até ao momento em que a Vida nos devolve 
à Terra.  
Fruto dos avanços técnico-científicos, a longevidade é uma realidade! 
Vivemos claramente mais anos mas, e infelizmente, tal não tem uma relação 
linear com o viver bem e/ou melhor. Talvez o facto de o Homem não ter sido 
concebido para viver no ambiente complexo que caracteriza o século XXI 
possa constituir uma explicação. Já Darwin havia percebido que só os mais 
aptos sobreviveriam, pelo que, por vezes reflicto sobre as doenças como 
manifestação dessa inadaptabilidade, e que o Homem tanto tenta vencer.  
Assim, acredito na Farmacogenómica como contributo indispensável à 
Medicina Personalizada, e creio que o futuro da Saúde e a Qualidade de Vida 
dos doentes passará por “olhar cada doente” como um Ser único, integrando 
a Farmacogenómica na sua dimensão biopsicossociocultural, de forma a 
colmatar as suas imperfeições de adaptação às características do Mundo em 
que Vive.   
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REFLEXÃO DO AUTOR 
 
 
 
 
 
 
Este é mais um marco da minha Vida  
Pautado por esforço, trabalho, dedicação e sacrifício 
Marcado por quatro anos de lágrimas e gargalhadas,  
Por leitura, escrita, discussão de ideias e aquisição de saber.  
 
Tantas coisas aprendi e vivi.  
Como cresci… 
 
Muitos me perguntam como consegui?.  
Nem eu sei…  
 
No meio de tantas outras coisas, foi árduo 
Mas, hoje estou aqui!  
Estou certa de que algum sorriso eu perdi,  
Na esperança de um dia o resgatar.  
 
Mas só as lembranças que doem ou fazem sorrir deixam saudade… 
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RESUMO 
 
INTRODUÇÃO. A artrite reumatoide (AR) é uma doença autoimune, 
caracterizada pela inflamação crónica de múltiplas articulações, 
condicionando considerável incapacidade. O metotrexato (MTX) é o fármaco 
antirreumático modificador da doença mais utilizado no tratamento da AR. 
Embora o mecanismo responsável pelo seu efeito terapêutico não esteja 
completamente esclarecido, proteínas responsáveis pelo seu transporte 
membranar, bem como proteínas envolvidas nas suas vias intracelulares, 
podem ser determinantes na farmacocinética, da ocorrência de reações 
adversas (RAs) ao fármaco e de diferentes perfis de resposta clínica. 
Variáveis clinico-patológicas, bem como polimorfismos genéticos em genes 
codificantes para proteínas envolvidas no mecanismo de ação do MTX, têm 
sido descritos como contributivos para a variabilidade da resposta ao 
tratamento observada entre os doentes. Com o progresso da 
Farmacogenómica, a previsão da resposta ao tratamento dos doentes com AR 
sob terapêutica com MTX, oferecerá uma ferramenta preponderante para a 
tradução do papel dos polimorfismos genéticos na prática clínica, e será 
essencial para sustentar um avanço na área da Medicina Personalizada.  
OBJETIVO. Avaliar a influência de vinte variáveis clinico-patológicas e de 
vinte e oito polimorfismos genéticos, em treze genes codificantes para 
proteínas envolvidas no mecanismo de ação do MTX, como potenciais 
preditores da efetividade e/ou da toxicidade do MTX, em doentes 
Portugueses com AR.   
MATERIAS E MÉTODOS. Foi realizado um estudo retrospetivo num coorte de 
233 doentes com AR e sob terapêutica com MTX, recrutados 
consecutivamente entre janeiro de 2009 e dezembro de 2012. Os dados 
clínico-patológicos dos doentes foram colhidos dos registos clínicos 
individuais dos doentes, obtidos no decorrer das visitas hospitalares. A 
todos os doentes foram colhidas amostras de sangue total para posterior 
genotipagem. Os resultados terapêuticos, nomeadamente a inefetividade do 
MTX e a toxicidade decorrente do MTX, foram definidos atendendo a critérios 
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descritos na literatura. A análise estatística realizada incluiu análises 
univariada e multivariada, atendendo a genótipos, a haplótipos e ao índice de 
risco toxicogenético (IRT). 
RESULTADOS E DISCUSSÃO. Variáveis clinico-patológicas. Atendendo à 
efetividade do MTX, os resultados demonstraram que, não fumadores, 
anticorpo antipeptídeo citrulinado positivo, anticorpos antinucleares 
positivos, pontuação alta no questionário de avaliação da saúde e, uso de 
fármacos anti-inflamatórios não esteróides, estavam associados à 
inefetividade; enquanto a via de administração subcutânea demonstrou-se 
associada a efetividade. Relativamente à ocorrência de RAs ao MTX, a análise 
multivariada demonstrou uma associação entre a ocorrência de perturbações 
gastrointestinais (GI) e uma menor duração do tratamento, bem como com a 
não suplementação com ácido fólico. Mais ainda, a análise univariada revelou 
haver associação estatisticamente significativa entre a ocorrência de 
toxicidade global decorrente do MTX e valores mais elevados na velocidade 
de sedimentação eritrocitária. Polimorfismos genéticos. No que concerne ao 
transporte membranar do MTX, vinte e três polimorfismos, em dez genes 
codificantes para “solute carriers” (SLCs) e transportadores “adenosine 
triphosphate (ATP)-binding cassette” (ABCs), foram estudados relativamente 
à sua influência na ocorrência de RAs ao MTX. Dos resultados obtidos, um 
risco acrescido para a ocorrência de toxicidade global demonstrou-se 
associado aos portadores do alelo G para o SLC19A1 rs7499, aos 
homozigóticos GG para o SLC46A1 rs2239907 e, aos portadores do alelo T e 
homozigóticos TT para o SLCO1B1 rs4149056. Por outro lado, da análise do 
IRT constatou-se que os doentes com Índice 3 apresentavam um risco para 
toxicidade global em cerca de 18 vezes superior àqueles com Índice 1. Um 
risco aumentado para perturbações GI foi observado nos portadores do alelo 
G e nos homozigóticos GG para o SLC19A1 rs7499, nos portadores do alelo G 
para o SLC19A1 rs1051266, nos portadores do alelo A para o SLC19A1 
rs2838956 e, nos portadores do alelo T e nos homozigóticos TT para o 
SLCO1B1 rs4149056. Mais ainda, o modelo de regressão logística 
demonstrou que os portadores do alelo G para o SLC19A1 rs1051266 
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apresentavam um risco acrescido de gastrotoxicidade nos primeiros meses 
de tratamento. Adicionalmente, o haplótipo GGAG para o SLC19A1 rs7499, 
rs1051266, rs2838956 e rs3788200 demonstrou-se associado a um risco 
acrescido para gastrotoxicidade; e, da análise do IRT verificou-se que os 
doentes com Índice 4 apresentavam um risco para gastrotoxicidade em cerca 
de 9 vezes superior àqueles com Índice 1. Considerando a via dos folatos e a 
influência do metilenotetrahidrofolato redutase (MTHFR) rs1801133 na 
efetividade do MTX, os resultados demonstraram uma associação 
estatisticamente significativa entre os homozigóticos TT e a inefetividade. 
Atendendo à via da síntese de novo de purinas e à influência do 5-
aminoimidazol-4-carboxamida ribonucleótido transformilase (ATIC) 
rs4673993 na efetividade do MTX, os portadores do alelo T demonstraram-se 
associados a um risco acrescido para inefetividade. Quanto à via da síntese 
de novo de pirimidinas, mais precisamente de três dos polimorfismos 
genéticos no timidilato sintetase (TYMS) (rs34743033, rs2853542 e 
rs34489327), os resultados demonstraram não haver diferenças 
estatisticamente significativas em relação à ocorrência de RAs mas, e 
atendendo à efetividade do MTX, os genótipos 3R3R, 3RC3RG e os portadores 
do alelo 6bp-, demonstraram-se associados à inefetividade do MTX. A análise 
multivariada confirmou a associação entre um risco acrescido para 
inefetividade e os portadores do alelo 6bp-; e, da análise haplotípica 
verificou-se que os haplótipos portadores simultaneamente dos alelos 3R e 
6bp- estavam associados a inefetividade do MTX. 
CONCLUSÃO. Este trabalho sugere que polimorfismos genéticos, combinados 
com variáveis clínico-patológicas poderão auxiliar na identificação de 
doentes que não beneficiem do tratamento com MTX. Deste modo, poderão 
ser úteis como biomarcadores da resposta ao tratamento e, 
consequentemente, ajudar os médicos a personalizar o tratamento dos 
doentes com Artrite Reumatoide. 
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ABSTRACT 
 
INTRODUCTION. Rheumatoid Arthritis (RA) is autoimmune disease, 
characterized by a chronic inflammation of multiple peripheral joints, leading 
to serious disability. Methotrexate (MTX) is the most widely used disease-
modifying antirheumatic drug for RA treatment. Although the mechanism 
responsible for its therapeutic action is not thoroughly understood, MTX 
membrane transport proteins and proteins in intracellular pathways can be 
major determinants of pharmacokinetics, adverse drug reactions (ADRs) and 
clinical response profiles. Patients’ clinicopathological variables, as also as 
genetic polymorphisms in genes encoding for proteins involved in MTX 
action mechanism, have been described as contributors to the observed 
therapeutic outcome variability among the patients. With Pharmacogenomics 
progress, the improvement of the prediction of RA patients’ outcome to MTX 
treatment will offer a powerful tool for the translational role of genetic 
polymorphisms into clinical practice and will be essential to sustain a 
breakthrough in the field of Personalized Medicine.  
OBJECTIVE. Evaluate the influence of twenty clinicopathological variables and 
of twenty-eight genetic polymorphisms, in thirteen genes encoding for 
proteins involved in MTX action mechanism, as potential predictors of 
clinical response to MTX and/or MTX-related toxicity occurrence in 
Portuguese RA patients.  
MATERIAL AND METHODS. A retrospective study in a cohort of 233 RA 
patients treated with MTX recruited consecutively between January 2009 and 
December 2012, was performed. Clinicopathological data were collected from 
individual clinical records during patients’ regular visits to hospital and 
whole blood samples were used for genotyping. Therapeutic outcome 
endpoints, non-response to MTX and MTX-related toxicity occurrence, were 
defined attending literature described criteria. Statistical analyses were 
performed including univariate and multivariate analyses, using genotypes, 
haplotypes and toxicogenetic risk index (TRI).   
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RESULTS AND DISCUSSION. Clinicopathological variables. Regarding to 
clinical response to MTX, results demonstrated that non-current smokers, 
positivity to anti-cyclic citrullinated peptide and to antinuclear antibodies, 
increased score in higher health assessment questionnaire, and, non-
steroidal anti-inflammatory drugs users, were associated with non-response; 
while subcutaneous administration route was associated with response. In 
relation to MTX-related toxicity occurrence, multivariate analysis 
demonstrated that lower MTX treatment duration and non-folic acid 
supplementation were associated with MTX-related gastrointestinal (GI) 
toxicity occurrence and, from univariate analysis, higher erythrocyte 
sedimentation rate levels were associated with MTX-related overall 
toxicity. Genetic polymorphisms. Regarding to the MTX-carrier mediated 
transport pathway, twenty-three polymorphisms in ten genes encoding to 
solute carriers (SLCs) and adenosine triphosphate (ATP)-binding cassette 
(ABC) transporters were studied and evaluated their influence in the 
occurrence of MTX-related toxicity. An increased risk for MTX-related overall 
toxicity was observed for SLC19A1 rs7499 G carriers, SLC46A1 rs2239907 
GG and SLCO1B1 rs4149056 T carriers and TT. Moreover, TRI analysis 
revealed that patients with Index 3 were 18-fold more likely to present an 
ADR when compared to those with Index 1. An increased risk for MTX-related 
GI toxicity was associated with SLC19A1 rs7499 G carriers and GG, SLC19A1 
rs1051266 G carriers, SLC19A1 rs2838956 A carriers and, SLCO1B1 
rs4149056 T carriers and TT. Furthermore, multivariate Cox regression 
model demonstrated a higher risk of earlier MTX-related GI toxicity for 
SLC19A1 rs1051266 G carriers. Additionally, the haplotype GGAG for 
SLC19A1 rs7499, rs1051266, rs2838956 and rs3788200 has shown to be 
associated with increased GI toxicity; and, TRI analysis revealed that patients 
with Index 4 were 9-fold more likely to present a GI disorder when compared 
to those with Index 1. Considering the folate pathway and the influence of 
methylenetetrahydrofolate reductase (MTHFR) rs1801133 in MTX clinical 
response, analyses demonstrated that T homozygotes were associated with 
over 4-fold increased risk for non-response. Attending to the de novo purine 
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synthesis pathway and the influence of 5-aminoimidazole-4-carboxamide 
ribonucleotide transformylase (ATIC) rs4673993 in clinical response to MTX, 
T carriers were associated with over 4-fold increased risk for non-response. 
For de novo pyrimidine synthesis pathway, more precisely of three 
polymorphisms in thymidylate synthase (TYMS) (rs34743033, rs2853542 and 
rs34489327), the obtained results demonstrated no statistically significant 
differences regarding MTX-related toxicity but, and considering the clinical 
response to MTX, genotypes 3R3R, 3RC3RG and 6bp- carriers were associated 
with non-response. Multivariate analysis confirmed the increased risk for 
non-response to MTX in 6bp- carriers; and, haplotype multivariate analysis 
revealed that haplotypes harboring both 3R and 6bp- alleles were associated 
with non-response to MTX.  
CONCLUSION. This work suggests that genetic polymorphisms combined 
with clinicopathological data may help to identify patients whom will not 
benefit from MTX treatment and, therefore, could be helpful as biomarkers of 
MTX therapeutic outcome and, thereby, assist clinicians to personalize RA 
treatment. 
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THESIS OUTLINE 
 
This thesis is structured in eleven main chapters as follow: 
 
Chapter I. Introduction  
This introductory chapter provides a description of Rheumatoid 
Arthritis and Methotrexate, and exploits the applicability of 
Pharmacogenomics in the field of Personalized Medicine in Rheumatoid 
Arthritis patients. 
 
Chapter II. Objectives  
This chapter presents the main and specific objectives of the thesis. 
 
Chapter III. Materials and Methods 
This chapter includes all the information about the search strategy, 
study design and participants’ selection, and provides the description of the 
data and sample collection, genotyping procedures and statistical analysis. 
 
Chapter IV. Genetic polymorphisms in low-dose methotrexate 
transporters: the current relevance as methotrexate therapeutic outcome 
biomarkers 
This chapter presents a comprehensive review about Methotrexate 
pharmacokinetics processes and the current data on genetic polymorphisms 
in genes encoding for low-dose Methotrexate membrane transporters as also 
their influence in Methotrexate therapeutic outcome. 
 
Chapter V. SLC19A1 80G allele as a biomarker of methotrexate-related 
gastrointestinal toxicity in Portuguese rheumatoid arthritis patients 
This chapter presents an original work that elucidates the clinical 
relevance of the solute carrier 19 family 1 G80A polymorphism and a set of 
clinicopathological variables as putative biomarkers of Methotrexate-related 
toxicity in Portuguese Rheumatoid Arthritis patients.  
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Chapter VI. SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as 
predictors of methotrexate-related toxicity in Portuguese rheumatoid 
arthritis patients 
This chapter elucidates the influence of single nucleotide 
polymorphisms in genes encoding for Methotrexate membrane transport 
proteins on the occurrence of Methotrexate-related toxicity in Portuguese 
Rheumatoid Arthritis patients. 
 
Chapter VII. Prediction of methotrexate clinical response in Portuguese 
rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC 
rs4673993 polymorphisms 
This chapter elucidates the association of clinical response to 
Methotrexate of several clinicopathological variables as also of 
methylenetetrahydrofolate reductase C677T and aminoimidazole 
carboxamide adenosine ribonucleotide transformylase T675C 
polymorphisms in Portuguese Rheumatoid Arthritis patients. 
 
Chapter VIII. Current approaches on thymidylate synthase 
polymorphisms and its importance on molecular epidemiology and 
pharmacogenetics 
This chapter presents a review about thymidylate synthase biological 
and pharmacological role and its genetic polymorphisms association with 
diseases susceptibility, Methotrexate therapeutic outcome (clinical response 
and toxicity occurrence) and patients’ survival. 
 
Chapter IX. Role of key TYMS polymorphisms on methotrexate 
therapeutic outcome in rheumatoid arthritis Portuguese patients 
This chapter elucidates the clinical relevance of the most studied 
thymidylate synthase polymorphisms (rs34743033, rs2853542 and 
rs34489327), by genotype and haplotype-based approaches, in Methotrexate 
therapeutic outcome of Portuguese Rheumatoid Arthritis patients. 
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Chapter X. General Discussion 
This chapter discusses several aspects of this work’ results including 
clinicopathological and genetic variables association with therapeutic 
outcome to Methotrexate and explores its limitations. 
 
Chapter XI. Concluding Remarks and Future Perspectives 
This chapter presents the main conclusions and highlights future work 
that is needed to be done and its importance. 
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ACRONYMS & SYMBOLS 
 
Letters 
A 
A: Adenine 
aa: Amino acid 
Ab: Antibody 
ABC: Adenosine triphosphate (ATP)-binding cassette 
ABCB1: Adenosine triphosphate (ATP)-binding cassette sub-family B member 1 
ABCC1: Adenosine triphosphate (ATP)-binding cassette sub-family C member 1 
ABCC2: Adenosine triphosphate (ATP)-binding cassette sub-family C member 2 
ABCC3: Adenosine triphosphate (ATP)-binding cassette sub-family C member 3 
ABCC4: Adenosine triphosphate (ATP)-binding cassette sub-family C member 4 
ABCG2: Adenosine triphosphate (ATP)-binding cassette sub-family G member 2 
ACPA: Anti-citrullinated protein antibody  
ACR: American College of Rheumatology  
ACRped70: American College of Rheumatology 70 pediatric criteria  
ADA: Adenosine deaminase 
ADORA: Adenosine receptor 
ADORA1: Adenosine receptor subtype A1 
ADORA2a: Adenosine receptor subtype A2a 
ADORA2b: Adenosine receptor subtype A2b 
ADR: Adverse drug reaction  
AHCY: S-Adenosylhomocysteinase 
Ag: Antigen 
AI: Autoimmune 
AICAR: Aminoimidazole carboxamide adenosine ribonucleotide 
AMP: Adenosine monophosphate 
AMPD1: Adenosine monophosphate deaminase 1 
ANA: Antinuclear antibody 
ANCA: Antineutrophil cytoplasmic antibody  
Anti-CCP: Anti-cyclic citrullinated peptide 
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Ala: Alanine  
ALT: Alanine aminotransferase  
APC: Antigen-presenting cell 
ARE: Adenylate uridylate-rich element 
Arg: Arginine 
AS: Ankylosing spondylitis  
Asp: Aspartate   
AST: Aspartate aminotransferase 
ATIC: 5-Aminoimidazole-4-carboxamide ribonucleotide transformylase  
ATP: Adenosine triphosphate 
AUC: Area under the curve  
AUF1: Adenine-uracil-rich factor 1  
Auto-Ab: Autoantibody  
Auto-Ag: Autoantigen  
 
B 
B19V: Parvovirus B19  
BC: Before Christ 
BCRP: Breast cancer resistance protein 
bDMARD: Biological disease-modifying antirheumatic drug 
BMI: Body mass index 
boDMARD: Biological originator disease-modifying antirheumatic drug 
bp: Base pairs 
bsDMARD: Biosimilar disease-modifying antirheumatic drug 
 
C 
C: Cytosine 
cAMP: Cyclic-adenosine monophosphate 
CCP: Cyclosporine   
CD3: Cluster of differentiation 3 
CDAI: Clinical disease activity index 
Chr: Chromosome  
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CI: Confidence interval 
CMV: Cytomegalovirus   
CNS: Central nervous system  
COX-2: Cyclooxygenase-2  
CRP: C-reactive protein 
csDMARD: Conventional synthetic disease-modifying antirheumatic drug 
CSF: Cerebrospinal fluid  
CTCAE: Common Terminology Criteria for Adverse Events  
CTLA4: Cytotoxic T-lymphocyte-associated protein 4  
CV: Cardiovascular  
 
D 
DAS: Disease activity score 
DAS28: Disease activity score in twenty-eight joints  
DC: Dendritic cell 
Del: Deletion 
DHEA: Dehydroepiandrosterone  
DHF: Dihydrofolate 
DHFR: Dihydrofolate reductase 
DIP: Deletion-insertion polymorphism 
DMARD: Disease-modifying antirheumatic drug 
DNA: Deoxyribonucleic acid 
dTMP: Deoxythymidine monophosphate 
dTTP: Deoxythymidine triphosphate 
dUMP: Deoxyuridine monophosphate 
 
E  
E: Extend primer   
E-box: Enhancer box   
EBV: Epstein–Barr virus  
E. coli: Escherichia coli 
EDTA: Ethylenediaminetetraacetic acid 
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e.g.: For example (Latim origin: exempli gratia)  
eGFR: Estimated glomerular filtration rate  
ESR: Erythrocyte sedimentation rate  
EULAR: European League Against Rheumatism 
 
F 
F: Forward primer 
FAICAR: Formyl-aminoimidazole carboxamide adenosine ribonucleotide 
FBP: Folate binding protein  
Fc: Fragment, crystallizable  
FDA: Food and Drug Administration  
FGAR: Formyl glycineamide ribonucleotide 
FLS: Fibroblast-like synoviocytes 
FOLR1: Folate receptor alpha 
FOLT: Folate transporter 
FPGS: Folylpolyglutamate synthetase 
 
G 
G: Guanine 
GAR: Glycineamide ribonucleotide 
GARS: Glycineamide ribonucleotide synthase 
GART: Glycineamide ribonucleotide formyl transferase 
GCA: Giant cell arthritis 
GGH: Gamma-glutamyl hydrolase 
GI: Gastrointestinal  
GIT: Gastrointestinal tract  
Gln: Glutamine 
Gly: Glycine 
 
H 
HAQ: Health assessment questionnaire 
HCP1: Heme carrier protein 1  
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HCQ: Hydroxychloroquine 
His: Histidine 
HLA: Human leukocyte antigen  
HLA-DRB1: Human leukocyte antigen, class II, DR beta 1   
hnRNPD: Heterogeneous nuclear ribonucleoprotein D  
HWE: Hardy-Weinberg equilibrium 
  
I 
ID: Identification 
IFN-: Interferon-gamma 
Ig: Immunoglobulin   
IL: Interleukin  
Ile: Isoleucine 
IMP: Inosine monophosphate 
IP: Interphalangeal  
IQR: Interquartile range 
IU: International units 
 
J 
JIA: Juvenile idiopathic arthritis  
JSN: Joint space narrowing  
 
L 
LD: Linkage disequilibrium 
LEF: Leflunomide 
LST1: Liver-specific transporter 1 
Lys: Lysine  
 
M 
MAT: Methionine adenosyltransferase 
MCP: Metacarpophalangeal 
MCT2: Monocarboxylic acid – transporter 2 
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MDR: Multidrug resistance protein 
MDR1: Multidrug resistance protein 1  
MMP: Matrix metalloproteinase 
MMP-3: Matrix metallopeptidase 3 
mRNA: Messenger ribonucleic acid 
MRP: Multidrug resistance-associated protein  
MRP1: Multidrug resistance-associated protein 1 
MRP2: Multidrug resistance-associated protein 2 
MS: Methionine synthase 
MTHFD1: Methylenetetrahydrofolate dehydrogenase 1 
MTHFR: Methylenetetrahydrofolate reductase 
MTP: Metatarsophalangeal 
MTR: Methyltransferase  
MTRR: 5-Methyltetrahydrofolate-homocysteine methyltransferase reductase  
MTX: Methotrexate 
MTXPG: Methotrexate polyglutamate 
 
N 
n.a.: Not assigned  
NA: Not analyzed 
NCBI: National Center for Biotechnology Information 
NPY: Number pack years 
NS: Not-statistically significant 
NSAID: Non-steroidal anti-inflammatory drug 
 
O 
OA: Osteoarthritis  
OAT: Organic anion transporter 
OATP-2: Organic anion-transporting polypeptide 2  
OR: Odds ratio  
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P 
P: Prospective 
PADI4: Peptidyl arginine deiminase type IV  
PAS: Patient activity score  
PASII: Patient activity score-II  
PCFT: Proton-coupled folate transporter 
PCR: Polymerase chain reaction 
PD: Pharmacodynamics 
P-GP1: P-glycoprotein1 
PGx: Pharmacogenomics 
PK: Pharmacokinetics  
PO: Per os  
PPAT: Phosphoribosyl pyrophosphate amidotransferase 
PRA: 5-Phosphoribosyl amine 
PRPP: 5-Phosphoribosyl-1-pyrophosphate 
PTPN22: Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) 
 
R 
R: Retrospective 
RA: Rheumatoid arthritis 
RANKL: Receptor activator of nuclear factor kappa B ligand  
RAPID: Routine assessment of patient index data  
Ref: Reference 
RF: Rheumatoid factor  
RFC1: Reduced folate carrier 1 
RFLP: Restriction fragment length polymorphism 
RNA: Ribonucleic acid 
RNS: Reactive nitrogen species 
ROS: Reactive oxygen species  
 
S 
S: Statistically significant 
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SAH: S-Adenosyl homocysteine 
SAM: S-Adenosyl methionine 
SC: Subcutaneous 
SCr: Serum creatinine  
SD: Standard deviation 
SDAI: Simplified disease activity index  
sDMARD: Synthetic disease-modifying antirheumatic drug 
SE: Shared epitope  
Ser: Serine 
SHMT1: Serine hydroxymethyltransferase 1  
SJC: Swollen joints count 
SLC: Solute carrier  
SLC16A7: Solute carrier family 16 member 7 
SLC19A1: Solute carrier family 19 member 1 
SLC22A11: Solute carrier family 22 member 11 
SLC22A6: Solute carrier family 22 member 6 
SLC22A8: Solute carrier family 22 member 8 
SLC46A1: Solute carrier family 46 member 1 
SLCO1A2: Solute carrier organic anion transporter family member 1A2 
SLCO1B1: Solute carrier organic anion transporter family member 1B1 
SLCO1B3: Solute carrier organic anion transporter family member 1B3 
SLE: Systemic lupus erythematosus  
SNP: Single nucleotide polymorphism 
SOC: System organ class  
SSZ: Sulfasalazine 
STAT4: Signal transducer and activator of transcription 4 
SvH: Sharp-van der Heijde score 
 
T  
T: Thymine 
TCR: T-cell receptor  
Th0: Type-0 T helper  
Th1: Type-1 T helper  
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Th17: Type-17 T helper  
THF: Tetrahydrofolate 
Thr: Threonine 
TJC: Tender joints count 
TNF-: Tumor necrosis factor-alpha  
TRI: Toxicogenetic risk index  
Trp: Tryptophan   
TS: Thymidylate synthase (protein) 
tsDMARD: Targeted synthetic disease-modifying antirheumatic drug 
TSER: Thymidylate synthase enhancer region  
TYMS: Thymidylate synthase (gene) 
 
U  
UK: United Kingdom 
USA: United States of America 
USF: Upstream stimulating factor 
UTR: Untranslated region 
 
V 
Val: Valine 
VAS: Visual analog scale 
VNTR: Variable number tandem repeat 
 
 
Numbers 
4v: Four variables  
5-MTHF: 5-methyltetrahydrofolate 
5,10-MTHF: 5,10-methylenetetrahydrofolate 
5,10-CH-THF: 5,10-methenyltetrahydrofolate 
7-OH-MTX: 7-hydroxymethotrexate 
10-CHO-THF: 10-formyltetrahydrofolate 
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Symbols 
Alfa:  
Beta:  
Centimeter: cm 
Day: d 
Decreased: ↓ 
Euro: € 
Gram: g 
Higher: > 
Hour: h 
Increased: ↑ 
Liter: L  
Lower: < 
Meter: m 
Microgram: µg 
Milligram: mg 
Milliliter: mL 
Millimeter: mm 
Mole: mol 
Percentage: % 
Picogram: pg 
Week: w 
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CHAPTER I - INTRODUCTION 
This chapter provides a description of Rheumatoid Arthritis and 
Methotrexate, and exploits the applicability of Pharmacogenomics in the field 
of Personalized Medicine in Rheumatoid Arthritis patients. 
 
 
1. RHEUMATOID ARTHRITIS 
This section includes information about Rheumatoid Arthritis historical 
aspects, epidemiological data, natural history, pathogenesis, classification 
criteria, disease monitoring, disease burden and prognostic, and, therapeutic 
strategies. 
 
  
1.1. General Concepts 
Rheumatoid Arthritis (RA) is a complex, systemic autoimmune (AI) 
disease, characterized by a chronic inflammation of multiple peripheral 
joints, often symmetric, which leads to cartilage and bone destruction, 
progressive deformity and disability (1, 2).  
 
 
1.2. Historical Aspects 
The earliest evidence of RA comes from pre-Columbian North America 
installation, with symmetrical, polyarticular erosive arthritis reported in 
Native American remains from as far back as 4500 Before Christ (BC) in what 
is now Tennessee (3). Paleopathological evidence of RA exists only in 
skeletal remains from New World populations and RA was not documented in 
the Old World until the late 16
th
 century, whereas other rheumatic diseases 
have been well described in biblical and ancient texts (4, 5). The lapse 
suggests that RA either migrated to Europe after New World colonization or 
arose as a response to a new environmental exposure (6). In 1591, the French 
physician Guillaume de Baillou applied the age-old catch-all term 
"rheumatism" to a condition characterized by soreness, inflammation, 
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stiffness and pain (6). Sporadic medical and literary depictions of RA-like 
illnesses followed, but the first medical literary evidence was penned in 1800 
by Augustin Jacob Landré-Beauvais, a French medical student at Salpêtrière 
Hospital (7). He described, in nine female patients, a painful, inflammatory 
arthritis that left the hand joints swollen and deformed that he called 
"asthenic gout" (“La goutte asthénique primitive”), distinguishing it from 
classic gout based on inflammation pattern, female predominance, 
polyarticular involvement and its chronic course (7). In 1859, Alfred Garrod 
coined the term “Rheumatoid Arthritis” (8). Rubens seems to be the first 
painter to depict what seems to be RA of the hands in the mid-17
th
 century 
(9). Paintings such as “The three graces” and “The miracle of St. Ignatius”, 
show ulnar deviation, boutonniere deformities and metacarpophalangeal 
(MCP) swelling (9, 10) (Figure 1).  
 
 
 
 
Figure 1. Historical, literary, artistic and paleopathological evidence of rheumatoid arthritis as 
a New World disease that has “spread” to the rest of the world. 
(Adapted from Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nature reviews 
Rheumatology. 2011;7(10):569-78) 
BC: before Christ; RA: rheumatoid arthritis; USA: United States of America.  
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1.3. Epidemiology 
Several studies have been reported during the last few decades about 
the incidence and prevalence of RA. As previously described, epidemiological 
evidence supports the notion that RA is a disease of the New World  and, 
keeping with this theory, the last populations to be in contact with European 
conquistadors have a strikingly low prevalence of RA (6). 
 
1.3.1. Prevalence 
The worldwide prevalence of RA is relatively constant ranging from 
0.5% to 1.1%, as reported in North European and North American populations 
(11-15). Southern European countries have slightly lower median prevalence 
rates (of 0.3% to 0.7%) compared to these countries (12, 16-18). However, 
there are some exceptions, such as Southern American, African and Asian 
populations, which have even more lower prevalence than Southern 
European countries (13, 19-21). In contrast, certain native American-Indian 
populations have an extremely increased disease prevalence (of 5.3% to 6.8%) 
(Figure 2) (13). In Portugal, the prevalence in 2011 was of 0.36%, in 
accordance to other Southern European countries (22). 
 
 
 
 
Figure 2. Prevalence of rheumatoid arthritis in some world countries. 
(Adapted from Silman A, Pearson J. Epidemiology and genetics of rheumatoid arthritis. Arthritis research. 
2002;4(Suppl 3):S265 - S72 and Branco JC, Canhao H. Epidemiological Study of Rheumatic Diseases in 
Portugal - EpiReumaPt. Acta Reumatol Port. 2011;36(3):203-4) 
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1.3.2. Incidence 
Among all the countries, the incidence of RA is higher in females than in 
males, with a gender ratio from about 2:1 to 3:1 (23) and a peak of disease 
onset age occurring in the fifth decade of life (24). The annual incidence 
rates of RA vary between 20 to 60 cases per 100 000 inhabitants in North 
European and North American populations (11, 15, 25, 26), in Southern 
European countries is lower (9 to 24 cases per 100 000 inhabitants) (27, 28) 
and it was not reported or studies are outdated for other countries. In 
Portugal, the incidence in 2001 was reported as varying between 20 to 40 
cases per 100 000 inhabitants (29).  
 
1.3.3. Time trends in epidemiology 
Limited data are available on time trends of RA incidence and 
prevalence. Several longitudinal studies for the same region suggested 
declines after the 1960s, mainly in women (25, 30). This trend is supposed to 
be influenced by some factors such as differences in studies methodologies 
and difficulties in differentiate RA from unspecified polyarthritis 
(misclassification), and thus should be interpreted with precaution (31). 
However, the changes over time may be true and the declining trend mainly 
observed in women (25), could be explained by the greater exposure to oral 
contraceptives (30), as further discussed in accordance to hormonal factors 
(see Gender and Susceptibility genes - 1.5.1. Prearthritis phase – 1.5. 
Pathogenesis).  
 
 
1.4. Natural History  
Natural history of RA varies considerably regarding disease onset, 
pattern of presentation, pattern of progression and clinical course.  
 
1.4.1. Disease onset 
Rheumatoid arthritis onset may be sudden and acute, gradual and 
insidious, or sub-acute between these extremes (32). A gradual onset is most 
common (at least 50% of cases) when compared to a sudden onset (10% to 
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25%) (32). Rheumatoid arthritis begins predominantly as an articular disease, 
and one or many joints may be affected (32). It may also start with an extra-
articular or non-articular presentation, such as a local bursitis, tenosynovitis, 
carpal tunnel syndrome, or as a systemic presentation, with diffuse 
polyarthralgia or polymyalgia (32). Although the onset is predominantly 
articular, it is frequently associated with a variety of extra-articular features, 
including generalized weakness, anorexia, weight loss or fever (32). In some 
cases, fatigue alone or diffuse non-specific aching with other extra-articular 
features, such as pulmonary disease, may herald - by weeks or months - the 
onset of polyarthritis (32). 
 
1.4.2. Pattern of presentation 
There are six possible patterns of presentation, as follow: 1) gradual 
onset; 2) slow monoarticular presentation; 3) sudden acute polyarthritis; 4) 
acute monoarthritis; 5) local extra-articular features; and, 6) systemic extra-
articular features (33). The most common early presentation is the gradual 
onset (33). It affects small peripheral joints (e.g. wrists, ankles or MCP, 
interphalangeal – IP - and metatarsophalangeal – MTP - joints) and it is 
usually symmetric, with considerable morning stiffness (33). The slow 
monoarticular presentation, which affects larger joints (e.g. shoulders or 
knees) and confines the symptoms to one or two joints, as also the sudden 
acute polyarthritis of shoulders, elbows, wrists, fingers, hips, knees, ankles, 
and feet, with intense joint pain, diffuse swelling and limitation, are less 
common (33). It is rare the acute monoarthritis of the knee, shoulder or hip, 
in which is presented a picture suggesting a septic, pseudo gout or gouty 
process with a characteristic severe joint pain (33). In addition, local extra-
articular features (e.g. bursitis and tenosynovitis) and systemic presentation, 
particularly in elderly patients, may be observed (33).  
 
1.4.3. Pattern of progression 
Independently of the onset or presentation, patients’ subsequent 
progress may follow different patterns. It may be a course that is brief and 
self-limited, episodic (palindromic) or prolonged and progressive, or 
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something intermediate (34). The severity may vary from mild to intense. 
Crises can be prolonged and smoldering or prolonged and progressive (34). 
There are at least three possible disease patterns (Figure 3): 1) Progressive: 
with increasing joint involvement; 2) Monocyclic: a single cycle with 
remission for at least 1 year and without reoccurrence; and, 3) Polycyclic: 
with either intermittent or continuing subtypes. The latter group shows 
smoldering activity with incomplete remission or progression (34). 
 
 
 
 
Figure 3. Patterns of the clinical (articular) course of rheumatoid arthritis.  
(Adapted from Masi AT. Articular patterns in the early course of rheumatoid arthritis. The American 
journal of medicine. 1983;75(6A):16-26) 
 
1.4.4. Clinical course  
The clinical course of RA, which can be predicted by disease onset and 
patterns of presentation and progression, could provide insights into 
outcome variables and disease prognosis (32). In acute-onset pattern, 
patients with sudden disease onset are associated with a better functional 
outcome when compared with patients presenting a slow onset of disease 
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(32). Moreover, patients with gradual-onset disease are associated with 
worse prognosis when large joints and the first and second MTP joints are 
involved (32).  
 
 
1.5. Pathogenesis 
The mechanisms involved in the pathophysiology of RA are currently 
not fully established. Nevertheless, the innate immune system, responsible 
for the initial non-specific response to foreign antigens, seems to be 
involved early in RA (35, 36). The antigens which trigger these response have 
not yet been identified, but probably resemble or mimic synovial tissue 
antigens, resulting in a multistep progression until the development of RA: 1) 
Prearthritis phase; 2) Transitional phase; and 3) Clinical phase (37). 
 
1.5.1. Prearthritis phase 
The cause of RA is unknown, however, it seems that involves a complex 
factorial interplay among genotype, environmental triggers, and chance (24, 
38) (Figure 4).  
 
 
 
 
Figure 4. Prearthritis phase.  
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1.5.1.1. Gender and Susceptibility genes 
Females are two to three more times affected than men (23) but the 
mechanism by which gender influences RA susceptibility is unknown. 
Nevertheless, it is suggested a possible role of hormonal fluctuations to 
which woman are exposed throughout life (39, 40). This is in agreement with 
the peak disease onset age - the fifth decade of life - a time of great 
hormonal changes, such as those occurring at the beginning of menopause 
phase, which could be possible disease risk factors (24). Sex hormones 
(estrogen, androgen, prolactin and testosterone) and common intermediate 
metabolites (dehydroepiandrosterone – DHEA, and estradiol - the most 
potent naturally occurring estrogen) have all been proposed as having a role 
in susceptibility to AI diseases, since they modulate the immune response 
via androgen and estrogen receptors (41). In addition, low levels of gonadal 
androgens (testosterone/dihydrotestosterone) and adrenal androgens (DHEA 
and its sulfate), as well as lower androgen/estrogen ratios, have been 
detected in body fluids of both male and female RA patients, supporting the 
possibility of a pathogenic role for the decreased levels of the immune-
suppressive androgens (41). Since estrogen and prolactin are both 
proinflammatory hormones (41), longer lifetime period of menstruation leads 
to greater lifetime exposure to proinflammatory sex hormones; and, very 
irregular menstrual cycles, which are presumed to be a consequence of 
excess hormone production, were associated with an increased risk of RA 
(42). In addition, there is evidence of reduced levels of androgens (natural 
anti-inflammatory hormones) and progesterone in RA patients (43). Men with 
RA have low levels of testosterone, DHEA and estrone, while estradiol is 
increased and correlates with the inflammatory indices (43). Furthermore, 
females have enhanced immunoreactivity, with higher immunoglobulin levels 
and enhanced antibody (Ab) production to antigen (Ag) stimulation, and a 
predominant T-helper type 2 immune response when compared to men (39, 
40). 
In accordance to RA susceptibility genes, literature describes that 
siblings of individuals affected with RA have a higher risk of developing 
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disease when compared with unrelated individuals (44). This  increased  risk  
could  be  the  result  of  either  their  shared  genetic background or factors 
in their shared family environment (see Environmental factors - 1.5.1. 
Prearthritis phase – 1.5. Pathogenesis). These influences can be 
distinguished by comparing disease recurrence risks (disease concordance) 
in co-twins of affected monozygotic and dizygotic twins. Because both types 
of twins are assumed to share their common environment to a similar extent, 
a greater concordance in monozygotic (concordance rates of 15 to 30%) than 
in dizygotic twins (concordance rates of 5%) suggests a genetic influence 
(45). The elevated risk among family members was also demonstrated in a 
study based on a multiple-generation register (46). 
The nature of much of the genetic risk in RA is becoming increasingly 
clear. The long-established association with the human leukocyte antigen 
(HLA), class II, DR beta 1 (HLA-DRB1) locus has been confirmed and alleles 
that contain a common amino acid motif in the HLA-DRB1 region, termed 
shared epitope (SE), confer particular susceptibility mainly in positive 
patients for rheumatoid factor (RF), an autoantibody (auto-Ab) directed 
against the  fragment, crystallizable (Fc) region, of immunoglobulin G (IgG) 
and anti-cyclic citrullinated peptide (anti-CCP), an auto-Ab directed against 
proteins containing citrulline (47). These findings suggest that some 
predisposing T-cell repertoire selection, Ag presentation, or alteration in 
peptide affinity has a role in promoting autoreactive adaptive immune 
responses (47). Other possible explanations for the link between RA and the 
SE include molecular mimicry of the SE by microbial proteins, increased T-cell 
senescence induced by SE–containing HLA molecules, and a potential 
proinflammatory signaling function that is unrelated to the role of the SE in 
Ag recognition (48, 49). Nevertheless, HLA-DRB1 may explain only 30% of the 
population's genetic susceptibility to disease (47). Among other genes, the 
main RA susceptibility factor is the gene that codify for protein tyrosine 
phosphatase, non-receptor type 22 (lymphoid) (PTPN22) (50). A missense 
cytosine (C)>thymine (T) substitution at nucleotide position 1856 of PTPN22 
leads to substitution of tryptophan (Trp) for arginine (Arg) at residue 620 of 
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the protein product (50). The resulting gain of function, with enhanced 
regulation of T-cell receptor (TCR) signaling during thymic selection, permits 
autoantigen (auto-Ag) specific T-cells to escape clonal deletion, thereby 
predisposing to autoimmunity (50). Other non-HLA genetic risk factors such 
as signal transducer and activator of transcription 4 (STAT4) (51) and 
cytotoxic T-lymphocyte-associated protein 4 (CTLA4) (52) have also been 
described. 
 
1.5.1.2. Environmental factors  
Environmental factors may affect RA susceptibility in individuals who 
share the same genetic background – epigenetic factors. Besides this, 
environmental factors include: socio-demographic conditions; cigarette 
smoking; alcohol consumption; diet; and, infectious agents. 
 
Socio-demographic conditions 
There is an increased prevalence of RA in the Pima and Chippewa 
Indians, in contrast with certain populations, including Southern American, 
African and Asian populations (13, 19-21) (see 1.3.1. Prevalence – 1.3. 
Epidemiology). The high frequency of RA in these populations strongly 
suggests a genetic basis of disease, since RA is a “New World disease”, 
raising the possibility that RA is transmissible (53). Even so, possible 
environmental triggers such region particularities in diet (54), infections 
agents, cigarette smoking and sex hormones are thought to have an effect 
on RA, although not well known for now (53).  
Furthermore, urbanized regions have been associated with an increased 
prevalence of RA. For example, in Taiwan, the prevalence of RA is higher 
among individuals living in an urban rather than a rural environment (55). 
Regions with a greater exposure to traffic pollution were related with an 
increased risk for RA (56). Moreover, the risk of developing RA may be also 
influenced by diet particularities of these regions (54) (57).  High birth 
weight, mostly in developed countries, was positively associated with RA, 
 
 
13 
 
whereas increased breast feeding time, mostly in development countries, 
was protective (58).  
 
Cigarette smoking 
Cigarette smoking represents the most prominent environmental risk 
factor in RA (59-61) and an increased risk for RA has been observed among 
heavy smokers (60). In fact, the risk of RA increases after ten pack-years of 
smoking and remains elevated up to twenty years after smoking 
discontinuation (61). Multiple reports were developed in order to elucidate 
epigenetic modifications induced by cigarette smoking and, the most 
important genetic risk factor associated with RA, the HLA-DRB1 SE–
containing allele, appears to have robust interactions with smoking in 
disease susceptibility (59, 60, 62). The interaction between smoking and HLA-
DRB1 SE is most evident in seropositive RA (59, 60), particularly in disease 
that is characterized by positive serology for anti-CCP (59), and in heavy 
smokers (59, 60, 62).  
 
Alcohol consumption 
Alcohol consumption has been associated with decreased risk for 
developing RA, particularly for anti-CCP-positive patients (63). A dose-
dependent effect was also observed whereby individuals with the highest 
consumption (≥5 drinks or 80g ethanol/w) had a decreased risk of RA on the 
order of 40-50% compared with those with low to no consumption (<0.5g 
ethanol/w) (64).    
 
Diet 
A diet rich in fish, olive oil, cooked vegetables and foods with high 
content of omega-3 fatty acids has been shown to protect against RA (54). 
Several studies found that populations of Southern Europe had milder forms 
of RA, with fewer extra-articular and radiological manifestations, when 
compared to other populations (54). This difference may be ascribable in 
part to the Mediterranean diet (54). Protein and red meat intake were found 
to increase the risk of inflammatory arthropathy (57), but a subsequent 
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study showed no association between protein, red meat and fish 
consumption with the risk of developing RA (65). Vitamins were also 
associated with RA. Vitamin D, an important modulator of the inflammatory 
response and of bone and mineral homeostasis (66), has been associated 
with a decreased risk for RA (67, 68) and vitamin K, which is found primarily 
in legumes and other vegetables, may inhibit the proliferation of fibroblast-
like synoviocytes, thereby diminishing the severity of inflammation  (69). 
 
Infectious agents 
Infectious agents such as Parvovirus B19 (B19V), Epstein–Barr virus 
(EBV), Porphyromonas gingivalis and gastrointestinal (GI) microbiome, have 
long been linked with RA, and although unifying mechanisms remain elusive, 
some form of molecular mimicry is postulated (70). Clearly, no single 
microorganism is responsible for triggering the development of RA possibly 
in individuals who carry genetic susceptibility factors to the disease (70). 
Evidence supporting a role for B19V includes the presence of viral 
deoxyribonucleic acid (DNA) in the synovial fluid, synovial cells, and/or 
synovial tissue of RA patients (71). Serums from RA patients contain high 
titles of EBV Ags and of Abs to latent and replicative EBV antigens (70, 72). In 
addition, EBV ribonucleic acid (RNA) has been identified in B-cells in synovial 
tissue from RA patients (70). Furthermore, RA appears to be associated with 
periodontal disease: Porphyromonas gingivalis expresses peptidyl arginine 
deiminase, type IV (PADI4), which is capable of promoting citrullination of 
mammalian proteins by the promotion of post-translational modifications 
(73). Finally, the GI microbiome is now recognized to influence the 
development of autoimmunity in articular models and, specific (and 
potentially tractable) clinical bacterial signatures that are associated with 
auto-Ab-positive RA are emerging (74). Other infectious agents (e.g. 
Cytomegalovirus - CMV, Proteus species, and Escherichia coli – E. coli) and 
their products (e.g., heat-shock proteins) have been also associated with the 
development of RA (70). 
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1.5.2. Transitional phase 
From prearthritis phase results environment–gene interactions that 
promote loss of tolerance to self-proteins that contain a citrulline residue, 
which is generated by citrullination (48). Citrullination (conversion of 
peptidyl-arginine to peptidyl-citrulline) is a post-translational modification of 
proteins, also known as self-protein citrullination, that is thought to be 
important in the initiation of the AI response that leads to the development 
of RA (75). This anticitrulline response can be detected in T-cell and B-cell 
compartments and is probably initiated in secondary lymphoid tissues or 
bone marrow. Autoantibodies, such as RF and anti-CCP, are often (but not 
always) detected in patients before the development of arthritis; in some 
series, their levels are increased and epitope spreading occur as the onset of 
disease approaches (76). 
Why the systemic loss of tolerance is linked to a localized onset of 
inflammation in the joint is still unclear (transition to arthritis). Localization 
of the inflammatory response occurs in the joint by virtue of poorly 
understood mechanisms that probably involve microvascular, neurologic, 
biomechanical, microtrauma-related mechanisms, or other tissue-specific 
pathways (48). It is possible that biologic features of the targeted auto-Ags 
(e.g. regulation of cellular metabolism in the case of α-enolase and glucose-6-
phosphatase) may contribute (Figure 5).  
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Figure 5. Transitional phase.  
(Adapted from McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 
2011;365(23):2205-19) 
Anti-CCP: anti-cyclic citrullinated peptide; DC: dendritic cell; RF: rheumatoid factor. 
 
1.5.3. Clinical phase 
Synovitis is initiated and perpetuated by positive feedback loops and in 
turn promotes systemic disorders that make up the “syndrome of 
rheumatoid arthritis” (48) (Figure 6).  
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Figure 6. Clinical phase – Feedback loops between synovitis and structural damage.  
(Adapted from McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 
2011;365(23):2205-19) 
 
Antigen stimulation leads to a cascade of events in a genetically 
predisposed individual with a particular gender and in the presence of 
certain environmental factors. This cascade include the activation of antigen-
presenting cells (APCs), such as dendritic cells (DCs), that start several 
costimulation-dependent interactions among DCs, T- and B-cells at lymph 
node (77). Thereafter, the adaptive immune system (Ag-specific immune 
responses) launches a sustained and specific attack on synovial tissue, 
which is now perceived as “foreign” (37). The immune response leads to the 
characteristic histological features of RA. This is characterized by synovial 
proliferation, neoangiogenesis (induced by local hypoxic conditions and 
cytokines), insufficient lymphangiogenesis, cell migration of T-cells (type-1 T 
helper – Th1 - and type-17 T helper – Th17), B-cells, macrophages and 
fibroblasts and increased expression of adhesion molecules and chemokine’s 
(78, 79). This process is eventually followed by pannus formation, local joint 
destruction and auto-Abs production (e.g. RF and anti-CCP) by plasma cells 
(80). The inflammatory infiltrate secretes numerous proinflammatory 
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cytokines, glycoproteins that act via cell surface receptors to regulate 
cellular function by promotion of inflammation. Tumor necrosis factor -alpha 
(TNF-), interleukin (IL) -1, IL-6 and IL-17 are the pivotal cytokines in the 
pathogenesis of RA since they are potent stimulators of fibroblast-like 
synoviocytes (FLS), chondrocytes and osteoclasts (37).  
Fibroblast-like synoviocytes synthesize metalloproteinases (MMPs), a 
family of enzymes responsible for degradation and reorganization of matrix, 
that promote the degradation of collagen-rich structures associated to joint 
tissues (bone, cartilage, ligaments and tendons), and other tissues (81). Since 
endogenous enzyme inhibitors (e.g. tissue inhibitors of MMPs) fail to reverse 
this destructive cascade and articular cartilage itself has limited regenerative 
potential, this process will lead to joint damage and systemic manifestations 
(81). These manifestations include not only extra-articular disease but 
accelerated atherosclerosis and consequent increased cardiovascular (CV) 
morbidity and mortality (80). In addition, FLS proliferation contributes 
directly to local cartilage destruction and the chronicity of synovial 
inflammation (37). This synovial inflammation chronicity is also promoted by 
the synthesis of prostaglandins, proteases and reactive oxygen species (ROS) 
intermediates by neutrophils, which reside mainly in synovial fluid (82).  
Chondrocytes physiologically regulate matrix formation and cleavage: 
under the influence of synovial cytokines (particularly IL-1 and IL-17) and 
reactive nitrogen species (RNS), cartilage is progressively deprived of 
chondrocytes, which undergo apoptosis (37). These processes ultimately lead 
to the destruction of the surface cartilage and the radiographic appearance 
of joint-space narrowing (37). 
Synovial cytokines, particularly macrophage colony-stimulating factor 
and receptor activator of nuclear factor kappa B ligand (RANKL), a molecule 
responsible for inducing osteoclastogenesis, promote osteoclast 
differentiation and invasion of the periosteal surface adjacent to articular 
cartilage (83). Tumor necrosis factor- and IL-1, IL-6 and, potentially, IL-17 
amplify osteoclast differentiation and activation, leading to bone erosion (84) 
(Figure 7). 
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1.6. Classification Criteria  
The 1987 American College of Rheumatology (ACR), formerly the 
American Rheumatism Association, criteria for the classification of RA were 
initially developed in 1957 by a committee of expert rheumatologists who 
compiled components  of  the  physical  examination  and  diagnostic testing 
that they considered important for RA diagnosis (85). Subjects were 
classified into four groups as follow: 1) “possible RA”, 2) “probable RA”, 3) 
“definite RA”, and 4) “classic RA” (added in 1958) (85). ln 1987 the criteria 
were revised, simplifying the classification to identify individuals with 
“definite RA” (85) (Table 1).  
 
Table 1. 1987 ACR criteria for classification as “definite RA”* 
1. Morning stiffness  Morning stiffness in and around the joints, lasting at least 1 hour 
before maximal improvement.  
2. Arthritis in 3 or more 
joint areas
§
 
Soft tissue swelling or fluid (not body overgrowth) observed by a 
physician presenting simultaneously for at least 6 weeks. 
3. Arthritis of hand joints Swelling of wrist and MCP or proximal IP joints for at least 6 weeks. 
4. Symmetric arthritis  Simultaneous involvement of the same joint area (defined in 2, above) 
on both sides of the body (bilateral involvement of proximal IP, MCP or 
MTP joints is acceptable without absolute symmetry) for at least 6 
weeks. 
5. Rheumatoid nodules  Subcutaneous nodules over bony prominences, extensor surfaces, or in 
justarticular regions, observed by a physician. 
6. Rheumatoid factor Detected by a method that is positive in fewer than 5% of normal 
controls. 
7. Radiographic changes Typical of RA on posteroanterior hand and wrist radiographs; they 
must include erosions or unequivocal bony decalcification localized in 
or most marked adjacent to the involved joints (OA changes alone do 
not qualify).  
*At least 4 criteria (in a total of 7) must be fulfilled for classification of RA; patients with 2 clinical diagnoses are not 
excluded.  
§
Possible areas: right or left proximal IP, MCP, wrist, elbow, knee, ankle and MTP joints.  
ACR: American College of Rheumatology; IP: interphalangeal; MCP: metacarpophalangeal; MTP: metatarsophalangeal 
OA: osteoarthritis; RA: rheumatoid arthritis.   
(Adapted from Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American 
Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and 
rheumatism. 1988;31(3):315-24) 
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Because of the cohort nature for which criteria were developed, the 
criteria performs best at distinguishing subjects with long duration and 
active RA from those with other arthritis (85). Yet, there is a strong interest 
in identifying the disease earlier in the clinical setting and for research 
studies since an early aggressive treatment for RA can break or slow the 
progression of synovitis and bone erosions, decreasing disease-related 
disability and increasing the rate of disease remission (86). However, 
criteria such as joint erosions and rheumatoid nodules (masses of 
inflammatory tissue with a central focus of necrosis, presumably the 
consequence of vascular inflammation, surrounded by chronic inflammatory 
cells) are often absent early in the disease, thus decreasing the sensitivity 
of the classification criteria (85).  
In fact, the performance of 1987 ACR criteria on patients with early 
RA found a wide range of sensitivities from 25% to 90% and a specificity 
ranging from 60% to 90% (87, 88).
 
Because of the lack of sensitivity in early 
disease, the 1987 ACR classification criteria for RA have been criticized (89). 
Therefore, since 1987, there have been several advances in the approach 
for diagnosing RA, most notably, the use of RF and of anti-citrullinated 
protein antibody (ACPA), tested as anti-CCP. Anti-cyclic citrullinated 
peptide and RF are involved in RA pathogenesis (1, 76) and have been 
shown to be specific markers for RA, particularly for subjects with early 
disease (anti-CCP: 94-100%; RF: 23-96%) (87, 90, 91). In relation to sensitivity 
of RF and anti-CCP, it is equivalent in both early and established disease 
(91).  
Current criteria were developed in 2010 by the ACR and European 
League Against Rheumatism (EULAR) (89). In the new criteria, classification 
as “definite RA” is based on: synovitis in at least one joint, absence of an 
alternative diagnosis that better explains the synovitis, and achievement of a 
total score of six or greater (of a possible ten) from the individual scores in 
four domains, as follow: 1) location and number of swollen and tender joints; 
2) serologic levels of RF and anti-CCP; 3) elevated acute-phase reactants such 
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) (related to 
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inflammation and disease activity); and 4) symptoms duration (89) (Table 2). 
These classification criteria enable the stratification of individuals groups 
into those with and without RA, in order to standardize recruitment into 
clinical trials and related studies, and provide the basis for a common 
approach to disease definition that can be used to compare across studies 
and centers (89). These criteria also provide the possibility of determine the 
group at highest risk for developing persistent or erosive RA and of aid 
diagnosis (89). 
 
Table 2. 2010 ACR/EULAR criteria for classification as “definite RA”* 
Domains Score 
Location and number of swollen and tender joints 
1 large joint 0 
2-10 large joints 1 
1-3 small joints (with or without involvement of large joints) 2 
4-10 small joints (with or without involvement of large joints) 3 
>10 joints (at least one small joint)  5 
Serology 
RF (-) and anti-CCP (-) 0 
RF (+) or anti-CCP (+) (≤ 3 times than normal) 2 
RF (+) or anti-CCP (+) (> 3 times than normal) 3 
Acute-phase reactants 
Normal CRP and ESR levels 0 
Elevated CRP and ESR levels 1 
Symptoms duration 
<6 weeks 0 
≥6 weeks 1 
*Based in at least a total score of 6 or greater, the presence of synovitis in at least 1 joint and absence of an 
alternative diagnosis that better explains the synovitis. 
ACR: American College of Rheumatology; anti-CCP: anti-cyclic citrullinated peptide; CRP: C-reactive protein; 
ESR: erythrocyte sedimentation rate; EULAR: European League Against Rheumatism; RA: rheumatoid arthritis; 
RF: rheumatoid factor. 
(Adapted from Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 
rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against 
Rheumatism collaborative initiative. Annals of the rheumatic diseases. 2010;69(9):1580-8) 
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1.7. Diagnosis 
Rheumatoid arthritis is the paradigm of a systemic AI disease 
characterized by inflammatory polyarthritis. As a practical matter, a patient 
older than the age of eighteen who has symmetric joint pain and swelling in 
the hands and feet and morning stiffness is likely to have RA, especially if RF 
and/or anti-CCP findings are positive (89). Its early presentation can be quite 
similar to several other conditions that must be excluded and, thus, caution 
must be taken to avoid overdiagnosis of RA. On the other hand, early 
diagnosis is critical so that appropriate treatment can be administered and 
irreversible damage prevented. The hallmark of RA is symmetric synovial 
proliferation and tenderness of multiple joints, particularly the small joints 
of the hands and feet such the MCP, proximal IP and MTP joints (1, 2). Most 
patients experience joint stiffness or gelling for more than an hour in the 
morning (24). The blood of approximately 80% of RA patients contains RF 
(92). Rheumatoid nodules are quite specific for RA and occur in about 20% of 
patients, generally those with more severe disease and high-title RF (92). 
Therein lies the advantage for the 2010 ACR/EULAR classification criteria for 
the contemporary clinician: they provide diagnostic support for recognition 
of early RA, allowing the physician to make a definitive diagnosis without 
delay and thus to make a decision to administer disease-modifying 
antirheumatic drug (DMARD) therapy timely and before joint destruction 
occurs (89). Nevertheless, these criteria only provide a useful starting point 
for one to become familiar with the key clinical features of RA. In fact, the 
complex interplay between various risk factors for RA development makes 
this multifactorial disease very complex and its diagnosis extremely difficult. 
Therefore, no single physical finding or laboratory tests definitely confirm 
the existence of RA (24). In this way, the diagnosis is essentially clinical, 
which combines anamnesis, physical exam and diagnostic complementary 
exams (particularly, laboratory and imaging exams) (24).  
Laboratory tests include blood count, quantification of RF and anti-CCP, 
measurement of ESR, quantification of CRP and evaluation of renal and liver 
functions (24).  
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The blood count allows, among other parameters, to assess the levels of 
hemoglobin, hematocrit, white blood cells, platelets and complement (24). 
The platelet count, white blood cells and complement may be elevated in 
patients with RA and, typically, these patients present a normochromic 
normocytic anemia or sometimes microcytic (24). The RF test is readily 
available and positive in about 80% of patients with RA (93). However, RF 
may be negative in early RA and positive in many other conditions, especially 
hepatitis C infection (92). Therefore, the advent of detection of anti-CCP has 
been a major advance in the diagnosis of early RA (88). Anti-cyclic 
citrullinated peptide is highly specific for RA and can be detected very early 
in disease (94). The combination of a positive anti-CCP test with a positive RF 
test further increases the specificity for RA (combination of these two tests: 
99% specificity compared to 70% sensitivity for each of these tests) (76, 95). 
Thus, seropositivity for either one of these tests, in a patient with 
polyarthritis in the hands and feet, makes the diagnosis of RA quite likely. 
The ESR and CRP are the biomarkers most used to, in an indirect way, 
determine the presence and severity of inflammation, predict the functional 
status of the joints and assess disease activity (96). Typically, CRP and ESR 
are elevated (frequently, CRP >3mg/L and ESR >30mm/h) in patients with RA 
(24). As previously described, the 2010 ACR/EULAR classification criteria 
recognize the importance of the number of involved joints as well as of RF, 
anti-CCP, ESR and CRP (89).  
The evaluation of renal and liver functions, performed by the 
determination of serum creatinine (SCr), estimated glomerular filtration rate 
(eGFR), urea, transaminases, albumin and coagulation factors, may be useful 
in the prediction of therapeutic impact on these organs (24).  
In addition, other laboratory tests can be performed such the 
assessment of synovial fluid of affected joints, looking for inflammatory 
patterns; quantification of antinuclear antibodies (ANAs), which are positive 
in about 25% of patients, and of antineutrophil cytoplasmic antibodies 
(ANCAs); and, the analysis of urine, which can confirm the presence of 
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microscopic hematuria or proteinuria, usually present in patients with RA 
(24). 
Concerning to imaging exams, radiographs of the hands and feet are 
sometimes diagnostic at presentation, and musculoskeletal ultrasound and 
magnetic resonance imaging can detect early evidence of synovitis and 
erosions not seen on radiographs, although the aim today is to prevent joint 
damage from occurring (97).  
 
 
1.8. Disease Monitoring 
Anamnesis and physical exam are also aimed to quantify the disease 
severity, such as intensity and duration of morning stiffness, assess 
patient's general condition (including the analysis of the presence of extra-
articular manifestations), quantitative assessment of pain, functional testing 
of the joints, and others (98). Disease monitoring is performed taking into 
account the quantification of disease activity, joint damage, and health-
related quality of life impact. 
 
1.8.1. Quantification of joint damage 
Several methods have been introduced for the annual or biannual 
scoring of plain radiographs (normally of the anatomic regions with the 
joints most frequently affected, such as hands, wrists and foots) in patients 
with RA for the quantification of joint damage.  
Nowadays, the two most widely used measures are based on the work 
of Sharp and Larsen, which provide a continuous quantitative scale rather 
than a limited qualitative measure of radiographic damage (99-102).  
 
1.8.1.1. Sharp-van der Heijde score 
The Sharp method modified by van der Heijde - Sharp-van der Heijde 
score (SvH) - involves separate scores for erosions and for joint space 
narrowing (JSN). Erosion score is evaluated in sixteen areas from each hand 
and wrist, and each side of the ten MTP and two IP joints of the big joints of 
the feet (103, 104) and erosions are classified as: 1) normal; 2) discrete 
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erosions; 3) larger erosions according to surface area involved; 4) erosions 
extending over middle of the bone; and, 5) complete collapse (103, 104). Joint 
space narrowing score includes fifteen areas from the hands and wrists and 
six areas from the feet (103) and is classified according to the original Sharp 
method as: 1) normal; 2) focal narrowing; 3) reduction of less than 50% of 
joint space; 4) reduction of greater than 50% of joint space; and, 5) ankylosis  
(Table 3) (102, 103, 105). 
 
Table 3. Sharp-van der Heijde score 
 Erosion score Joint space narrowing score 
 
 
Classification Score Classification Score 
Normal 0 Normal 0 
Discrete erosions  1 Focal narrowing 1 
Larger erosions according to 
surface area involved 
2 or 3 Reduction of less than 50% of joint 
space 
2 
Erosions extending over middle of 
the bone 
4 Reduction of greater than 50% of 
joint space 
3 
Complete collapse 5 Ankylosis 4 
56 joints scored 42 joints scored 
Maximum erosion score: 160 - hands and wrists  
Maximum erosion score: 120 - feet 
                             Total: 280 
Maximum JSN score: 120 - hands and wrists  
Maximum JSN score: 48 - feet 
                                           Total: 168        
Total maximum score: 448 
JSN: joint space narrowing.  
(Adapted from http://rheumatology.usherbrooke.ca/radiographie_formulaire.pdf) 
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1.8.1.2. Larsen method  
The Larsen method is based in a global score of each joint, including 
both erosions and JSN of all synovial joints, on a scale of zero to five 
according to reference radiographs (100). It is applied to standard 
radiographs in sixteen areas in both hands, eight areas in both wrists, and 
eight areas in both feet (106). 
The classification is the follow: 1) intact bony outlines and normal joint 
space; 2) erosion less than 1mm in diameter or JSN; 3) one or several small 
erosions, diameter more than 1mm; 4) marked erosions; 5) severe erosions, 
where there is usually no joint space left, and the original bony outlines are 
partly preserved; and, 6) mutilating changes, where the original bony 
outlines have been destroyed  (Table 4) (106).  
 
Table 4. Larsen method 
 
Classification Score 
Intact bony outlines and normal joint space 0 
Erosion less than 1mm in diameter or JSN  1 
One or several small erosions, diameter more than 1mm  2 
Marked erosions  3 
Severe erosions, where there is usually no joint space left, and the 
original bony outlines are partly preserved  
4 
Mutilating changes, where the original bony outlines have been destroyed 5 
32 joints scored 
Total maximum score: 160 
JSN: joint space narrowing.  
(Adapted from Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in 
long-term studies. The Journal of rheumatology. 1995;22(10):1974-5) 
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Sharp and Larsen scores are correlated significantly and the minimal 
clinically important difference is roughly 1% of the maximum for both of the 
methods (107). Overall, the Larsen method is more easily scored and less 
time-consuming when compared to the Sharp method (107).  
 
1.8.2. Disease activity measure 
Although radiographic evidence of disease progression is a useful and 
specific way to evaluate disease progression and the effectiveness of 
treatment, it is less useful for routine monitoring in the office (108). The 
development of routine standardized measures of disease activity allows a 
“treat-to-target” strategy using pharmacologic therapy (109). These targets 
permit physicians and patients to set goals for treatment (109). Furthermore, 
they provide clinically meaningful and reliable estimates of disease activity 
with interpretation of multiple data points simultaneously, are less 
susceptible to selection bias related to the reporting of a single 
measurement and are preferable for statistical analysis in studies for 
quantifying disease activity, even in the lower ends of the scales (110-112). 
Therefore, a number of disease activity indexes have been developed, based 
on expert panel recommendations, for use in clinical trials and the office 
setting to standardize definitions and guide treatment (109).  
Some of these commonly disease activity indexes used in daily practice 
are: 1) Disease Activity Score (DAS); 2) Disease Activity Score in twenty-eight 
joints (DAS28); 3) Simplified disease activity index (SDAI); 4) Clinical disease 
activity index (CDAI); 5) Patient activity score (PAS) and patient activity score-
II (PASII); and, 6) Routine assessment of patient index data (RAPID) (108, 113). 
From all of these methods, one of the most used in clinical practice is DAS28 
(108, 114).  
The DAS28 is calculated attending to four variables (4v) as described by 
Prevoo et al.: 1) 28 tender joints count (TJC); 2) 28 swollen joints count (SJC); 
3) ESR in the first hour (ranges from 0–100mm/h) or the CRP levels (range 
from 0.20–1440mg/L) (108, 113); and 4) patient global assessment of disease 
activity or global health on a visual analog scale (VAS) (114, 115) (Figure 8).  
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Figure 8. Twenty-eight regions used to the count of tender and swollen joints for Disease 
Activity Score 28. The joints used include: 2 in shoulder, 2 in elbow, 2 in wrist, 10 
metacarpophalangeal, 10 proximal interphalangeal and 2 in knee. 
(Adapted from The Institute for Continuing Healthcare Education. Disease activity score in 28 joints 
(DAS28)  [06 June 2014]. Available from: http://www.iche.edu/newsletter/DAS28.pdf) 
 
The DAS28 evaluation is carried out quarterly to semiannual and 
permits the disease activity interpretation in activity degrees as remission 
(DAS28≤2.6), low activity (2.6<DAS28<3.2), moderate activity (3.2<DAS28≤5.1) 
or high activity or uncontrolled disease (DAS28>5.1) (114). However, recent 
data from two large observational studies suggested that DAS28(CRP) scores 
tended to be lower than DAS28(ESR) scores and, thus, Inoue et al. suggested 
potential new thresholds for disease activity categories for DAS28(CRP) (116, 
117). 
Despite DAS28 have been extensively validated and endorsed by the 
ACR and EULAR for RA disease activity measurement in clinical trials and 
often considered the “gold standard” (113), some disadvantages are 
observed in clinical practice such as the need for a blood sample, time 
needed for physicians to perform joint counts, complicated mathematical 
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calculation of the composite score, and potential confusion from choosing 
among the multiple formulas available and interpreting into activity degrees 
(113). 
 
1.8.3. Health-related quality of life impact  
The ability to effectively measure health-related quality-of-life 
longitudinally is central to describing the impact of disease, treatment, or 
other insults upon the patient (118). 
The Health Assessment Questionnaire (HAQ) is one of the most widely 
used comprehensive, validated, patient-oriented outcome assessment 
instruments for establishing health outcome assessment as a quantifiable 
set of reliable, valid and responsive hard data points (118). It’s designed to 
capture prospectively and by protocol the long term influence of multiple 
chronic illnesses and to allow supplementation by additional measures for 
particular studies (118). The HAQ, that collects data on five generic patient-
centered health dimensions, which is a comprehensive outcome measure 
that assesses a hierarchy of patient outcomes in four domains: 1) disability; 
2) discomfort and pain; 3) adverse drug reactions (ADRs); and, 4) costs. 
Disability is assessed by the eight categories of dressing, arising, eating, 
walking, hygiene, reach, grip, and common activities (119, 120). Discomfort is 
determined by the presence of pain and its severity. Specific ADRs are 
classified according to their severity and whether the drug was stopped (119, 
120). Costs are divided into direct (e.g., hospitalization, surgery, nursing 
home care, physician and health worker visits and medications) and indirect 
costs (e.g., those associated with productive days lost for the employed, 
housewives, students and retired persons, and changes in lifestyle and 
activities for the patient and family) (119, 120). Death, while obviously not a 
self-report outcome, is a requisite part of the conceptual model of patient 
outcome (119).  
The HAQ is usually self-administered, but can also be given face-to-face 
in a clinical setting or in a telephone interview format by trained outcome 
assessors, and has been validated in these settings. The questionnaire is 
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typically mailed to patients every six months, and they are asked to complete 
it without additional instructions. Follow-up phone calls are sometimes 
needed to obtain missing data or to clarify ambiguous responses in the high-
quality research data applications (119). 
 
1.8.4. Limitations 
However, and unfortunately, the above described tools have their 
limitations, namely the existence of errors in self-assessment of disease 
activity, due to the presence of other diseases which leads to deviations from 
the "true" activity, and the variability among health professionals (91). These 
limitations can be minimized if professionals make use of various tools and 
promote patients education about the impact that other diseases may have 
in the perception of pain and impaired function of the joints (91). 
 
 
1.9. Disease Burden and Prognostic 
The complex pathophysiology of RA leads to a synovitis associated with 
hyperplasia of synovial cells, pannus formation, excess of synovial fluid, 
cartilage damage and bone erosion (1) (Figures 6 and 7).  
This inflammatory joint disease usually affects up to 80% of patients 
within one year of diagnosis and the eroded bone does not appear to be 
repaired, suggesting that the main goal should be to prevent this irreversible 
bone erosion (37, 89). The distinct pattern of bone and joint destruction in 
RA is translated in pain, stiffness (worse in morning) and swelling of 
involved joints, which difficult the daily living activities (1, 2). Additionally, 
there is also a persistent systemic inflammatory state that may promote a 
number of other extra-articular effects such lung fibrosis, osteoporosis, 
infections, and CV, hematological and GI diseases (31, 121, 122). These 
systemic complications related to the underlying disease process impact the 
average life expectancy of patients with RA (84). In accordance, life 
expectancy in females is reduced by ten years whereas in males is 
diminished by four years (123). Studies have demonstrated improvements in 
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survival rates over time (124, 125), however, others appointed that RA 
patients have not experienced improvements in survival rates over the past 
four decades, when compared to general population (126-128). No less 
important is the fact that about 20% of RA patients have approximately 2-
fold to 4-fold higher risk of developing affective disorders, such as 
depression and anxiety, than general population (129). Furthermore, RA 
affects not only the patient but also the society in general, since the disease 
represents great economic losses, mostly caused by work withdrawal due to 
failure or pain associated with the disease, loss of work productivity and 
constant use of health care services (130). With continuous joint damage, 
mostly irreversible, there is a greater inevitability of worsening disability, 
not only due directly to RA but also to her complications (Figure 9).  
 
 
 
 
Figure 9. Rheumatoid arthritis coexisting conditions. 
(Adapted from McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 
2011;365(23):2205-19) 
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1.10. Therapeutic Strategies 
An earlier detection of RA and a rapid effective and more aggressive 
therapeutic institution are the key factors to achieve the disease remission 
and improve survival rates (81, 124, 125). Some data suggest that definitive 
treatment should be administered within three months of the onset of 
disease (131). From the foregoing, it is understood that the later treatment is 
started, the greater the extent of damage is later scored (131).  
Normally, RA treatment is directed to control the inflammation and the 
pain, and ultimately, to retard or limit the joint destruction progression. 
Thus, the treatment is based both in non-pharmacologic and pharmacologic 
strategies (131) (Figure 10).   
 
 
 
 
Figure 10. Non-pharmacologic and pharmacologic treatment strategies for rheumatoid 
arthritis. 
DMARDs: disease-modifying antirheumatic drugs; NSAIDs: non-steroidal anti-inflammatory drugs. 
 
1.10.1. Non-Pharmacologic treatment 
Non-pharmacologic treatment includes a wide range of modalities, such 
exercise therapy, physical modalities, assistive and adaptation devices and 
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self-management interventions (132). Nowadays, the large majority of RA 
patients has been told to use and tried at least one type of non-
pharmacologic treatment (132).  
 
1.10.1.1. Exercise therapy 
The objectives of exercise therapy in patients with RA are the 
restoration, preservation or improvement of joint range of motion, muscle 
strength, aerobic capacity and the performance of specific activities or skills 
(133).  
 
1.10.1.2. Physical modalities 
The physical modalities include electro-physical modalities (e.g. 
thermotherapy, electrotherapy, laser therapy and spa therapy) and manual 
therapy (e.g. massage), used to facilitate and restore movement and function 
(134).  
 
1.10.1.3. Assistive and adaptation devices 
Assistive and adaptation devices of the physical environment (e.g. 
orthoses and special shoes and inserts) are frequently prescribed to ease 
pain, overcome joint limitations, compensate for muscle weakness and 
enhance safety with the ultimate aim to prevent or reduce dependence (134).  
 
1.10.1.4. Self-management interventions 
Self-management interventions are seen as key components of 
rheumatologic care, in particular of RA (135), aimed to directly and/or 
indirectly improve health-related quality of life, healthcare utilization and 
perceived self-efficacy (136-139). These include: 1) educational and 
psychosocial interventions, such as, techniques to deal with problems and 
promotion of adequate decision making; 2) lifestyle interventions, such as 
appropriate exercise for maintaining and improving strength, flexibility and 
endurance, and making adequate nutrition; and, 3) treatment interventions 
for appropriate use of medications (136-139). 
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1.10.2. Pharmacologic treatment 
The pharmacologic management of RA rests primarily on the use of 
symptomatic therapy, supplements and DMARDs. 
 
1.10.2.1. Symptomatic therapy 
Usually, as symptomatic therapy, are used the non-steroidal anti-
inflammatory drugs (NSAIDs) and corticosteroids (24). Non-steroidal anti-
inflammatory drugs are a heterogeneous group of drugs aimed for 
controlling the inflammation and pain of affected joints by inhibition of 
cyclooxygenase-2 (COX-2) (24). Usually they are administered orally in low-
doses and for a short period of time in order to minimize the possible 
occurrence of undesirable ADRs (24). Corticosteroids are fast action anti-
inflammatory drugs since are responsible for decreasing cytokines synthesis 
and inhibiting lymphocyte function (140). Nevertheless, and because its 
ADRs, they are generally administered orally in low-dose (≤ 5mg), which 
allows their continuously use over several years (140).  
 
1.10.2.2. Supplements 
Corticosteroids chronic use requires supplementation with calcium and 
vitamin D to circumvent osteopenia appearance (93, 141). Methotrexate 
(MTX) use requires folic acid supplementation to prevent the occurrence of 
ADRs-related to MTX, and folic acid is usually administered twenty-four 
hours after MTX administration (142, 143). 
 
1.10.2.3. Disease-modifying antirheumatic drugs 
Disease-modifying antirheumatic drugs are commonly characterized by 
their capacity to reduce or reverse signs and symptoms, disability, 
impairment of quality of life, inability to work, and progression of joint 
damage and thus to interfere with the entire disease process (144). They are 
a heterogeneous drugs group that form two major classes: synthetic 
chemical compounds  - synthetic DMARDs (sDMARDs) - and biological agents 
- biological DMARDs (bDMARDs), which could be used in monotherapy or in 
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combination (1). Some conventional sDMARDs (csDMARDs) include chemical 
agents such as MTX, sulfasalazine (SSZ) hydroxychloroquine (HCQ), 
cyclosporine (CCP) and leflunomide (LEF), whereas targeted sDMARD 
(tsDMARD) include new chemical agents such as tofacitinib (1, 145). 
Regarding to bDMARDs, these can be divided into biological originator 
DMARDs (boDMARDs) that include the TNF- inhibitors (adalimumab, 
certolizumab pegol, etanercept, golimumab and infliximab), non-TNF- 
inhibitors (tocilizumab, abatacept, rituximab and anakinra), and biosimilars 
DMARDs (bsDMARDs), such as the recently approved bs-infliximab (145, 
146). 
Despite all of these drugs, the most used and cost-effective DMARD for 
RA treatment is MTX (147). 
 
 
2. METHOTREXATE 
This section provides information about Methotrexate historical aspects, 
chemical characteristics, pharmacokinetics and pharmacodynamics. 
 
 
2.1. Historical Aspects 
The introduction of high-dose MTX in the treatment regimen of children 
with acute lymphoblastic leukemia by Sidney Farber in 1948 resulted from 
the observation that folic acid antagonists interfered with the normal growth 
of cells (148). Only in 1951, Gubner demonstrated that low-dose MTX (up to 
25mg/w) could be effective in controlling disease activity both in patients 
with psoriatic arthritis and RA (149). In 1988 this drug was approved by US 
Food and Drug Administration (FDA) for RA treatment. In the late of 1980s, 
low-dose MTX started to be used in juvenile idiopathic arthritis (JIA) patients 
with polyarthritis (150) and in ankylosing spondylitis (AS) (151). Moreover, 
low-dose MTX have been used in other rheumatic diseases, such as Felty’s 
syndrome (152), ANCA-associated vasculitis (153), polymyalgia 
rheumatic/giant cell arthritis (GCA) (154), inflammatory myopathy (155) and 
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systemic lupus erythematosus (SLE) (156), and also in dermatological 
diseases, such as psoriasis (157). 
 
 
2.2. Chemical Characteristics 
Methotrexate (2,4-diamino-N10-methyl propyl glutamic acid), a 
Biopharmaceutical Classification Systems class III drug, is an antifolate 
negatively charged drug with low permeability (ClogP = 0.53) and poor 
aqueous solubility (0.01mg/ml). Structurally, it’s composed by three parts as 
follows: 1) pteridine ring, 2) p-aminobenzoic acid and 3) glutamic acid (158, 
159) (Figure 11).  
 
 
 
Figure 11. Methotrexate chemical structure. Methotrexate is composed by a pteridine ring, p-
aminobenzoic acid plus glutamic acid.  
 
Methotrexate is a weak bicarboxylic acid (pKa value = 4.7-5.5) with a 
molecular weight of 454.5g/mol (C20H22N8O5), structurally similar to folic acid, 
differing only by the substitution of a hydroxyl group for an amine in the 
pteridine ring (at C4 carbon) and the addition of a methyl group on tenth 
nitrogen of p-aminobenzoic acid (159-161) (Figure 12).  
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Figure 12. Chemical structures of Methotrexate (A) and Folic Acid (B). Methotrexate and Folic 
Acid chemical structures are similar, differing in the pteridine ring (by substitution of a 
hydroxyl group for an amine) and on the 10(th) nitrogen of p-aminobenzoic acid (by addition 
of a methyl group).  
 
 
2.3. Pharmacokinetics 
Pharmacokinetics (PK) describes what the body does to a drug. 
Pharmacokinetics parameters result from the absorption, distribution, 
metabolism and excretion of drugs and provide information about the rates 
of these processes and systemic exposure of drugs (162).  
The bioavailability of MTX is relatively high but can vary depending of 
the dose and administration route (enteral or parental) (163, 164). MTX 
absorption in gastrointestinal tract (GIT) occurs via proton-dependent active 
transport, which is partially shared with folic acid (163). Methotrexate 
follows saturable (Michaelis-Menten) kinetics and, thus, its absorption 
becomes dose dependent in GIT (165). Consequently, at 7.5mg/w, enteral and 
parenteral absorption is the same, but at doses of 15mg/w or more, enteral 
absorption may decrease by as much as 30% compared with parenteral 
dosing (163, 166). Bioequivalent doses of MTX were compared and mean 
intramuscular bioavailability was nearly 76% compared with 33% via per os 
(PO) route (167). Therapeutic and toxic plasma concentrations of MTX are 
0.005 and 0.01μg/ml in low-dose therapy; and, on high-dose therapy, those 
concentrations are 2.27 and 4.54μg/ml at 24h, 0.23 and 0.45μg/ml at 48h, 
and 0.02 and 0.04μg/ml at 72h (168). Methotrexate shows high inter- and 
intrapatient variability in both serum and cerebrospinal fluid (CSF) (169). Due 
to its erratic GI absorption, it has been suggested that doses 25mg should 
be administered parenterally (170). Factors that influence its absorption 
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include food intake, oral non-absorbable antibiotics, flow transit through GIT 
(such diarrhea and constipation) and intestinal pathology (163, 170, 171). 
After absorption, 10% of MTX is converted in the liver, by aldehyde oxidase, 
to 7-hydroxymethotrexate (7-OH-MTX), an active metabolite (161). 
Approximately 50% of MTX is albumin-bound, whereas 90% to 95% of 7-OH-
MTX is albumin-bound (163). Nevertheless, other drugs such NSAIDs alter 
MTX and 7-OH-MTX binding to plasmatic proteins and impair MTX hepatic 
metabolism (161). The half-life of MTX in the serum ranges from 6 to 8 hours 
after administration and, MTX is undetectable in the serum by 24 hours 
(161). The majority of both MTX and 7-OH-MTX is excreted in the urine, 
although a small portion is also excreted in the bile (161, 163, 172). Renal 
clearance is likely due to a combination of filtration and secretion in the 
proximal tubule with subsequent reabsorption in the distal tubule (173). 
Therefore, renal insufficiency can lead to toxicity caused by impaired 
clearance of MTX. Excretion of MTX is reduced by interactions with weak 
organic acids such as NSAIDs (161). These interactions are generally only 
clinically relevant at the typical higher weekly maintenance MTX dosage 
range (up to 25mg/w) but not at the lower doses, commonly used to begin 
RA treatment (166).  
During PK processes, a drug molecule passes through several biological 
membranes. The extent of drug movement through these membranes is 
generally affected by the physicochemical properties of a drug, namely size, 
lipophilicity and charge (or degree of ionization) (162). In addition, 
membrane transporters have a significant role in facilitating or preventing 
drug movement (174). Transporters may be classified as influx (uptake into 
cell) and efflux (out of cell) transporters, which are typically located either at 
the basolateral or apical membrane in polarized cells. Interplay of influx and 
efflux transporters together with phase I and II metabolism may be required 
for the sequential traverse of the basolateral and apical membranes (175). 
Therefore, drug transporters can be regarded as completing the phase I and 
II enzyme-based detoxification system; drug uptake delivers the drug to the 
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detoxification system to facilitate metabolism, whereas drug efflux 
decreases the load on detoxification enzymes (176). 
 
2.3.1. MTX cellular transport 
In enterocytes, at apical membrane, MTX is absorbed through active 
transport mediated predominately by solute carrier (SLC) family 19 member 
1 (SLC19A1), followed by SLC family 46 member 1 (SLC46A1) (161, 163, 177).  
Methotrexate may also bind, with lower affinity than folic acid, to folate 
receptor alpha (FOLR1), which transports MTX via endocytosis (178). 
Methotrexate efflux from enterocytes can occur to intestinal tract lumen 
mediated by adenosine triphosphate (ATP)-binding cassette (ABCs) 
transporters, i.e., by ATP-binding cassette sub-family C member 2 (ABCC2), 
ATP-binding cassette sub-family B member 1 (ABCB1) and ATP-binding 
cassette sub-family G member 2 (ABCG2); or to bloodstream by ATP-binding 
cassette sub-family C member 1 (ABCC1) and ATP-binding cassette sub-
family C member 3 (ABCC3) (179). In bloodstream, MTX can be distributed for 
hepatocytes or renal cells (148). Hepatic uptake of MTX involves SLC19A1, 
SLC organic anion transporter family member 1B1 (SLCO1B1) and SLCO 
family member 1B3 (SLCO1B3) (173). Most of this drug, inside the 
hepatocytes, re-enters into bloodstream by ABCC3 and ABC sub-family C 
member 4 (ABCC4) and, the remaining, is oxidized to 7-OH-MTX or is excreted 
into the bile duct by ABCC2, ABCB1 and ABCG2 (173, 174). Systemic clearance 
of MTX happens primarily through renal glomerular filtration and active 
secretion over the proximal tubular cells (173). Some renal transporters have 
affinity to MTX and 7-OH-MTX, which allow their entrance in renal cells by 
solute carrier family 22 member 6 (SLC22A6) and solute carrier family 22 
member 8 (SLC22A8), in basolateral membrane, and by SLC family 22 
member 11 (SLC22A11) and SLCO family member 1A2 (SLCO1A2), in apical 
membrane (179, 180). Moreover, SLC family 16 member 7 (SLC16A7) has been 
described as having a moderate to low expression in plasma membrane of 
kidney but its function on MTX transport remains unclear (181, 182). 
Furthermore, MTX excretion through urinary tract can be mediated by ABCB1, 
ABCC2, ABCC4 and ABCG2 (147, 161, 180) (Figure 13).  
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Figure 13. Methotrexate transporters cells location and representation of their influx and/or 
efflux function. 
ABCB1: adenosine triphosphate (ATP)-binding cassette sub-family B member 1; ABCC1: adenosine 
triphosphate (ATP)-binding cassette sub-family C member 1; ABCC2: adenosine triphosphate (ATP)-binding 
cassette sub-family C member 2; ABCC3: adenosine triphosphate (ATP)-binding cassette sub-family C 
member 3; ABCC4: adenosine triphosphate (ATP)-binding cassette sub-family C member 4; ABCG2: 
adenosine triphosphate (ATP)-binding cassette sub-family G member 2; ATP: adenosine triphosphate; 
FOLR1: folate receptor alpha; SLC16A7: solute carrier family 16 member 7; SLC19A1: solute carrier family 
19 member 1; SLC22A6: solute carrier family 22 member 6; SLC22A8: solute carrier family 22 member 8; 
SLC22A11: solute carrier family 22 member 11; SCL46A1: solute carrier family 46 member 1; SLCO1B1: 
solute carrier organic anion transporter family member 1B1; SLCO1B3: solute carrier organic anion 
transporter family member 1B3; SLCO1A2: solute carrier organic anion transporter family member 1A2. 
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2.4. Pharmacodynamics  
Pharmacodynamics (PD) describes the extent and time course of the 
effects of drugs on physiological and pathophysiological processes (162). 
The relationship between drug concentration and drug effect is important in 
determining PD (162). Thus, once inside the cells MTX is metabolized to 
methotrexate polyglutamates (MTXPGs) by a sequential addition of glutamic 
acid residues via the enzyme folylpolyglutamate synthetase (FPGS) (163, 
183). Nevertheless, gamma-glutamyl hydrolase (GGH) enzyme removes the 
glutamic acid residues of MTXPGs and, consequently, MTX can be 
transported out of the cells by efflux transporters (163). Polyglutamation of 
MTX enhances the intracellular retention of MTX promoting the inhibition of 
folate, methionine and adenosine pathways and also of purines and 
pyrimidines de novo synthesis, crucial for the MTX anti-inflammatory and 
antiproliferative effects (161, 163, 184) (Figure 14) (see 2.4.1. MTX action 
mechanism: the role of the principal pathways).   
 
 
 
Figure 14. Methotrexate pharmacodynamics. Left panel represents the intervention of MTX in 
de novo pyrimidine synthesis, folate and methionine pathways. Right panel shows the effect 
of MTX in de novo purine synthesis adenosine pathway. These action mechanisms contribute 
to MTX antiproliferative and anti-inflammatory effects. 
ABC: adenosine triphosphate (ATP)-binding cassette; ADORA: adenosine receptor; FPGS: folylpolyglutamate 
synthetase; GGH: gamma-glutamyl hydrolase; MTX: methotrexate; MTXPG: methotrexate polyglutamate; 
SLC: solute carrier. 
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Other proposed mechanisms include: 1) modifications in the expression 
of cellular adhesion molecules; 2) reduction of proinflammatory cytokines 
production; 3) apoptosis induction, limiting synovial tissue hyperplasia; and, 
4) alterations in humoral responses and in bone formation (161, 185).  
 
2.4.1. MTX action mechanism: the role of the principal pathways  
Methotrexate pharmacological effects (antiproliferative and anti-
inflammatory effects) are primarily attributed to its ability to inhibit multiple 
enzymes involved in folate pathway and de novo nucleotides synthesis (179). 
This inhibitory capacity is then reflected in other pathways, such methionine 
and adenosine pathways, which along will contribute to MTX action 
mechanism (179).  
 
2.4.1.1. Folate and Methionine Pathways 
Methotrexate effects are achieved by MTX and MTXPGs high affinity 
binding to dihydrofolate reductase (DHFR) (186-188) leading to its inhibition 
and, consequently, preventing the conversion of dihydrofolate (DHF) to 
tetrahydrofolate (THF). Since THF is essential for the generation of folate 
cofactors, required for de novo purine and pyrimidine synthesis (161, 189) 
(see De novo nucleotides synthesis pathways), lower THF levels result in the 
depletion of metabolically active intracellular folates, accumulation of 
homocysteine and reduction in methionine (161, 189). Thus, is hypothesized 
that MTX, by decreasing THF levels, indirectly increases ROS, leading to 
apoptosis (185). Furthermore, THF can be transformed into 10-
formyltethrahydrofolate (10-CHO-THF) by methylenetetrahydrofolate 
dehydrogenase 1 (MTHFD1), which can convert 10-CHO-THF into 5,10-
methenyltetrahydrofolate (5,10-CH-THF) and then into 5,10-
methylenetetrahydrofolate (5,10-MTHF). The 5,10-MTHF can regenerate the 
THF via serine hydroxymethyltransferase 1 (SHMT1) or can be converted to 
5-methyltetrahydrofolate (5-MTHF) via methylenetetrahydrofolate reductase 
(MTHFR). The conversion of 5-MTHF to THF is mediated by methionine 
synthase (MS), in the presence of methylcob(III)alamin, with simultaneously 
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remethylation of homocysteine to methionine (190, 191). Additionally, 
methionine synthase reductase (MTRR), maintains adequate levels of 
methylcob(III)alamin, the activated cofactor for MS. Additionally, methionine 
can be transformed into S-adenosyl methionine (SAM), catalysed by 
methionine adenosyltransferase (MAT), and then to S-adenosyl homocysteine 
(SAH), catalysed by methyltransferases (190). Furthermore, S-
adenosylhomocysteinase (AHCY) catalyses the reversible hydrolysis of SAH 
to adenosine and homocysteine without added cofactors, leading to 
accumulation of homocysteine and adenosine, and, reduction in methionine 
(192) (Figure 15). 
  
 
 
 
Figure 15. Methotrexate action mechanism - Folate and Methionine Pathways.  
5-MTHF: 5-methyltetrahydrofolate; 5,10-MTHF: 5,10-methylenetetrahydrofolate; 5,10-CH-THF: 5,10-
methenyltetrahydrofolate; 10-CHO-THF: 10-formyltetrahydrofolate; ABC: adenosine triphosphate (ATP)-
binding cassette; AHCY: S-adenosylhomocysteinase; DHF: dihydrofolate; DHFR: dihydrofolate reductase; 
FPGS: folylpolyglutamate synthetase; GGH: gamma-glutamyl hydrolase; MAT: methionine 
adenosyltransferase; MS: methionine synthase; MTHFD1: methylenetetrahydrofolate dehydrogenase 1; 
MTHFR: methylenetetrahydrofolate reductase; MTRR: methionine synthase reductase; MTX: methotrexate; 
MTXPG: methotrexate polyglutamate; SAH: S-adenosyl homocysteine; SAM: S-adenosyl methionine; SHMT1: 
serine hydroxymethyltransferase 1; SLC: solute carrier; THF: tetrahydrofolate.  
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2.4.1.2. De novo nucleotides synthesis pathways 
Nucleotides (pyrimidines and purines) are crucial for DNA and RNA 
synthesis as well as for additional cellular processes where they, for 
example, serve as energy carriers or signaling molecules cofactors, 
necessary for normal cellular proliferation (193-195). Intracellular nucleotide 
pools are controlled by de novo synthesis pathways, where nucleotides are 
synthesized from small metabolites, that work in coordination with salvage 
pathways, in which nucleotides are synthesized from intermediates in the 
degradative pathway for nucleotides (193). Salvage pathways are used to 
recover bases and nucleosides that are formed during DNA and RNA 
degradation. This is important in some organs because some tissues cannot 
undergo de novo synthesis (193).  
 
Pyrimidine synthesis pathway 
Methotrexate antiproliferative effect is partly achieved by intracellular 
inhibition of thymidylate synthase (TS) by MTXPGs (161, 163, 196). 
Thymidylate synthase is a key protein for the de novo pyrimidine synthesis 
and is responsible for the simultaneous conversion of deoxyuridine 
monophosphate (dUMP) and 5,10-MTHF to deoxythymidine monophosphate 
(dTMP) and DHF. Subsequently, the dTMP is phosphorylated to 
deoxythymidine triphosphate (dTTP) and used for the DNA synthesis and 
repair (161, 197) (Figure 16).  
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Figure 16. Methotrexate action mechanism - Pyrimidine Pathway. 
5,10-MTHF: 5,10-methylenetetrahydrofolate; ABC: adenosine triphosphate (ATP)-binding cassette; DHF: 
dihydrofolate; dTMP: deoxythymidine monophosphate; dTTP: deoxythymidine triphosphate; dUMP: 
deoxyuridine monophosphate; FPGS: folylpolyglutamate synthetase; GGH: gamma-glutamyl hydrolase; 
MTX: methotrexate; MTXPG: methotrexate polyglutamate; SLC: solute carrier; TS: thymidylate synthase. 
 
Purine synthesis pathway 
The de novo purine synthesis pathway inhibition by MTXPGs 
contributes to MTX antiproliferative and anti-inflammation effects (194, 195). 
Methotrexate polyglutamates inhibits three enzymes of this pathway as 
follow: 1) phosphoribosyl pyrophosphate amidotransferase (PPAT); 2) 
glycineamide ribonucleotide formyl transferase (GART); and, 3) 5-
aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC) (194, 
195) (Figure 17). Phosphoribosyl pyrophosphate amidotransferase is 
responsible for catalyzing the first step of the de novo purine synthesis 
pathway by the simultaneous conversion of 5-phosphoribosyl-1-
pyrophosphate (PRPP) and glutamine into 5-phosphoribosyl amine (PRA) and 
glutamate, respectively (198). The 5-phosphoribosyl amine is converted into 
glycineamide ribonucleotide (GAR) by incorporation of glycine mediated by 
GAR synthase (GARS) (199). Glycineamide ribonucleotide formyl transferase, 
also inhibited by MTXPGs, simultaneously converts GAR into formyl 
glycineamide ribonucleotide (FGAR) and 10-CHO-THF into THF. The FGAR is 
then used in several reactions still being converted into aminoimidazole 
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carboxamide adenosine ribonucleotide (AICAR). The AICAR is converted to 
formyl-AICAR (FAICAR) by ATIC and, simultaneously, 10-CHO-THF is 
converted into THF (200) (Figure 17). The ATIC inhibition by MTXPGs seems 
to be stronger then PPAT and GART inhibition, contributing to intracellular 
accumulation of AICAR, which consequently will lead to adenosine increased 
levels (184, 200).  
 
 
  
Figure 17. Methotrexate action mechanism - Purine Pathway. 
10-CHO-THF: 10-formyltetrahydrofolate; ABC: adenosine triphosphate (ATP)-binding cassette; AICAR: 
aminoimidazole carboxamide adenosine ribonucleotide; ATIC: 5-aminoimidazole-4-carboxamide 
ribonucleotide transformylase; FAICAR: formyl-aminoimidazole carboxamide adenosine ribonucleotide; 
FGAR: formyl glycineamide ribonucleotide; FPGS: folylpolyglutamate synthetase; GAR: glycineamide 
ribonucleotide; GARS: glycineamide ribonucleotide synthase; GART: glycineamide ribonucleotide formyl 
transferase; GGH: gamma-glutamyl hydrolase; MTX: methotrexate; MTXPG: methotrexate polyglutamate; 
PPAT: phosphoribosyl pyrophosphate amidotransferase; PRA: 5-phosphoribosyl amine; PRPP: 5-
phosphoribosyl-1-pyrophosphate; SLC: solute carrier; THF: tetrahydrofolate.  
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2.4.1.3. Adenosine pathway 
An alternative mechanism for MTX anti-inflammatory effect has gained 
favor, since has been supported by in vitro, in vivo, and clinical data studies 
that theorize that adenosine, a potent anti-inflammatory agent, is released in 
high concentrations from cells after treatment with MTX (166, 184, 201, 202). 
Literature hypothesizes that methionine pathway (192) (Figure 15) and AICAR 
accumulation, as a consequence of ATIC inhibition (200) (Figure 17), are the 
major responsible for adenosine increased levels. Accumulated AICAR 
inhibits adenosine monophosphate deaminase 1 (AMPD1) and adenosine 
deaminase (ADA) (184, 200). Since ADA catalyzes the hydrolysis of adenosine 
into inosine and AMPD1 catalyzes the deamination of adenosine 
monophosphate (AMP) to inosine monophosphate (IMP), the inhibition leads 
to an accumulation of AMP and adenosine (184, 200). Intracellular 
accumulation of AMP and adenosine results in an increase of these 
compounds in the extracellular space, where AMP is converted to adenosine, 
which binds to the specific adenosine receptor subtypes A1, A2a and A2b 
(ADORA1, ADORA2a and ADORA2b, respectively). Probably, there will be 
preponderance of ADORA2a receptor pathway compared to the other 
subtypes (200), yielding an increase of cyclic-AMP (cAMP) in the cell. The 
increased cAMP leads to immunosuppression by decreasing the secretion of 
proinflammatory mediators, such TNF- and interferon-gamma (IFN-) (189, 
203). 
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Figure 18. Methotrexate action mechanism - Adenosine Pathway. 
10-CHO-THF: 10-formyltetrahydrofolate; ABC: adenosine triphosphate (ATP)-binding cassette; ADA: 
adenosine deaminase; ADORA: adenosine receptor; AHCY: S-adenosylhomocysteinase; AICAR: 
aminoimidazole carboxamide adenosine ribonucleotide; AMP: adenosine monophosphate; AMPD1: AMP 
deaminase 1; ATIC: 5-aminoimidazole-4-carboxamide ribonucleotide transformylase; ATP: adenosine 
triphosphate; cAMP: cyclic-adenosine monophosphate; FAICAR: formyl-aminoimidazole carboxamide 
adenosine ribonucleotide; FPGS: folylpolyglutamate synthetase; GGH: gamma-glutamyl hydrolase; IMP: 
inosine monophosphate; MTX: methotrexate; MTXPG: methotrexate polyglutamate; SAH: S-adenosyl 
homocysteine; SLC: solute carrier; THF: tetrahydrofolate.  
 
With a better knowledge of the MTX action mechanism it’s conceivable 
that it is most likely that some combination of all of these mechanisms is 
responsible for its potent anti-inflammatory and antiproliferative effects 
(201) (Figure 19). 
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2.5. Adverse Drug Reactions and Contraindications  
Toxicity development related to MTX could be caused by several factors 
such as MTX dose and administration route (163, 164); erratic GI absorption 
(170); concomitant administered drugs or diseases that conditioned MTX 
hepatic metabolism and/or renal clearance (161); and, cellular folate status 
(204). Since the cell populations that divide more require more folates, and 
folates are important to prevent toxicity occurrence, those cells are most 
vulnerable to toxicity (142, 143, 204). Therefore, the first and most affected 
organic systems are the gastrointestinal and hematopoietic, as also skin and 
subcutaneous tissues and testicular tissue involved in spermatogenesis 
(205). 
Considering low-dose MTX, the observed ADRs are minor and the most 
frequent ADRs being gastrointestinal disorders (particularly nausea and 
anorexia) (206), hepatobiliary disorders (particularly transaminases serum 
elevation), and blood and lymphatic system disorders (207, 208). Not 
frequently, respiratory, thoracic and mediastinal disorders, as also infections 
and infestations can occur (209). 
Because of teratogenic effect, MTX in contraindicated in pregnancy and 
breastfeeding (208). Furthermore, MTX should be used with precaution in the 
event of liver disorder and/or renal insufficiency (208).  
 
 
3. PHARMACOGENOMICS AND PREDICTORS OF THERAPEUTIC OUTCOME 
This section describes the potential of Pharmacogenomics moving 
towards to Personalized Medicine in Rheumatoid Arthritis. 
 
 
Personalized medicine is based on using an individual's genetic profile 
to make the best therapeutic choice by facilitating predictions about whether 
that person will benefit from a particular medicine or to be prone to suffer 
serious side effects (210). The aim of personalized medicine is based on five 
assumptions (Figure 20).  
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Figure 20. Personalized medicine assumptions.  
 
Drugs are generally tested on a large population of people and the 
average response is reported. This sort of evidence-based medicine (that is, 
medical decision making based on empirical data) relies on the law of 
averages; personalized medicine, on the other hand, recognizes that there 
are not two patients that are alike and, thus different therapeutic outcomes 
are possible (210). These inter- and intrapatient variability will define if the 
drug is safe and effective, safe and not-effective, unsafe and effective, or 
unsafe and not effective (211).  
Since not all patients benefit from specific therapies, there is a strong 
and unmet need for pretreatment predictions on therapy outcome (211). This 
concept of personalizing treatment has raised interest for the discovery of 
clinically applicable pretreatment biomarkers to allow predictions on 
outcome before the start of treatment (210).  
The study of individual patient therapeutic outcomes to drugs, either in 
accordance to clinical response and ADRs occurrence using genomic 
information is carried by Pharmacogenomics (PGx) (211-213). Together, PGx 
and personalized medicine aim to get drugs simultaneously safe and 
effective (Figure 21).  
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Figure 21. Drug therapeutic outcome profiles.   
 
When a gene variant is associated with a particular therapeutic outcome 
in a patient, there is the potential for making clinical decisions based on 
genetics, for example by adjusting the dosage or changing the 
administration route. Scientists assess gene variants affecting an individual's 
therapeutic outcome the same way they assess gene variants associated with 
diseases: by identifying genetic loci associated with known drug therapeutic 
outcomes, and then testing individuals whose therapeutic outcome is 
unknown (210). 
With the completion of the Human Genome Project, anticipation was 
high that genetic information would radically improve medicine, that ADRs 
would be more predictable, and that patients could be screened for likely 
drug clinical responses. But thus far, progress has been much slower than 
what the initial excitement suggested. A great deal of this delay relates to 
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the fact that an individual's response to drugs is multifactorial, resulting 
from multiple gene and environmental interactions. Modern approaches 
already include multigene analysis or whole-genome single nucleotide 
polymorphism (SNP) profiles, and these approaches are just coming into 
clinical use for drug discovery and development (213).  
In rheumatology, genes and gene signatures may be associated with 
therapeutic outcome variability among patients (213). Indeed, RA patients do 
not form a homogenous population and several clinical subsets of RA, such 
as erosive versus non-erosive, anti-CCP seropositive versus seronegative, 
progressive versus mild-course, have been identified. Factors that possibly 
contribute to this variability include: 1) clinicopathological variables, which 
can be divided into patient-related (e.g. age, gender, ethnicity and 
comorbidities), disease-related (e.g. duration, activity, disability and 
biomarkers) and treatment-related (e.g. compliance, dose and concomitant 
drugs used); and 2) genetic factors, such genetic polymorphisms implicated 
in key MTX pathway genes (Figure 22). 
 
 
 
Figure 22. Factors that possibly influence Rheumatoid Arthritis disease course and 
Methotrexate therapeutic outcome.  
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Therefore, over the past decade, numerous PGx studies have been 
undertaken to decipher associations between polymorphisms in genes 
encoding proteins involved in MTX carrier-mediated transport systems 
and/or intracellular pathways with MTX therapeutic outcome in RA. 
The literature reported PGx studies analyzing the association with MTX 
therapeutic outcome in RA and grouped by MTX pathways are described 
below.  
 
 
3.1. Influx Carrier-Mediated Transport Pathway & Pharmacogenomics 
 
SLC19A1 
 
Reduced folate carrier protein (RFC1) or folate transporter (FOLT) is 
encoded by SLC19A1, located on chromosome 21q22.3 (214). It is a cell 
surface transmembrane protein and a bidirectional transporter of primarily 
reduced folates, including MTX, ubiquitously expressed in many tissues, 
showing particularly high expression in absorptive tissues (intestine, kidney 
and placenta) either on apical and/or basolateral membranes (215). The 
rs7499 leads to a change of a guanine (G) into an adenine (A) at position 16 
(SLC19A1 G*16A), and occurs in the 3´-untranslated region (UTR), thought to 
be important in messenger RNA (mRNA) stability, localization and 
translational efficiency (216). Despite there are no functional studies on this 
SLC19A1 variant, there is one study in RA patients demonstrating an 
association between A allele and non-response to MTX, but no associations 
were related to ADRs occurrence (217). The rs1051266 is the most studied 
variation in SLC19A1 and is characterized by a substitution of a G by an A at 
position 80, leading to the change of Arg into histidine (His) at codon 27 in 
the first transmembrane domain, a region implicated to carrier function 
(218). Literature described G homozygotes as associated with lower MTX 
influx activity in lymphocytes (219) and decreased MTXPGs levels in 
erythrocytes (220). Studies in RA patients, analyzing the impact of this SNP in 
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MTX therapeutic outcome, demonstrated an association of A homozygotes 
and A allele with better response to MTX (221-223) and for MTX-related 
overall toxicity (224, 225). Additionally, other studies demonstrated no 
associations with clinical response and/or toxicity to low-dose MTX (183, 
224, 226-233). The rs1131596 leads a change of T into C in 5´UTR of 
SLC19A1, which is thought to modify gene transcription regulatory 
mechanisms, since it was found in the putative consensus sequence of the 
activating protein-1 transcription factor enhancer (228). Functional studies in 
RA patients demonstrated that C homozygotes were associated with a 
decreased SLC19A1 expression and influx capability (228) and, literature 
describes a trend for lower SLC19A1 expression in lymphoblastic cell lines 
related with C carriers (225). Regarding the influence in MTX therapeutic 
outcome, Bohanec Grabar et al. associated C carriers with a decreased risk 
for MTX therapy discontinuity, due to overall toxicity and infections in RA 
(225), but others showed no association with therapeutic outcome (228). The 
rs2838956 polymorphism, characterized by a substitution of an A for a G, is 
located in the fifth intron at position 707 (225) and its impact is currently 
unknown. Thus, functional studies are needed to evaluate the potential of 
this SNP on ribonucleic acid splicing, which may affect the protein structure 
and function (234). Nevertheless, there are studies relating this variant with 
MTX therapeutic outcome in RA: while Owen et al. associated G allele with 
non-response to MTX but not with toxicity (217); Bohanec Grabar et al. 
demonstrated that A allele has a trend to skin and subcutaneous tissue 
disorders, but no associations were observed regarding clinical response to 
MTX (225).  
 
SLC46A1 
 
Proton-coupled folate transporter/heme carrier protein 1 (PCFT/HCP1), 
is encoded by SLC46A1, located on chromosome 17q11.2 and mostly 
expressed in apical membrane of small-intestine and kidney cells, acting as a 
key transporter for normal folate absorption and homeostasis (177). The 
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rs2239907 is characterized by a change of an A into a G at position 928 
(A928G) in the 3´UTR region, which is reported as important for mRNA 
stability and translational efficiency (214, 216). The impact of this variant in 
SLC46A1 is currently unknown but Kato et al. investigated the role of this 
SNP in MTX therapeutic outcome, and found no significant associations with 
clinical response (231).  
 
SLCO1B1 
 
Liver-specific organic anion transporter 1 (LST1) or sodium-independent 
organic anion-transporting polypeptide 2 (OATP-2) is a bidirectional 
transporter with twelve transmembrane domains encoded by SLCO1B1 
located on chromosome 12p12 (235). It is mainly expressed in basolateral 
membrane of hepatocytes and plays a key role in the uptake of a wide 
variety of endogenous and exogenous anionic compounds, including MTX 
(236). Methotrexate hepatic uptake via SLCO1B1 was demonstrated as the 
major pathway for MTX clearance from systemic circulation (237). Moreover, 
SLCO1B1 mRNA has been detected also in other tissues, including small 
intestinal enterocytes (238). The rs2306283 is a common variant in SLCO1B1 
that results in a change of A into a G at position 88 and, substitution of 
asparagine into aspartate (Asp) at position 130 (235). In vitro studies 
associated G homozygotes with an increased transport activity for MTX (237) 
and Kato et al. showed no associations with MTX clinical response in RA 
(231). The rs4149056 is characterized by a change of a T into a C at position 
521 leading to an amino acid substitution of valine (Val) into an alanine (Ala) 
at codon 174 (235). The C allele was associated with a loss-of-function 
phenotype, resulting in a decreased SLCO1B1 expression, reduced MTX influx 
and decreased MTX clearance from systemic circulation (235, 239). 
Nevertheless, Kato et al. reported no associations regarding this SNP and 
MTX clinical response (231). 
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3.2. Efflux Carrier-Mediated Transport Pathway & Pharmacogenomics 
 
ABCB1 
 
Multidrug resistance protein 1 (MDR1) or P-glycoprotein 1 (P-GP1) is 
encoded by ABCB1 located on chromosome 7q21 (240). This energy-
dependent unidirectional transporter, expressed in the apical membrane of 
many epithelial and endothelial cells, as well in lymphocytes, is a 
transmembrane protein with twelve regions that plays an important role in 
drug absorption and distribution within the body (230, 240, 241).  Substrates 
include a variety of drugs, including MTX (164). The rs1045642 is one of the 
most studied SNPs in ABCB1, characterized by a substitution of a C to a T at 
position 3435 (C3435T) leading to a synonymous change of an isoleucine 
(Ile) at codon 1145 (214). The T homozygotes have been associated with 
decreased mRNA stability and enzyme expression, and thus to reduced 
efflux, and with increased intracellular levels of MTX (242). Pharmacogenetic 
studies have demonstrated that T homozygotes were associated with better 
response to MTX in RA (231, 243, 244). Nevertheless, Takatori et al. 
associated T homozygotes with non-response in RA patients (226). Regarding 
MTX-related toxicity in RA, an increased risk was associated to T 
homozygotes and to T carriers (224, 245), but Plaza-Plaza et al. associated T 
homozygotes with non-toxicity occurrence (233). Controversially, there are 
several studies that show no associations with either clinical response to 
MTX and/or MTX-related toxicity occurrence (224, 226, 230, 245, 246). The 
rs1128503 results in a T to C transition at nucleotide 1236 in exon 13 of 
ABCB1 and results in a synonymous change of a glycine (Gly) at residue 412 
in a cytoplasmic loop of ABCB1 (247). Literature bears no consensus with 
concern to the effect of this silent SNP in transporter function and thus, more 
studies are needed to elucidate this (247). In accordance to the influence of 
this SNP in MTX therapeutic outcome, Ranganathan et al. associated T 
homozygotes with increased risk for MTX-related toxicity in RA patients 
(246), while other studies did not present statistically significant 
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associations regarding the clinical response to MTX (231). The rs2032582 
consists in a transversion of a G to a T or A at position 2677 in exon 21 
(G2677A/T) corresponding to a replacement of Ala by threonine (Thr) or 
serine (Ser) in position 899 on the intracellular side of ABCB1, which results 
in a change from a lipophilic to a hydrophilic residue (248). The A/T alleles 
have been described as correlated with decreased protein expression, and 
thus, reduced efflux capability (248). Considering the studies analyzing the 
impact of this SNP in MTX therapeutic outcome, Kato et al. revealed a 
statistically significant association of A/T alleles with better response to 
MTX in RA patients (231) but Bohanec Grabar et al. did not show associations 
with MTX therapeutic outcome (224). 
 
ABCC1  
 
Multidrug resistance-associated protein 1 (MRP1) is encoded by ABCC1 
located on chromosome 16p13 (214). It is a polytopic membrane protein 
present in basolateral plasma membranes in all intestinal regions 
constituted by seventeen transmembrane regions (240, 249). It was reported 
as being expressed on cluster of differentiation 3 (CD3)-positive T cells in 
lymphocytic aggregates and in less extends in RA synovial tissue 
macrophages in the intimal lining layer and the synovial sublining and on 
endothelial cells (250). Moreover, it has been described as a transporter of 
several different drugs including MTX (251). The rs35592 is characterized by 
a substitution of a T to a C in an intron region of ABCC1. Its impact in 
transporter function is unknown and studies are needed to address this 
issue. Besides that, Stamp et al. presented no associations of this 
polymorphism with low-dose MTX therapeutic outcome (230). The rs2074087 
polymorphism denotes a substitution of a C to a G in an intronic region 
(ABCC1 IVS 18-30C>G) (214). Its functional impact is unknown and 
Ranganathan et al. demonstrated no significant associations of this SNP with 
MTX-related toxicity (246). The rs2230671 consists in a substitution at region 
4002 of a G to an A that leads to a synonymous change of a Ser at codon 
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1334 (Ser1334Ser) (214). Literature describes G homozygotes as having 
increased mRNA levels in peripheral blood cells and, thus, possibly increased 
MTX efflux (252). However, no associations were observed in accordance to 
MTX-related toxicity occurrence (246). 
 
ABCC2  
 
Canalicular multispecific organic anion transporter 1 or multidrug 
resistance-associated protein 2 (MRP2) is encoded by ABCC2 located on 
chromosome 10q24 (240). It is present in apical (brush border) membranes 
of hepatocytes and epithelial cells of the small intestine and kidney (240, 
253). This protein is an anionic conjugate efflux pump, constituted by 
seventeen transmembrane regions, that plays a role in the excretion of both 
endogenous and exogenous compounds, and influences the PK of many 
drugs such as MTX (254). The ABCC2 seems to be the main determinant in 
the elimination of MTX and of 7-OH-MTX (254). The rs717620 is a SNP 
characterized by a substitution of a G to an A in the 5´UTR (214). Studies 
reporting the influence of this SNP in transporter function have associated A 
homozygotes with increased drugs clearance, including MTX (255). 
Nevertheless, studies evaluating the impact of this polymorphism in low-
dose MTX therapeutic outcome have showed no influence in clinical response 
to MTX (231) or to MTX-related toxicity (246). The rs2273697 consists in the 
substitution of a G to an A at position 1249, which corresponds to a 
nonsynonymous change of a Val to an Ile at codon 417 (214). Literature 
describes the effect of A homozygotes as conditioning an in vitro increased 
efflux (256). Considering pharmacogenetic studies, Ranganathan et al. 
associated A homozygotes with increased risk for MTX-related 
gastrointestinal disorders (246). Nevertheless, other studies did not 
demonstrated associations of this SNP with low-dose MTX therapeutic 
outcome (230, 231). The rs4148396 is characterized by a change of a T to a C 
in an intronic region (ABCC2 IVS 23+56T>C) (214). To the best of my 
knowledge there are no studies regarding the functional analysis of this 
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polymorphism in ABCC2. However, studies analyzing its impact in low-dose 
MTX therapeutic outcome associated C homozygotes with increased risk for 
MTX-related skin and subcutaneous tissue disorders (246), gastrointestinal 
disorders and overall toxicity (230). Regarding clinical response, no 
associations were reported by Stamp et al. in RA (230). The rs7080681 SNP is 
characterized by an alteration of a G to an A at position 1058 (G1058A) 
leading to a nonsynonymous amino acid substitution from Arg to His 
substitution at position 353 (214). The impact of this SNP in the function of 
ABCC2 is currently unknown. Regarding pharmacogenetic studies, 
Ranganathan et al. observed that A homozygotes were associated with an 
increased risk for MTX-related hepatobiliary disorders (246). 
 
ABCG2 
 
Multidrug resistance efflux transport ATP-binding cassette sub-family G 
member 2 or breast cancer resistance protein (BCRP) is expressed by ABCG2 
located on chromosome 4q22 (240). This transporter has six transmembrane 
regions and is present in apical membranes of several tissues, including 
hepatocytes, intestine and kidney (230, 240, 253) and also in synovial tissue 
macrophages, at the intimal lining layer and synovial sublining, and on 
endothelial cells in RA patients (250). Higher ABCG2 expression levels were 
associated with the persistence of infiltrated synovial tissue macrophages 
after treatment with MTX and a diminished response to DMARD therapy 
(250). It seems that, when ABCC2 is absent, ABCG2 plays a significant role in 
the elimination of MTX and 7-OH-MTX [116]. Moreover, ABCG2 seems to 
transport not only MTX but also MTXPGs, particularly those with two and 
three glutamic acid residues (257). The rs2231142 SNP is characterized by a 
change of a C to an A at position 421 (C421A), which corresponds to a 
substitution of a glutamine (Gln) to a lysine (Lys) at codon 141 (214). 
Functional studies have associated A homozygotes with reduced efflux 
capability (258) and pharmacogenetic studies reported A allele as associated 
with increased risk for MTX-related overall toxicity, but no associations were 
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observed regarding clinical response (230, 231). The rs17731538 is 
characterized by a change of a G to an A in an intronic region (214). There 
are no studies regarding the functional impact of this SNP in ABCG2 and 
Stamp et al. demonstrated no associations with either MTX clinical response 
or toxicity occurrence (230). 
 
  
3.3. Polyglutamation Pathway & Pharmacogenomics 
 
FPGS 
 
Once inside the cells MTX is metabolized to MTXPGs by the sequential 
addition of glutamic acid residues via FPGS (163, 183). Folylpolyglutamate 
synthetase is located at chromosome 9q34 (214). Several SNPs have been 
studied, even though the functional significance is unknown, and significant 
associations with clinical response and/or toxicity to MTX have been 
observed in RA. For rs1054774, there is a substitution of a T for an A at 
5´UTR region (214) and literature describes A allele as associated with an 
increased risk for MTX-related toxicity, but no associations were observed 
regarding clinical response to MTX (259). For rs1544105, which is 
characterized by a substitution of a C to a T at position 2572 in an intronic 
region (214), A carriers were associated with non-response to MTX (260). 
Another SNP, rs4451422, consists in an alteration of an A to a C at position 
714 in 3´UTR (214), and the C allele for this SNP was related with increased 
risk for MTX-related toxicity (259). Additionally, no associations with MTX 
therapeutic outcome were described for rs10106, characterized by a T for a C 
substitution at 192 position in 3´UTR, rs7033913 C>T and rs10760503 A>G, 
both in an intronic region (261), and rs16887801, consisting in substitution 
of an A to a G at position 1994, in a 3´UTR (214, 262).  
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GGH 
 
Gamma-glutamyl hydrolase enzyme removes the glutamic acid residues 
of MTXPGs and, consequently, MTX can be transported out of the cells by 
efflux transporters (163). Single nucleotide polymorphisms in GGH promoter 
region have been associated with changes in GGH expression as well in MTX 
polyglutamation turnover (rs719235, rs3758149) (263). In fact, for rs719235, 
which consists in a 5´UTR alteration of a G to a T at position 354 (214), T 
carriers were associated with non-toxicity to MTX but no associations were 
described for clinical response to MTX (264) or MTX-related toxicity in other 
studies (261). For rs3758149, that consists in an alteration of a C for a T at 
position 401 in 5´UTR (214), T carriers were associated with non-toxicity 
(183) and with non-response to MTX (222) but, one study described no 
association with clinical response to MTX (183). The rs11545078 is 
characterized by a substitution of a C to an T at position 452, leading to a 
substitution of Thr to an Ile at codon 151 (214). Literature describes T allele 
as associated with lower GGH activity, resulting in intracellular accumulation 
of long-chain MTXPGs (220, 262). Nevertheless, no associations were 
observed regarding the influence in MTX therapeutic outcome (230, 231, 259, 
262, 264). Moreover, other SNPs with unknown functional significance have 
been studied. Davis et al. analyzed the impact of rs4617146 C>T, rs7010484 
C>T and rs12548933 A>G, all in intronic regions, and, rs11988534 C>T at 
3´UTR (214), and described no associations with MTX-related toxicity (261). 
Owen et al. studied the rs12681874, consisting in a substitution of a C to a T 
in an intronic region (214), and a better clinical response to MTX was 
associated to T allele, but no associations were reported regarding MTX-
related toxicity (259). 
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3.4. Folate and Methionine Pathways & Pharmacogenomics 
 
DHFR 
 
The DHFR enzyme is a major MTX target and its gene (DHFR) is located 
at 5q11 chromosome (161, 189). The frequently studied polymorphisms in 
DHFR include rs1650697, characterized by a G to an A replacement in 5´-UTR 
at 473 position, and rs1232027, a substitution of an A to a G near the 
translation initiation site (214). Nevertheless, they were not associated with 
MTX clinical response or toxicity (227). Recently, three other SNPs were 
described as associated with MTX-related toxicity: the intronic’ rs12517451 
C>T and rs1643657 A>G, and rs10072026 T>C at 3´UTR (214, 259). The 
rs408626 (A-317G) consists in an A to a G substitution at 5´UTR in position 
317 (214), and studies described an association between A homozygotes and 
non-response to MTX, but no associations were reported in relation to MTX-
related toxicity (265). Additionally, rs7387 consists in a substitution of a T 
into A at 3´UTR (214) and A allele was associated with better response to 
MTX (260). 
 
MTHFD1 
 
The MTHFD1 is responsible for providing folate cofactors and its gene 
(MTHFD1) is located at chromosome 14q24 (161, 189). The G to A 
substitution at position 1958 leads an Arg to Gln substitution at codon 653 
(rs2236225) and has unknown functional impact (230). Nevertheless, one 
study associated A allele with better response and with non-toxicity (266), 
while other associated A allele with an increased risk for MTX-related toxicity 
(230). 
 
MTHFR 
 
Methylenetetrahydrofolate reductase, an enzyme involved in folate 
pathway, is responsible for the conversion of 5,10-MTHF to 5-MTHF, a carbon 
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donor for the remethylation of homocysteine into methionine (191). Its gene 
(MTHFR), located at chromosome 1p36, plays an important role in MTX 
therapeutic outcome. The SNPs C677T (rs1801133) and A1298C (rs1801131) 
are described as the most important polymorphisms because of their 
influence in MTHFR activity and, consequently, in MTX action mechanism 
(161, 189). Nevertheless, results are still inconsistent. The rs1801133, 
responsible for a substitution of an Ala to a Val, leads to a thermolabile form 
of MTHFR with reduced activity (267). In fact, it has been suggested that T 
homozygotes and T carriers were associated with non-response to MTX (183, 
227) and increased risk for MTX-related toxicity (233, 246, 268-271). But, 
other studies demonstrated no associations with MTX therapeutic outcome 
(183, 224, 227, 230, 231, 259, 261, 270, 272-276). The rs1801131 consists in a 
substitution of an A to a C at position 1298, leading to a change of a 
glutamine to an Ala at codon position 429 (214). It has been showed that C 
allele reduces MTHFR enzymatic activity (277) and several studies have 
investigated this SNP role in MTX therapeutic outcome; C carriers were 
associated with better response (231, 270) and with non-response (227) to 
MTX. In accordance to MTX-related toxicity, C homozygotes and C carriers 
were associated with an increased risk for MTX-related toxicity in some 
studies (227, 261, 275, 276), while other study associated with non-toxicity to 
MTX (224). Moreover, there are studies demonstrating no associations with 
MTX therapeutic outcome (224, 233, 259, 270, 271, 274). Another described 
SNP is the rs2066462. Consisting in a substitution of a C to a T, leading to a 
synonymous change of a Ser at position 352, the impact in protein 
expression is actually unknown  and studies demonstrated no significant 
associations with MTX therapeutic outcome (270). Additionally, the 
rs2274976 consists in a substitution of an A to a G at 3´UTR region (214). 
Despite the unknown functional significance, G allele was associated with 
non-toxicity and no association were observed in relation to clinical response 
to MTX (270). 
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MS 
 
In the presence of methyl(III)cobalamin, the conversion of 5-MTHF to 
THF is mediated by MS (also known as methyltransferase - MTR), which 
occurs simultaneously with the addition of a methyl group to homocysteine, 
forming methionine (190, 191). Its gene (MS) is located at 1q43 chromosome 
and the rs1805087, characterized by a substitution of an A to a G at 2756 
position leading to a change of an Asp to a Gly at 919 codon, is considered to 
affect enzyme activity (278). Some studies associated G carriers with non-
toxicity (183) and G homozygotes with increased risk for toxicity (279) to 
MTX, while others obtained no significant associations with clinical response 
and/or MTX-related toxicity occurrence (223, 231, 280). 
 
MTRR 
 
Methionine synthase reductase, which gene is located at 5p15 
chromosome, maintains adequate levels of methylcob(III)alamin, the 
activated cofactor for MS (281). The rs1801394 consists of an alteration of an 
A to G at position 66 leading to a substitution of Ile into methionine at codon 
22, and, G allele has been associated with lower MTRR activity in vivo (282). 
Moreover, some studies reported associations between G homozygotes and 
an increased risk for MTX-related toxicity (183), while others demonstrated 
no associations with MTX clinical response and/or MTX-related toxicity 
occurrence (183, 230, 231, 280). 
 
SHMT1 
 
Serine hydroxymethyltransferase 1 encodes a vitamin B6–dependent 
enzyme that plays a pivotal role in providing 1-carbon units for purine and 
thymidylate synthesis (283). Its gene (SHMT1) is located at 17p11 
chromosome and the rs1979277, consisting in a C for a T substitution at 
1420 position that leads to a change of leucine to phenylalanine at 474 
codon (214). Literature reported T carriers as associated with increased 
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plasma and erythrocytes folate levels (284). In addition, T carriers were 
associated with MTX non-toxicity (269) and non-response (183). Other 
literature reports described no associations with MTX therapeutic outcome 
(183, 223, 230). 
 
 
3.5. De novo Pyrimidine Synthesis Pathway & Pharmacogenomics 
 
TYMS 
 
Thymidylate synthase is a key protein for the de novo pyrimidine 
synthesis and is responsible for the simultaneous conversion of dUMP and 
5,10-MTHF to dTMP and DHF (196, 285, 286). Subsequently, the dTMP is 
phosphorylated to dTTP and used for the DNA synthesis and repair (196, 
285, 286). Thymidylate synthase is encoded by TYMS, located on 
chromosome 18p11 (214). Polymorphism rs34743033 is a 28 base pairs (bp) 
variable number tandem repeat (VNTR), located on 5´UTR (287). Is 
characterized by exhibiting a putative Enhancer box (E-box) sequence on the 
first 28bp repeat of 2R allele and on the two first repeats of 3R allele (288, 
289). Therefore, a higher number of repeats should increase the amount of E-
box binding sites for the upstream stimulating factors (USF), leading to an 
increased transcription of TYMS and, consequently, to higher TS levels (290). 
Studies demonstrated that 2R homozygotes were associated with better 
response (221, 291) as well as with non-response (183) to MTX. Moreover, 
Weisman et al. described 2R homozygotes with increased risk for MTX-
related toxicity (269) while Bohanec Grabar et al. associated 2R carriers with 
non-toxicity to MTX (224). Other studies demonstrated no association with 
either clinical response to MTX and/or MTX-related toxicity occurrence (183, 
223, 224, 259, 264, 291, 292). A SNP characterized by a C to G transition on 
the twelfth nucleotide of the second repeat of VNTR 3R allele (rs2853542) 
has been also described (289) and, in the presence of cytosine (3RC), the E-
box seems to be disrupted, reducing the stimulation of transcription (in 
comparison to 3RG) and, thereby, decreasing TS levels (289). Since this SNP 
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occurs within the TYMS 28bp VNTR polymorphism, several studies have been 
performed combining the information from both TYMS enhancer region 
(TSER) polymorphisms (264, 286). Only one study in RA analysed the TSER 
polymorphisms, associating the 3RG homozygotes with non-response to MTX 
but, no association were observed in relation to MTX-related toxicity (264). 
Another important polymorphism in TYMS is a deletion-insertion 
polymorphism (DIP) of a 6bp sequence (TTAAAG) at 3´UTR (1494del6, 
rs34489327), which seems to affect a region of TS pre-mRNA that contains 
cis adenylate-uridylate-rich elements (AREs) (293, 294). These elements bind 
to a trans AU-rich factor 1 (AUF1), also named heterogeneous nuclear 
ribonucleoprotein D (hnRNPD), preferentially in the presence of deletion 
allele (6bp-), diminishing mRNA stability and, consequently, decreasing TS 
levels (293-295). Literature has reported deviating results. Some studies 
associated  6bp- allele with better response to MTX (291, 292), while others 
reported no associations with clinical response and/or MTX-related toxicity 
(223, 226, 246, 259, 291). Another TYMS polymorphism, the rs2853539, is a 
change of an A to a G in an intronic region (214). To the best of my 
knowledge there are no functional studies about this SNP but, Sharma et al. 
demonstrated that A homozygotes were associated with non-response to 
MTX (260). 
 
 
3.6. De novo Purine Synthesis Pathway & Pharmacogenomics 
 
ATIC 
 
The 5-aminoimidazole-4-carboxamide ribonucleotide transformylase is 
an enzyme involved in the de novo purine synthesis pathway responsible for 
the conversion of AICAR into FAICAR (221). It is encoded by ATIC, which is 
located on chromosome 2q35 (214). The rs2372536, the most studied 
polymorphism in ATIC, is characterized by a substitution of a C to a G at 
position 347 leading, at protein level, to a change of a Thr into a Ser at codon 
116 (214). Some studies have been associating the G homozygotes with 
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better response to MTX (183, 221), while other demonstrated G carriers as 
associated with non-response (280). Moreover, G homozygotes and G carriers 
were associated with MTX-related toxicity occurrence (183, 266, 269, 280), 
but, other studies revealed no associations with either clinical response to 
MTX and/or MTX-related toxicity (223, 226, 230, 231, 259, 260, 266, 296, 297). 
Some authors have studied the role of rs4673993, a SNP characterized by a T 
for a C alteration at position 675 in an intronic region, of which C allele has 
been associated with better response to MTX (273). In addition, C allele for 
rs12995526, in which occurs an intronic substitution of a T for a C at 
position 26293, and T allele for rs16853834, an intronic alteration of a C for 
a T, were described as associated with non-response to MTX, while T allele 
for rs3821353, characterized by a G to a T alteration in an intronic region, 
was associated with better response to MTX (259).  
 
 
3.7. Adenosine Pathway & Pharmacogenomics 
 
ADA 
 
Adenosine is catabolized by ADA and blocking ADA induces the 
accumulation of adenosine (184, 200). Its gene is located at 20q13 
chromosome and several genetic changes have been identified (214), some 
of them resulting in the substitution of one protein building block (amino 
acid) for another amino acid in the ADA enzyme; and others leads the 
enzyme to be unstable, or, prevent it from being produced at all (260). One of 
the most studied SNP is rs244076, a change of an A for a G at position 534, 
leading to a synonymous change of a valine at codon 178 (214).  For this SNP, 
G carriers were described as associated with better response to MTX (260). 
The rs1799880, characterized by a C for a G substitution at intronic region, 
was also studied concerning the clinical response to MTX and no 
associations were observed (260). 
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ADORA2a 
 
Adenosine receptor subtype A2a is member of the adenosine receptor 
group of G-protein-coupled receptors, responsible for the adenosine 
transport (184, 200). The ADORA2a is localized on chromosome 22q11.23 
(214) and Hider et al. described several intronic SNPs with possible 
functional impact (rs2236624 C>T, rs2267076 T>C, rs2298383 C>T, 
rs3761422 C>T, and rs5760410 G>A) and, all were associated with increased 
risk for MTX-related toxicity (298). Sharma et al. studied rs5751876, that 
consists in a substitution of a T for a C at 1976 leading to synonymous 
alteration of a tyrosine at 361 codon, and associated C allele with better 
response to MTX (260). 
 
AMPD1 
 
Adenosine monophosphate deaminase 1 catalyzes the conversion of 
AMP to IMP (280). The  AMPD1 is located at 1p13 chromosome and 
rs17602729, characterized by a C for a T alteration at position 34, generates 
an AMPD1 enzyme with lower activity due to the non-synonymous change of 
a cysteine for an Arg at codon 12 (299). Thus, deficiency of AMPD1 could 
enhance adenosine release (280). Pharmacogenetic studies demonstrated 
that T carriers were more likely to have a better response to MTX (266, 280) 
but also presented an increased risk for MTX-related toxicity (230). Other 
studies demonstrated no associations with MTX clinical response and/or 
toxicity (230, 259, 260, 266, 280, 297). 
 
Pharmacogenetic studies relating to MTX therapeutic outcome in RA 
patients are summarized in Table 5. 
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For RA, very inconsistent results were obtained in conducted studies, raising 
skepticism about the clinical utility of the reported genetic polymorphisms, 
possibly due to the complex interplay between pathogenesis and MTX 
pharmacology in RA. 
As not all RA patients are the same, there is an increasing need to 
establish personalized medicine in rheumatology, as well as in other fields in 
medicine. This will only happen when clinical and molecular properties of 
each patient are well characterized. Therefore, and besides there have been 
major advances in personalized medicine field, we are still very far from 
finding the optimal genetic biomarkers. 
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CHAPTER II – OBJECTIVES 
This chapter presents the main and specific objectives of this work. 
 
 
Considering the ultimate key challenges of Pharmacogenomics in the 
field of Personalized Medicine, the general objective of this work was to 
evaluate the influence of clinicopathological and genetic variables, as 
potential predictors of methotrexate therapeutic outcome, both regarding 
clinical response and adverse drug reactions occurrence, in rheumatoid 
arthritis Portuguese patients.  
 
Among the specific objectives, this work aimed to:  
1) Select the study population with rheumatoid arthritis according 
to the defined inclusion and exclusion criteria;  
2) Reclassify rheumatoid arthritis patients according the 2010 
criteria of the American College of Rheumatology and the 
European League Against Rheumatism;  
3) Construct a database with the collected clinicopathological data 
from the selected population;  
4) Define the endpoints to be measured - methotrexate therapeutic 
outcome, expressed as clinical response to methotrexate and as 
methotrexate-related toxicity, according to well defined 
standards and guidelines;  
5) Analyze the influence of the clinicopathological variables in 
methotrexate therapeutic outcome prediction;  
6) Select potential genetic polymorphisms for methotrexate 
therapeutic outcome prediction in rheumatoid arthritis;  
7) Investigate the role of solute carriers and adenosine 
triphosphate-binding cassette transporters polymorphisms on 
the occurrence of methotrexate-related toxicity;  
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8) Study the association between thymidylate synthase 
polymorphisms and methotrexate therapeutic outcome, both 
regarding clinical response and toxicity occurrence;  
9) Elucidate the influence of methylenetetrahydrofolate reductase 
and 5-aminoimidazole-4-carboxamide ribonucleotide 
transformylase polymorphisms in the clinical response to 
methotrexate;  
10) Analyze and define a profile of clinicopathological variables and 
genetic polymorphisms that could be used to predict MTX 
response and/or toxicity occurrence and its concluding 
remarks, and reflect on future perspectives.  
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CHAPTER III – MATERIALS AND METHODS 
This chapter includes the information about the search strategy, study 
design (selection of participants, data and sample collection), genotyping 
procedures and statistical analysis. 
 
 
1. SEARCH STRATEGY & SELECTION CRITERIA 
 
For reviewing purposes it was developed a sensitive search strategy in 
the PubMed database using various combinations of search terms including 
‘ABCs’, ‘acute lymphoblastic leukemia’, ‘adverse drug reactions’, ‘association’, 
‘clinical response’, ‘effectiveness’, ‘efficacy’, ‘expression’, ‘function’, ‘genetic’, 
‘juvenile idiopathic arthritis’, ‘low-dose’, ‘methotrexate’, ‘molecular 
epidemiology’, ‘pharmacogenetics’, ‘pharmacogenomics’, ‘personalized 
medicine’, ‘polymorphism’, ‘psoriasis’, ‘rheumatoid arthritis’, ‘single 
nucleotide polymorphisms’, ‘SLCs’, ‘SNPs’, ‘survival’, ‘susceptibility’, 
‘therapeutic outcome’, ‘thymidylate synthase’, ‘toxicity’, ‘transporters’, ‘TS’ 
and ‘TYMS’. Moreover, the search strategy also included rs identification 
number, SNP or gene/protein denomination of proteins involved in MTX 
transport-mediated system or action mechanism. All English-language and 
Portuguese-language articles published were identified. Bibliographies of 
retrieved articles were screened for cross-references to identify additional 
publications not indexed in the search databases.  
Were selected, for inclusion in MTX transport-mediated system review, 
articles that met the following criteria:  
 aimed for disease models where MTX is used in low-dose (rheumatoid 
arthritis, psoriasis and juvenile idiopathic arthritis); 
 included genetic polymorphisms in genes encoding for proteins 
involved in MTX transport-mediated system; 
 analyzed genetic polymorphisms effects on protein function or 
expression levels; 
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 studied genetic polymorphisms association with MTX therapeutic 
outcome, regarding clinical response and/or toxicity occurrence; and, 
 explored pharmacogenomics and personalized medicine. 
Manuscripts were excluded if their full text was not available or 
explored disease models where MTX is used in high-dose (such for 
example, acute lymphoblastic leukemia).  
Likewise, were selected, for inclusion in TYMS review, articles that 
follow the criteria below:  
 aimed for disease models where MTX is used independently of dose; 
 included genetic polymorphisms in TYMS; 
 analyzed genetic polymorphisms effects on TS function or expression 
levels; 
 studied genetic polymorphisms association with MTX therapeutic 
outcome, regarding clinical response, toxicity occurrence and/or 
survival; 
 investigated genetic polymorphisms association with risk for 
developing diseases; and,  
 explored molecular epidemiology, pharmacogenomics and 
personalized medicine. 
Manuscripts were excluded if their full text was not available. 
 
 
2. CHARACTERIZATION OF THE STUDIED POPULATION 
 
A retrospective study was performed between January 2009 and 
December 2012 at the São João Hospital Center (Porto, Portugal) in a cohort 
of consecutive Caucasian patients (≥ 18 years) with RA treated with MTX. 
Patients were excluded from the study if had drug abuse history, recent 
pregnancy or desire to become pregnant during the study. The study was 
submitted to the local Ethical Committee (reference 33/2009), procedures 
were considered to be according to the standards of the Helsinki Declaration 
and all patients provided an informed written consent (300).  
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Patients were diagnosed with RA, classified according the 1987 criteria 
of the ACR and reclassified according the 2010 criteria of the ACR and EULAR 
(89). After RA diagnosis, all patients were treated with 10mg PO/w of MTX in 
monotherapy. This dose was increased 5mg at each three weeks if the 
patient did not meet the EULAR criteria for response; in other words, 
whenever the patient presented a DAS28>3.2. At three months, if patient was 
still without response, the administration route was changed from PO to 
subcutaneous (SC) maintaining the MTX dose. Moreover, if patients 
presented GI toxicity with PO route, independently of MTX dose, the 
administration route was also changed to SC keeping the same dose. If in 
three months using SC, MTX patients presented GI toxicity or if, at the 
maximum tolerable doses, the patient did not meet the response criteria, 
MTX therapy was discontinued or was associated with LEF 20mg/d. 
Exceptionally, in the case of RA patients without poor prognosis factors that 
did not responded to MTX in monotherapy, MTX was combined with other 
csDMARDS such SSZ, HCQ and/or CCP before making the switch to LEF. After 
more three months, if patients continued without response in two successive 
evaluations and did not present any contraindication, therapeutic was 
changed by associating a bDMARD. The occurrence of MTX-related toxicity 
was registered at each visit and, according to the severity, MTX dose was 
decreased or MTX was discontinued. Due to the well-known protective effect 
of folic acid supplementation for the prevention of toxicity occurrence, in 
particular for GI disorders (142, 143), this supplement was prescribed to all 
patients and their regular compliance was registered. Other concomitant 
drugs, such as corticosteroids and NSAIDs were allowed during the study. 
 
 
3. DATA COLLECTION & VARIABLE DEFINITION 
 
Patient demographics, clinicopathological and treatment characteristics 
were collected from clinical records by the patients’ clinicians during their 
regular visits to the hospital (Table 6). 
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3.1. Clinicopathological Variables Characterization 
 
Table 6. Clinicopathological variables of population enrolled in the study  
 At event  
Non-response 
At event 
Toxicity 
Patient-related   
Male, n (%)  37 (15.9) 37 (15.9) 
Female, n (%)  196 (84.1) 196 (84.1) 
       Postmenopausal, n (%)  96 (49.0) 101 (51.5) 
Age, mean ± SD, years 51.9 ± 11.9 52.0 (26.0-87.0) 
BMI, median (IQR), Kg/m
2
  27.1 (18.3-44.2) 26.2 (18.4-43.1) 
Current smokers, n (%)  32 (13.7) 32 (13.7) 
       NPY*, median (IQR) 19.5 (0.8-120.0) 20.1 (0.8-120.0) 
Comorbidity**, n (%)  126 (54.1) 126 (54.1) 
Disease-related    
Diagnosis age, mean ± SD, years  40.3 ± 13.2 40.3 ± 13.2 
Disease duration, median (IQR), years  8.0 (0.5-53.0) 10.0 (0.3-51.0) 
RF positive, n (%)  131 (56.2) 131 (56.2) 
Anti-CCP positive, n (%)  175 (75.1) 175 (75.1) 
ANAs positive, n (%)  66 (28.3) 66 (28.3) 
DAS28, mean ± SD 4.2 ± 1.3 4.1 ± 1.4 
Individual variables - DAS28   
      TJC (out of 28), median (IQR)  4.0 (0.0-27.0) 3.9 (0.0-26.0) 
      SJC (out of 28), median (IQR) 3.0 (0.0-24.1) 3.0 (0.0-24.1) 
      ESR, median (IQR), minutes (1
st
 hour) 18.0 (1.0-92.0) 17.8 (1.0-91.0) 
      Global Health on VAS, median (IQR)  48.0 (0.0-100.0) 47.5 (0.0-100.0) 
HAQ score, median (IQR)  1.25 (0.0-2.9) 1.24 (0.0-2.7) 
      HAQ 0.5, n (%)  39 (16.7) 39 (16.7) 
*NPY = (number of cigarettes smoked per day x number of years smoking)/20.  
**Comorbidity was defined as the presence of diabetes mellitus, hypertension, dyslipidemia and/or cardiac disorders 
beyond rheumatoid arthritis.  
§
Drugs co-administered with methotrexate when clinical response/toxicity to methotrexate was recorded.  
#
Patients with compliance to folic acid supplementation.  
ANAs: antinuclear antibodies; Anti-CCP: anti-cyclic citrullinated peptide; bDMARDs: biological disease-modifying 
antirheumatic drugs; BMI: body mass index; DAS28: disease activity score 28; DMARDs: disease-modifying antirheumatic 
drugs; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; IQR: interquartile range; MTX: 
methotrexate; NPY: number of pack years; NSAIDs: non-steroidal anti-inflammatory drugs; RF: rheumatoid factor; SD: 
standard deviation; sDMARDs: synthetic disease-modifying antirheumatic drugs; SJC:  swollen joints count; TJC: tender 
joints count; VAS: visual analog scale. 
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Table 6. Clinicopathological variables of population enrolled in the study (cont.) 
 At event  
Non-response 
At event 
Toxicity 
Treatment-related
§
   
Symptomatic   
      Corticosteroids, n (%)  188 (80.7) 188 (80.7) 
          Daily dose in prednisolone equivalents, median (IQR), mg 5.0 (0.0-20.0) 5.0 (0.0-20.0) 
      NSAIDs, n (%)  170 (73.0) 170 (73.0) 
Supplements   
      Folic acid
#
, n (%)  118 (50.6) 118 (50.6) 
DMARDs    
      MTX Monotherapy, n (%)  146 (62.7) 136 (58.4) 
      Combined MTX Therapy – sDMARDs, n (%) 59 (25.3) 44 (18.9) 
      Combined MTX Therapy – bDMARDs, n (%) 28 (12.0) 53 (22.7) 
MTX administration characteristics   
      Dose, median (IQR), mg/week 15.0 (2.5-25.0) 15.0 (2.5-25.0) 
      Treatment duration, median (IQR), months 28.0 (6.0-230.0) 47.0 (1.0-240.0) 
      Per os administration route, n (%) 201 (86.3) 210 (90.1) 
      Subcutaneous administration route, n (%) 32 (13.7) 23 (9.9) 
*NPY = (number of cigarettes smoked per day x number of years smoking)/20.  
**Comorbidity was defined as the presence of diabetes mellitus, hypertension, dyslipidemia and/or cardiac disorders 
beyond rheumatoid arthritis.  
§
Drugs co-administered with methotrexate when clinical response/toxicity to methotrexate was recorded.  
#
Patients with compliance to folic acid supplementation.  
ANAs: antinuclear antibodies; Anti-CCP: anti-cyclic citrullinated peptide; bDMARDs: biological disease-modifying 
antirheumatic drugs; BMI: body mass index; DAS28: disease activity score 28; DMARDs: disease-modifying antirheumatic 
drugs; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; IQR: interquartile range; MTX: 
methotrexate; NPY: number of pack years; NSAIDs: non-steroidal anti-inflammatory drugs; RF: rheumatoid factor; SD: 
standard deviation; sDMARDs: synthetic disease-modifying antirheumatic drugs; SJC:  swollen joints count; TJC: tender 
joints count; VAS: visual analog scale.  
 
 
3.2. Therapeutic Outcomes Definition 
 
Response / Non-Response  
 
Methotrexate clinical response was recorded at the time of each visit. 
Non-response was defined if patients presented a DAS28>3.2 calculated and 
defined as described by Prevoo et al. (114) (see 1.8.2. Disease activity 
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measure - 1.8. Disease Monitoring), in two consecutive evaluations. 
Therefore, non-response to MTX had a minimum period of MTX therapy, at 
least, of six months. Additionally, response to MTX was defined when 
patients presented a DAS28≤3.2.  
 
Toxicity / Non-Toxicity 
 
Methotrexate-related toxicity was defined when patients presented any 
ADR related to MTX. At the time of each visit, physician directly asked the 
patient whether MTX-related ADRs were currently occurring and ADRs were 
recorded. The type of ADR was classified in System Organ Class (SOC) 
disorders, in accordance with the Common Terminology Criteria for Adverse 
Events (CTCAE) (301). Additionally, non-toxicity occurrence related with MTX 
was defined when patients did not present any ADR related with MTX.  
 
 
4. SAMPLE COLLECTION AND PROCESSING  
 
Whole blood samples from each patient were obtained with standard 
venipuncture technique using ethylenediaminetetraacetic acid (EDTA) 
containing tubes. Genomic DNA was extracted with QIAamp
 
DNA Blood Mini 
Kit (QIAGEN, Hilden, Germany) according to the manufacturer instructions. 
Total genomic DNA was quantified and its purity and integrity were analyzed 
using the NanoDrop

 1000 Spectrophotometer v3.7 (Thermo Scientific, 
Wilmington DE, USA). 
 
 
5. GENOTYPING PROCEDURES 
 
Genotyping procedures for studied genetic polymorphisms are 
presented in Table 7 and a representative genotyping result for each 
technique is shown in Figures 23-26. Several molecular biology techniques 
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were used, such as polymerase chain reaction-restriction fragment length 
polymorphism (PCR-RFPL), Real-time PCR, automated sequencing and 
Sequenom® MassARRAY iPLEX. For quality control, 10% of the samples were 
randomly selected for a second analysis, and in case of PCR-RFLP and Real-
Time PCR protocols, 10% of cases were confirmed by automated sequencing. 
Results were 100% concordant. 
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Figure 23. Electrophoresis gels of PCR and RFLP-PCR techniques of MTHFR C677T (rs1801133). 
Left: PCR product of 198bp + Gene ruler DNA ladder of 50bp. Right: PCR-RFLP products (1
st
 
band: CC genotype; 2
nd
, 4
rd
 and 5
th 
bands: CT genotype; 3
th
 band: TT genotype) + Gene ruler DNA 
ladder of 50bp. 
 
 
 
 
 
 
 
Figure 24. Automatic sequencing of TYMS 1494del6 (rs34489327). Example of 6bp+6bp+ 
genotype due to the presence of the sequence CTTTAA (or TTAAAC) from position 49 to 54. 
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Figure 25. Real-time PCR technique of ATIC T675C (rs4673993). Upper: Results demonstrating 
a TC genotype due to the presence of two lines (yellow and purple) corresponding to T allele 
(left) and C allele (right). Middle: Results demonstrating a TT genotype due to the presence of 
one yellow line corresponding to T alleles. Lower: Results demonstrating a CC genotype due 
to the presence of one purple line corresponding to C alleles. 
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Figure 26. Sequenom® MassARRAY iPLEX technique of ABCG2 G>A (rs17731538). Upper: 
Results demonstrating a GA genotype due to the presence of two peaks corresponding to A 
allele (left) and G allele (right). Middle: Results demonstrating a AA genotype due to the 
presence of one higher peak corresponding to A alleles. Lower: Results demonstrating a GG 
genotype due to the presence of one higher peak corresponding to G alleles. 
 
 
6. STATISTICAL ANALYSIS  
 
Statistical analysis was performed with either IBM
®
 SPSS
® 
Statistics for 
Windows, Version 20.0 (IBM Corp, Armonk, NY, USA), OpenEpi for Windows, 
Version 2.3.1 (306), SNPStats software (307), MedCalc
®
 software for Windows, 
Version 13.1.2 (308) and Arlequin for Windows, Version 3.11 (309), when 
applicable. 
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6.1. Descriptive statistics 
Genotype frequencies were assessed and tested for Hardy-Weinberg 
equilibrium (HWE) according to Rodriguez et al. (310). Quantitative variables 
description was expressed in mean ± standard derivation (SD) for normally 
distributed variables and median and interquartile range (IQR) for non-
normally distributed variables, as evaluated by the Kolmogorov-Smirnov test. 
Categorical variables were described by number of cases (n) and percentages 
(%).  
 
6.2. Univariate analysis 
Pearson Chi-square test or Fisher’s exact test were used to assess the 
association between the outcome groups (response versus non-response or 
toxicity versus non-toxicity) and the different categorical variables. Odds 
ratio (OR) and the correspondent 95% confidence intervals (CI) were 
calculated as a measure of the association between the categorical variables. 
For the comparison of quantitative variables between outcome groups, two 
sample t-tests, for normally distributed variables, and non-parametric Mann-
Whitney U tests, for non-normally distributed variables, were applied. It was 
considered a probability (P) value of 5% or less as statistically significant. In 
the cases that univariate analysis was performed for clinicopathological 
variables, the variables that were statistically significant in this analysis 
were also adjusted in multivariate analysis. 
 
6.3. Multivariate analysis  
Multivariate analysis with binary logistic regression was used to 
identify which genotypes or clinicopathological variables could predict the 
occurrence of MTX-related toxicity and/or non-response to MTX. This 
analysis was performed in one or three-steps by adjusting to potential 
confounding variables, i.e. clinicopathological variables possibly influencing 
MTX-related toxicity, selected based on literature review and clinical 
significance (221, 311-316). When three steps were used, in the first step 
patient-related variables (age, gender and smoking) were considered; in a 
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second step, beyond patient-related variables, disease-related variables 
(diagnosis age and disease duration) were added; and in a third step, beyond 
patient and disease-related variables, treatment-related variables (folic acid 
supplementation, corticosteroids therapy, use of NSAIDs, other concomitant 
DMARDs used and MTX administration characteristics - dose, treatment 
duration and administration route) were also considered. When one step was 
used, the analysis corresponded only to the last step of the three-step 
analysis. In the case of carrier-mediated transport pathway, polymorphisms 
were adjusted for two extra patient-related variables concerning renal 
function (eGFR and SCr). It was considered a probability (P) value of 5% or 
less as statistically significant. 
 
6.4. Haplotype analysis 
Because haplotypes may have a particular significance in regard to 
functionality or as genetic markers for unknown functional variants, it 
appears more evident that, to better characterize the role of a candidate 
gene, the full haplotypic information should be exploited (317, 318). 
Therefore, haplotype analysis was performed, to assess of possible 
consequences on the phenotype in the copresence of several variants of the 
same gene. Haplotype analyses were performed by Arlequin for Windows, 
Version 3.11 (University of Berne, Bern, Switzerland) (309)
 
with 100,000 
number of steps in Markov chain or using a two-stage iterative method 
named expectation maximization algorithm (SNPStats software) (307). 
Linkage disequilibrium (LD) between SNPs in the same gene was estimated 
and expressed as D´ coefficients. The measure was interpretable as the 
proportion of the maximum possible level of association between two loci, 
given the allele frequencies, ranging from 0 (linkage equilibrium) to 1 
(complete LD) (26). Possible haplotypes were tested for association with risk 
for non-response to MTX and/or for MTX-related toxicity by taking the most 
frequent haplotype as reference.  
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6.5. Toxicogenetic risk index 
In order to elucidate the cumulative impact of risk genotypes on MTX-
related toxicity development, a toxicogenetic risk index (TRI) was created for 
each patient. The TRI resulted by the sum of risk genotypes from the SNPs in 
genes encoding for MTX membrane transport proteins that revealed to be 
statistically significant associated with MTX-related toxicity. 
  
6.6. Other analyses 
In order to understand the impact of the 5'UTR region in therapeutic 
outcome, polymorphisms in TSER were classified according to their 
theoretical TS functional status as previously described (286) and grouped 
by expression, as follow: low expression genotypes (2R2R, 2R3RC and 
3RC3RC), median expression genotypes (2R3RG and 3RC3RG) and high 
expression genotype (3RG3RG). 
When relevant, a Forest plot was performed using MedCalc
®
 software for 
Windows, Version 13.1.2 (319). Additionally, and using IBM® SPSS® Statistics 
for Windows, Version 20.0 (IBM Corp, Armonk, NY, USA), a Cox proportional 
hazard regression model was used to adjust for potential confounders and, 
to correct for multiple comparisons, Bonferroni’s method was applied in 
order to control the false positive rate, using a significance level of α=0.05/(n 
comparisons). 
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CHAPTER IV. GENETIC POLYMORPHISMS IN LOW-DOSE 
METHOTREXATE TRANSPORTERS: THE CURRENT RELEVANCE 
AS METHOTREXATE THERAPEUTIC OUTCOME BIOMARKERS 
This chapter presents a comprehensive review about Methotrexate 
pharmacokinetics processes and the current data on genetic polymorphisms 
in genes encoding for low-dose Methotrexate membrane transporters, as also 
their influence in Methotrexate therapeutic outcome. The search strategy 
was performed given the clinical implications of widespread use of low-dose 
Methotrexate in rheumatic and dermatological diseases. In addition, the 
extent of Methotrexate movement through cellular membranes, determining 
the Methotrexate pharmacokinetics, is partly conditioned by membrane 
transporters, both influx and efflux. Therefore, functional activity and 
expression level of these proteins, possibly conditioned by genetic 
polymorphisms in genes encoding to those proteins, can determine the 
amount of intracellular and systemic Methotrexate and, consequently, its 
pharmacodynamics.  
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Genetic polymorphisms in low-dose methotrexate transporters: the 
current relevance as methotrexate therapeutic outcome biomarkers 
 
ABSTRACT 
Methotrexate (MTX) is used in low-doses to treat a variety of diseases. 
Although the mechanism responsible for its therapeutic action is unknown, 
MTX membrane transport proteins (influx and/or efflux) can be major 
determinants of pharmacokinetics, adverse drug reactions and clinical 
response profiles. With pharmacogenomics progress, the improvement of the 
prediction of patients’ therapeutic outcome treated with low-doses of MTX 
will offer a powerful tool for the translational role of single nucleotide 
polymorphisms (SNPs) into clinical practice and will be essential to sustain a 
breakthrough in the field of personalized medicine. Therefore, this paper 
provides an update on the current data on SNPs in genes involved in low-
dose MTX membrane transport proteins and their relevance as possible 
biomarkers of MTX therapeutic outcome. 
 
Keywords: ATP-binding Cassette Transporters – ABCs; Low-dose; 
Methotrexate; Personalized Medicine; Pharmacogenomics; Therapeutic 
Outcome; Transporters; Single Nucleotide Polymorphisms - SNPs; Solute 
Carriers – SLCs 
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INTRODUCTION  
The observation that folic acid antagonists interfered with normal cell 
growth lead back to 1951, when high-dose methotrexate (MTX) was 
introduced as a treatment option for children with acute lymphoblastic 
leukemia [1]. Then, in 1951, Gubner demonstrated that low-dose MTX (up to 
25mg/week) could also be effective in controlling disease activity both in 
patients with psoriatic arthritis and rheumatoid arthritis (RA) [2] and, in the 
late 1980s, low-dose MTX debuted as treatment option in juvenile idiopathic 
arthritis (JIA) patients with polyarthritis [3] and in ankylosing spondylitis [4]. 
Low-dose MTX has been also used in other rheumatic diseases and 
dermatological diseases, such psoriasis [5]. 
Methotrexate (2,4-diamino-N10-methyl propyl glutamic acid) is an antifolate 
negatively charged drug with a molecular weight of 454.5g/mol 
(C20H22N8O5), low permeability and poor aqueous solubility [6]. 
Methotrexate is composed by a pteridine ring, p-aminobenzoic acid and 
glutamic acid, structurally differing from folic acid only by the substitution 
of a hydroxyl group for an amine in the pteridine ring (at C4 carbon) and the 
addition of a methyl group on the 10(th) nitrogen of p-aminobenzoic acid [6] 
(Figure 1).  
Although therapeutic effects elicited by low-dose MTX treatment may involve 
mechanisms distinct from those observed with high-dose MTX treatment, 
there are overlapping mechanisms of action. These are primarily attributed 
to MTX ability to inhibit multiple enzymes involved in folate and de novo 
nucleotides synthesis pathways [7]. This ability is then reflected in other 
pathways such as methionine and adenosine pathways, which along, will 
contribute for MTX anti-inflammatory and antiproliferative effects [7]. The 
extent and time course of MTX effects on pathophysiological processes, 
described by pharmacodynamics (PD), are partly determined by MTX 
intracellular retention, which occurs as a consequence of MTX 
polyglutamates (MTXPGs) formation via folylpolyglutamate synthetase (FPGS) 
[8, 9]. Nevertheless, gamma-glutamyl hydrolase (GGH) can revert this process 
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and then MTX can be transported out of the cells by efflux transporters [9] 
(Figure 2).  
For determining PD it is important to consider the relationship between drug 
effect and drug concentration [8]. The extent of drug movement through 
cellular membranes, determined by pharmacokinetics (PK), is partly affected 
by membrane transporters [9]. Therefore, functional activity and expression 
level of MTX membrane transport proteins, possibly altered by genetic 
polymorphisms, can determine the amount of MTX transported into or out of 
specific tissues [8]. These yet underlooked and subtle differences can be 
translated into interpatient therapeutic outcome variability, both regarding 
clinical response (effectiveness) and/or the occurrence of adverse drug 
reactions (toxicity) [6, 7]. Hence, and given the clinical implications of 
widespread use of low-dose MTX, this manuscript is devoted to provide an 
overview on MTX PK processes and an update on the current data on genetic 
polymorphisms in genes encoding for low-dose MTX membrane transporters 
as also their influence in MTX therapeutic outcome.  
 
LOW-DOSE METHOTREXATE PHARMACOKINETICS 
Pharmacokinetics generically describes what the body does to a drug and, PK 
parameters result from the release of the drug, its absorption, distribution, 
metabolism and excretion, and provides information about the rate of 
occurrence for these processes at a systemic level [8]. The bioavailability of 
MTX is relatively high but can vary depending of the dose and administration 
route [7]. At 7.5mg/week, enteral and parenteral absorption is similar, but at 
doses of 15mg/week or more, MTX enteral absorption may decrease by as 
much as 30% compared with parenteral dosing [7]. Enteral absorption is 
limited because MTX is absorbed from the gastrointestinal tract (GIT) 
primarily and predominantly from a saturable active transport system, the 
solute carrier (SLC) family 19 member 1 (SLC19A1) [7], later to be described 
in detail. Enteral absorption can also be affected by food intake, oral non-
absorbable antibiotics, flow transit alteration through GIT (such diarrhea and 
constipation) and intestinal pathology [7]. After absorption, 10% of MTX is 
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converted in the liver, by aldehyde oxidase, to 7-hydroxymethotrexate (7-OH-
MTX), an active metabolite [6]. Approximately 50% of MTX is albumin-bound, 
whereas 90-95% of 7-OH-MTX is albumin-bound [7]. Nevertheless, other drugs 
such as non-steroidal anti-inflammatory drugs (NSAIDs) alter MTX and 7-OH-
MTX binding to plasmatic proteins and impair MTX hepatic metabolism [6]. 
Methotrexate half-life in serum ranges from 6 to 8 hours after administration 
and MTX is undetectable by 24 hours [6]. The majority of both MTX and 7-OH-
MTX is excreted in the urine, although a small portion is also excreted in the 
bile [6, 7]. Methotrexate renal clearance results from a combination of 
filtration and secretion processes, taken place in the proximal tubule, with 
subsequent reabsorption in the distal tubule [10]. Excretion of MTX can be 
reduced by renal insufficiency, leading to toxicity, and also by interactions 
with weak organic acids, such as NSAIDs [6]. However, these interactions 
have general clinical relevance only at the typical higher weekly maintenance 
MTX dosage range (up to 25mg/week) but not at the lower doses, commonly 
used to begin treatment [11]. Besides all of these factors influencing PK, 
other factors include physicochemical properties of a drug, namely size, 
lipophilicity and charge (or degree of ionization) [8]. In addition, membrane 
transporters per se have a significant role in facilitating or preventing drug 
movement. Interplay of influx and efflux transporters together with phase I 
and II metabolism may be required for the sequential traverse of the 
basolateral and apical membranes [12]. Drug transporters can, therefore, be 
regarded as completing the phase I and II enzyme-based detoxification 
system; drug uptake delivers the drug to the detoxification system to 
facilitate metabolism, whereas drug efflux decreases the load on 
detoxification enzymes [13]. 
Methotrexate cellular transport can occur via influx (uptake into cell) and 
efflux (out of cell) transporters, which are typically located either at the 
basolateral or apical membranes in polarized cells [9, 10]. In enterocytes, at 
apical membrane, MTX is primordially absorbed through active transport 
mediated by SLC19A1, also known as reduced folate carrier (RFC), a saturable 
bidirectional anion exchanger, followed by SLC family 46 member 1 
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(SLC46A1) and, in less extent, by endocytosis via folate receptor alpha 
(FOLR1) [6, 7, 14]. Methotrexate efflux from enterocytes to intestinal tract 
lumen can be mediated by ATP-binding cassette (ABCs) transporters, i.e., by 
ATP-binding cassette sub-family C member 2 (ABCC2), ATP-binding cassette 
sub-family B member 1 (ABCB1) and ATP-binding cassette sub-family G 
member 2 (ABCG2); or to bloodstream, by ATP-binding cassette sub-family C 
member 1 (ABCC1) and ATP-binding cassette sub-family C member 3 (ABCC3) 
[9]. Once in the bloodstream, MTX either enters in circulation, inside 
circulating cells [15], aims for affected cells [16] or is distributed towards 
hepatocytes or renal cells to be excreted [1]. The hepatic uptake of MTX 
involves SLC19A1, SLC organic anion transporter family member 1B1 
(SLCO1B1) and SLCO family member 1B3 (SLCO1B3) [10]. Most of the hepatic 
distributed drug re-enters the sinusoidal bloodstream via ABCC3 and ABC 
sub-family C member 4 (ABCC4) and, the remaining, is oxidized to 7-OH-MTX 
or is excreted into the bile duct by ABCC2, ABCB1 and ABCG2 [10]. Systemic 
clearance of MTX happens primarily through renal glomerular filtration and 
active secretion over the proximal tubular cells [10]. Some renal transporters 
have affinity to MTX and 7-OH-MTX, allowing their entrance into renal cells 
by solute carrier family 22 member 6 (SLC22A6) and solute carrier family 22 
member 8 (SLC22A8) present at basolateral membrane, and by SLC family 22 
member 11 (SLC22A11) and SLCO family member 1A2 (SLCO1A2), expressed 
in apical membrane [9]. Moreover, SLC family 16 member 7 (SLC16A7) has 
been described as having a moderate to low expression in plasma membrane 
of kidney but its function on MTX transport remains unclear [17]. 
Furthermore, MTX excretion through urinary tract can also be mediated by 
ABCB1, ABCC2, ABCC4 and ABCG2 [6] (Figure 3).  
 
METHOTREXATE PHARMACOGENOMICS: THE ROLE OF MTX-TRANSPORTERS  
Multiple transporters and metabolic enzymes are involved in MTX PK and/or 
PD, prompting for the importance of genetic polymorphisms in genes 
encoding for related proteins. Assured about the presence of critical players 
in function and metabolism of MTX, it has been possible to study single 
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nucleotide polymorphisms (SNPs) in genes encoding for some of these 
proteins in order to determine their putative influence in MTX therapeutic 
outcome interpatient variability. Therefore, in the last few decades, 
numerous pharmacogenomics studies were conducted to decode 
associations of SNPs in genes encoding to MTX membrane transport proteins 
that could change MTX influx and/or efflux function and, consequently, could 
be responsible for interpatient MTX therapeutic outcome variability, both 
regarding clinical response and/or adverse drug reactions (ADRs) 
occurrence. The summary of the characteristics and putative effects of those 
SNPs in low-dose MTX transport function is presented in Table 1.  
 
Membrane Influx Transporters 
It has been previously accepted that MTX could enter cells by SLC19A1 and 
the presence of other influx transporters is not thoroughly explored. 
Nowadays, more transporters have been associated with MTX transport 
through cellular membranes and most of these transporters are related with 
MTX influx: SLC16A7, SLC19A1, SLC22A6, SLC22A8, SLC22A11, SLC46A1, 
SLCO1A2, SLCO1B1 and FOLR1. Table 2 summarizes the effect of SNPs in 
genes encoding for low-dose MTX influx transporters with interest to MTX 
therapeutic outcome. 
 
SLC16A7 
The SLC16A7, also known as monocarboxylate transporter 2 (MCT2), is a 
unidirectional proton-linked transport of monocarboxylates across the 
plasma membrane encoded by SLC16A7, located on chromosome 12q13 [17]. 
This transporter can mediate either influx or efflux depending of the 
prevailing substrate and pH gradients with net rates of monocarboxylate 
transport being determined by the difference between influx and efflux [17]. 
It is widely expressed in testis and has moderate to low expression in spleen, 
heart, kidney, pancreas, skeletal muscle, brain and leucocytes [17]. At the 
present, functional relationship of SLC16A7 expression and MTX mechanisms 
remains unclear.  
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rs3763980 
This variant of SLC16A7 results in a substitution of an adenine (A) with a 
thymine (T) and leads to an amino acid change from threonine (Thr) to a 
serine (Ser) at position 445 [18]. This polymorphism occurs in a predicted 
region encoding for a cytoplasmic domain, with implications in 
phosphorylation and signaling and, therefore, is potentially functional [18]. 
In fact, T carriers were associated with a reduced expression of SLC16A7 in 
transformed B cells from healthy donors and with better response to low-
dose MTX in JIA patients [18]. In this study, non-response to MTX was 
defined as a failure to reach the 30% response improvement in American 
College of Rheumatology 70 pediatric criteria (ACRped70) for United 
Kingdom cohort and defined using the joints count alone for United States 
cohort [18]. In addition, literature demonstrated evidences about its linkage 
disequilibrium (LD) with SLC16A7 T>G (rs10877333) [18]. 
rs10877333 
This SNP is characterized by a substitution of a T to a Guanine (G) in an 
intron region of SLC16A7 and, despite its impact in transporter function is 
unknown, there is one study that associates G allele with better response to 
MTX in JIA [18]. 
 
SLC19A1 
Human SLC19A1, also known as folate transporter 1 or reduced folate carrier 
protein (RFC), is encoded by SLC19A1, located on chromosome 21q22.3 [19]. 
It is a cell surface transmembrane protein and a bidirectional transporter of 
primarily reduced folates, including MTX, ubiquitously expressed in many 
tissues, showing particularly high expression in absorptive tissues (intestine, 
kidney and placenta) either on apical and/or basolateral membranes [20].  
rs7499 
This SNP leads to a change of a G into an A at position 16 (SLC19A1 G*16A), 
and occurs in the 3´-untranslated region (UTR), thought to be important in 
messenger ribonucleic acid (mRNA) stability, localization and translational 
efficiency [21]. Despite there are no functional studies on this SLC19A1 
 
 
115 
 
variant, there is one study in RA patients demonstrating an association 
between A allele and non-response to MTX, but no associations were related 
to toxicity occurrence [22]. In this study non-response to MTX was defined as 
physician statement of inefficacy plus failure to reduce erythrocyte 
sedimentation rate (ESR) and/or C-reactive protein (CRP) by at least 20% with 
MTX therapy after three months at a minimum dose of 15mg/week and 
toxicity was defined as the occurrence of an ADR, which needs to be 
persistent or serious, leading to treatment cessation, the ADR had to resolve 
on treatment cessation and, in the case of GI disorders, recur after MTX re-
challenge [22].    
rs1051266 
This SNP is the most studied variation in SLC19A1 and is characterized by a 
substitution of a G by an A at position 80, leading to the substitution of 
arginine (Arg) into histidine (His) at codon 27 in the first transmembrane 
domain, a region implicated to carrier function [23]. Literature described G 
homozygotes as associated with lower MTX influx activity in lymphocytes 
[24] and decreased MTXPGs levels in erythrocytes [25]. Studies in RA patients 
analyzing the impact of this SNP in MTX therapeutic outcome demonstrated 
an association of A homozygotes with better response to MTX [26-28], and of 
A allele with better response to MTX when combined with sulfasalazine (SSZ) 
and hydroxychloroquine (HCQ) [29]. Nevertheless, in Dervieux et al. study, 
non-response was defined as a visual analog scale (VAS) score superior 2cm, 
obtained by physician’s global assessment of disease activity [26]; Drozdzik 
et al. defined non-response when both tender joint count and swollen joint 
count improved <20% from baseline and, at least, three of the following 
criteria were not met: 20% improvement in VAS, in ESR, in physician’s global 
assessment of disease activity, in patient’s global assessment of disease 
activity, and in Health Assessment Questionnaire (HAQ) [27]; in Hayashi et al. 
work non-response was defined by the total inflammatory status during 
twelve months of MTX treatment calculated by the area under the curve 
(AUC) of serial CRP measurements [28]; and, James et al. defined non-
response as an no improvement between baseline and twelve months based 
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on the Disease Activity Score 28 (DAS28) [29]. Moreover, de Rotte et al. 
associated A homozygotes with MTX non-response in JIA patients [30]. In 
this study MTX was used in monotherapy or combined with other disease-
modifying antirheumatic drugs (DMARDs) and, non-response was defined by 
ACRped70 [31] and the use of anti-tumor necrosis factor-α  (TNF-α ) was a 
criteria for non-response [30]. Regarding MTX-related toxicity in RA patients, 
G allele was associated with an increased risk for GI disorders by Lima et al. 
[32] and for overall toxicity by Bohanec Grabar et al. [33, 34] while Warren et 
al. demonstrated that A homozygotes patients with psoriasis had an 
increased risk for MTX overall toxicity [35]. Nevertheless, Lima et al. defined 
toxicity as the occurrence of any ADR related to MTX treatment, 
independently of administration route and MTX dose, recorded at the time of 
each visit and, the type of ADR was classified in System Organ Class (SOC) 
disorders, in accordance with the Common Terminology Criteria for Adverse 
Events (CTCAE) [32]; Bohanec Grabar et al. recorded the ADRs retrospectively 
from patients’ files throughout the course of MTX therapy, ADRs were 
classified accordingly SOC disorders and considered as mild, moderate and 
serious [33, 34]; Warren et al. assessed the ADRs by clinical records, ADRs 
were classified accordingly SOC disorders enough to necessitate cessation of 
MTX or requiring treatment [35]. Additionally, other studies demonstrated no 
associations with clinical response and/or toxicity to low-dose MTX [22, 27, 
33, 35-41].  
rs1131596 
The change of a T to a cytosine (C) in 5´UTR of SLC19A1 is thought to alter 
gene transcription regulatory mechanisms, since it was found to be located 
in the putative consensus sequence of the activating protein-1 transcription 
factor enhancer [39]. Functional studies in RA patients demonstrated that C 
homozygotes were associated with a decreased SLC19A1 expression and 
influx capability [39] and in fact C carriers demonstrated a trend for lower 
SLC19A1 expression in lymphoblastic cell lines [34]. Regarding the influence 
in MTX therapeutic outcome, Bohanec Grabar et al. associated C carriers with 
a decreased risk for MTX therapy discontinuity, due to overall toxicity and 
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infections in RA [34], but others showed no association with therapeutic 
outcome [39]. This SNP was also described to be in high linkage 
disequilibrium with G80A (rs1051266) [34] and, therefore, haplotype studies 
may be important to be addressed when underlying differences in MTX 
therapeutic outcomes are compared. 
rs2838956 
The rs2838956 polymorphism, characterized by a substitution of an A for a 
G, is located in the fifth intron at position 707 (45525110A>G) [34] and its 
impact is currently unknown, thus functional studies are necessary to 
evaluate the potential of this SNP on ribonucleic acid (RNA) splicing, which 
may affect the protein structure and function [42]. Nevertheless, there are 
studies relating this variant with MTX therapeutic outcome in RA: while 
Owen et al. associated G allele with non-response to MTX but not with 
toxicity [22]; Bohanec Grabar et al. demonstrated that A allele has a trend to 
skin and subcutaneous tissue disorders, but no associations were observed 
regarding clinical response to MTX [34].  
rs3788200 
Despite there are no studies regarding the impact of this variant in SLC19A1 
function and low-dose MTX therapeutic outcome, this intronic SNP 
characterized by substitution of a G for an A is potentially functional and has 
been demonstrated to be in LD with rs1051266, rs1131596 and rs4819130 
[43].   
 
SLC22A6 
The SLC22A6, also known as organic anion transporter 1 (OAT1), is encoded 
by SLC22A6, located on chromosome 11q12.3 [44] and is mainly expressed in 
the basolateral membrane of renal cells in proximal tubules and plays a 
critical role in renal elimination of various endogenous anions and clinically 
important anionic drugs in humans, such as MTX [44, 45].  
rs11568626 
This SNP is characterized by substitution of C for a T, causing a substitution 
of an Arg to a His at codon 50 [19]. This change is not considered to be a 
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substantial chemical change but this residue does lie within the first 
extracellular loop of this transporter, a highly conserved structure within 
organic anion and cation transporters families [46]. This loop has previously 
been shown to be a potential glycosylation site, which is important for 
SLC22A6 function and cellular localization [46]. Literature describes T 
homozygotes as associated with a decreased expression of this transporter 
and, consequently, with reduced influx [46]. Nevertheless, there are no 
studies investigating the role of this SNP in low-dose MTX therapeutic 
outcome.  
 
SLC22A8 
The SLC22A8, also known as organic anion transporter 3 (OAT3), is encoded 
by the SLC22A8, located on chromosome 11q12.3 and is mainly expressed in 
the basolateral membrane of renal proximal tubules and can be found in 
luminal membrane of the choroid plexus in the brain [45]. 
rs45566039 
This SNP is a change of a C to an A at position 445 leading to a substitution 
of Arg into Ser at a crucial functional location of the protein, with A 
homozygotes to be associated with loss of transport functionality [47]. To 
date, there are no studies investigating the role of this SNP in low-dose MTX 
therapeutic outcome.  
  
SLC22A11 
Human SLC22A11, also known as organic anion transporter 4 (OAT4), is 
encoded by SLC22A11, located on chromosome 11q13.1 and acts as a 
bidirectional transporter in the apical membrane of renal proximal tubular 
cells [48]. It has been appointed as having a major role in the tubular 
reabsorption of organic anions and secretion of MTX [48].  
rs11231809 
This SNP occurs in an intronic region and is characterized by a substitution 
of a T for an A [19]. It was previously been shown that A homozygotes were 
 
 
119 
 
associated with higher clearance of some drugs [49], but there are no studies 
regarding the functional influence of this SNP on MTX PK and/or PD.  
 
SLC46A1  
The SLC46A1 or proton-coupled folate transporter/heme carrier protein 1 
(PCFT/HCP1), is encoded by SLC46A1, located on chromosome 17q11.2 and 
mostly expressed in apical membrane of small-intestine and kidney cells, 
acting as a key transporter for normal folate absorption and homeostasis 
[14]. 
rs2239907 
This SNP is characterized by a change of an A into a G at position 928 
(A928G) in the 3´UTR region, which is reported as important for mRNA 
stability and translational efficiency [19, 21]. The impact of this variant in 
SLC46A1 is currently unknown but Kato et al. and de Route et al. 
investigated the role of this SNP in MTX therapeutic outcome, and found no 
significant associations with clinical response in RA and JIA, respectively [30, 
40].  
 
SLCO1A2 
Human SLCO1A2, also known as solute carrier family 21 member 3 
(SLC21A3) or sodium-independent organic anion-transporting polypeptide 1 
(OATP-1), is encoded by SLCO1A2, located on chromosome 12p12.1 [50]. It 
has twelve transmembrane domains and transports a broad spectrum of 
substrates, including both endogenous and exogenous compounds such as 
MTX [50, 51]. This bidirectional transporter is present in several tissues 
including kidney (apical domains of the renal distal tubular cells), where it 
could be responsible for either reabsorption or secretion of drugs [50].  
rs10841795 
The T38C SNP occurs in exon 1 and causes a T to C change at position 38, 
which corresponds to an isoleucine (Ile) to Thr amino acid change at position 
13 (Ile13Thr) [19]. Badagnani et al. speculated, from in vitro results, that in 
vivo C homozygotes should be associated with increased reabsorption of 
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MTX from distal tubule, leading to increased exposure to MTX and 
subsequent systemic toxicity [51]. However, there are no studies elucidating 
the role of this SNP in low-dose MTX PK and/or PD. 
 
SLCO1B1  
The SLCO1B1, liver-specific organic anion transporter 1 (LST1) or sodium-
independent organic anion-transporting polypeptide 2 (OATP-2), is a 
bidirectional transporter with twelve transmembrane domains encoded by 
SLCO1B1 located on chromosome 12p12 [52]. It is mainly expressed in 
basolateral membrane of hepatocytes and plays a key role in the uptake of a 
wide variety of endogenous and exogenous anionic compounds, including 
MTX [53]. Methotrexate hepatic uptake via SLCO1B1 was demonstrated as the 
major pathway for MTX clearance from systemic circulation [54]. Moreover, 
SLCO1B1 mRNA has been detected also in other tissues, including small 
intestinal enterocytes [55]. 
rs2306283 
This common variant in SLCO1B1 results in a change of A into a G at position 
388 and, a change of an asparagine (Asn) into an aspartate (Asp) at position 
130 [52]. In vitro studies associated G homozygotes with an increased 
transport activity for MTX [54] and Kato et al. showed no associations with 
MTX clinical response in RA, defined by DAS28 [40]. 
rs4149056 
This SNP is characterized by a change of a T into a C at position 521 leading 
to an amino acid substitution of valine (Val) into an alanine (Ala) at codon 
174 [52]. The C allele was associated with a loss-of-function phenotype, 
resulting in a decreased SLCO1B1 expression, reduced MTX influx and 
decreased MTX clearance from systemic circulation [52, 56]. Nevertheless, 
Kato et al. reported no associations regarding this SNP and MTX clinical 
response [40]. 
rs56387224 
Characterized by a substitution of an A to a G at position 1295 (A1294G) this 
SNP leads to an amino acid change from Asn to an Asp at codon 432 [52]. In 
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fact, G homozygotes have been associated with a reduced influx capability 
mediated by SLCO1B1 [56]. To the best of our knowledge no studies have 
investigated the role of this SNP in low-dose MTX therapeutic outcome. 
 
SLCO1B3 
The SLCO1B3 or liver-specific organic anion transporter 3 (LST3), is encoded 
by SLCO1B3 located on chromosome 12p12 [50] and is a member of the 
organic anion transporting polypeptide (OATP) superfamily responsible for 
transporting a wide range of xenobiotics including MTX [57]. This is a 
transmembrane bidirectional transporter localized in the basolateral domain 
of the plasma membrane in liver [10]. Expression and tissue distribution of 
SLCO1B3 and SLCO1B1 in liver is similar [53]. Since MTX is transported by 
both transporters [50] and there are no studies analyzing the contribution of 
SNPs in SLCO1B3 for low-dose MTX therapeutic outcome, it seems important 
to conduct combined studies to address the importance of these SNPs. 
 
FOLR1 
The FOLR1, also identified as adult folate-binding protein (FBP), is encoded 
by FOLR1, which is located on chromosome 11q13.4 [58]. It is a variably 
expressed glycosylated membrane-associated protein present in the outer 
layer of plasma membrane facilitating unidirectional transport of folic acid, 
5-methyltetrahydrofolate and MTX [58]. While folates enter primarily by 
FOLR1, MTX enters the cell primarily by SLC19A1 mediated transport [7]. 
Nevertheless, MTX also bind to FOLR1, although with reduced affinity when 
compared to folic acid [59]. FOLR1 and SLC19A1 are known to be expressed 
separately or simultaneously but FOLR1 may be up-regulated in a cell with 
increased metabolic activity [60]. For FOLR1, there are no published studies 
that have addressed this SNPs contribution for low-dose MTX therapeutic 
outcome. Nevertheless, the search for SNPs that could alter the functionality 
of this transporter and the analysis of associations between these SNPs and 
therapeutic outcome are important. 
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Membrane Efflux Transporters 
Methotrexate is known as a substrate of ATP-binding cassette (ABC) efflux 
transporters which include: ABCB1, ABCC1, ABCC2, ABCC3, ABCC4 and 
ABCG2. The summary of literature analyzing the effect of SNPs in genes of 
low-dose MTX efflux transporters on therapeutic outcome is presented in 
Table 3.  
 
ABCB1  
The ABCB1, also identified as multidrug resistance protein 1 (MDR1) or P-
glycoprotein 1 (P-gp), is encoded by ABCB1 located on chromosome 7q21 
[61]. This energy-dependent unidirectional transporter, expressed in the 
apical membrane of many epithelial and endothelial cells, is a 
transmembrane protein with twelve regions that plays an important role in 
drug absorption and distribution within the body [41, 61]. Substrates include 
a variety of drugs including MTX [62]. ABCB1 is also expressed in peripheral 
blood lymphocytes, which was markedly higher in RA patients in whom 
disease was refractory to treatment than in RA patients with a good clinical 
response to DMARD therapy [63]. 
rs1045642 
This is one of the most studied SNPs in ABCB1, characterized by a 
substitution of a C to a T at position 3435 (C3435T) leading to a synonymous 
change of an Ile at codon 1145 [19]. The T homozygotes have been 
associated with decreased mRNA stability and enzyme expression, and thus, 
reduced efflux, and with increased intracellular levels of MTX [64]. 
Pharmacogenetic studies have demonstrated that T homozygotes were 
associated with better response to MTX [40, 65] and to MTX combined with 
SSZ [66] in RA and to MTX in monotherapy or combined with other DMARDs 
in JIA [30]. Nevertheless, Takatori et al. associated T homozygotes with non-
response to MTX in monotherapy or combined with other DMARDs [36]. 
Moreover, Kato et al. used DAS28 to define the MTX clinical response [40]; 
Drozdzik et al. defined non-response when both tender joint count and 
swollen joint count improved <20% from baseline and, at least, three of the 
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following criteria were not met: VAS ≤20 mm, ≥20% improvement in ESR, in 
physician’s global assessment of disease activity, in patient’s global 
assessment of disease activity, and in HAQ [65]; in Pawlik et al. study non-
response to MTX was defined as three swollen joints, morning stiffness >30 
and ESR >25mm/h [66]; and, Takatori et al. defined non-response to MTX 
patients to whom MTX was administered continuously for at least three 
months and the last maintenance dosage of MTX was >6mg/week or those in 
whom MTX was substituted with other DMARDs attending to modified HAQ 
and biochemical findings (such as CRP, ESR and matrix metallopeptidase-3) 
[36]. Regarding MTX-related toxicity in RA, an increased risk was associated 
to T homozygotes by Bohanec Grabar et al. [33] and to T carriers by Kooloos 
et al. [67], but Plaza-Plaza et al. associated T homozygotes with non-toxicity 
[38]. Nevertheless, Bohanec Grabar et al. recorded the ADRs retrospectively 
from patients’ files throughout the course of MTX therapy, ADRs were 
classified accordingly SOC disorders and considered as mild, moderate and 
serious [33]; Kooloos et al. evaluated the toxicity by counting each reported 
ADR and its consequences for the patient and treatment, ADRs were 
spontaneously reported by the patients or were reported as a result of 
nonspecific questioning on patients’ wellbeing by the investigator, by 
physical examination or laboratory measurements during follow-up [67]; and, 
for Plaza-Plaza et al. MTX toxicity was considered when the patient 
experienced an increase in liver enzymes (AST, aspartate aminotransferase; 
and ALT, alanine aminotransferase) to values higher than or equal to three 
times the upper limit of normal (AST: 1–40 IU/L; ALT: 1–41 IU/L) in the 
absence of previous enzyme elevations, positive viral hepatitis markers, or 
alcohol consumption, other ADR experiences were also collected and each 
ADR was described by its duration, frequency, severity, cause, and specific 
therapy requirements [38]. Controversially, there are several studies that 
show no associations with either clinical response and/or toxicity occurrence 
[33, 36, 41, 67, 68].  
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rs1128503  
This SNP results in a T to C transition at nucleotide 1236 in exon 13 of 
ABCB1 and results in a synonymous change (GGT glycine, GGC glycine) at 
residue 412 in a cytoplasmic loop of ABCB1 [69]. Literature bears no 
consensus with concern to the effect of this silent SNP in transporter 
function and, thus, more studies are needed to elucidate this [69]. In 
accordance to the influence of this SNP in MTX therapeutic outcome, 
Ranganathan et al. associated T homozygotes with increased risk for toxicity 
in RA patients [68], while other studies did not present statistically 
significant associations regarding the clinical response to MTX [30, 40]. In 
Ranganathan et al. study, MTX toxicity information was collected 
retrospectively in specifically designed forms on nine individual disorders 
(alopecia, GI disorders, hepatotoxicity - elevation of AST or ALT above the 
upper limit of normal, leukopenia, pulmonary disorders, stomatitis, central 
nervous system (CNS) disorders, post-dosing reactions and rash), and 
attending to overall toxicity, which included patients who had experienced 
one or more of the individual toxicities [68]. 
rs2032582 
This SNP consists in a transversion of a G to a T or A at position 2677 in 
exon 21 (G2677A/T) corresponding to a replacement of Ala by Thr or Ser in 
position 899 on the intracellular side of ABCB1, which results in a change 
from a lipophilic to a hydrophilic residue [70]. A/T alleles have been 
described as correlated with decreased protein expression, and thus, 
reduced efflux capability [70]. Considering the studies analyzing the impact 
of this SNP in MTX therapeutic outcome, Kato et al. revealed a statistically 
significant association of A/T alleles with better response to MTX in RA 
patients [40]. Nevertheless, other studies did not show associations with low-
dose MTX therapeutic outcome [30, 33]. Since this SNP was described as 
being in linkage disequilibrium with C3435T (rs1045642) [70], haplotype 
analysis should be performed in order to evaluate the repercussions on 
ABCB1 expression level, transport function and MTX therapeutic outcome. 
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ABCC1  
The ABCC1 or multidrug resistance-associated protein 1 (MRP1), is encoded 
by ABCC1 located on chromosome 16p13 [19]. It is a polytopic membrane 
protein present in basolateral plasma membranes in all intestinal regions 
constituted by seventeen transmembrane regions [61, 71]. It was reported as 
being expressed on CD3-positive T cells in lymphocytic aggregates and in 
less extends in RA synovial tissue macrophages in the intimal lining layer 
and the synovial sublining and on endothelial cells [72]. Moreover, it has 
been described as a transporter of a number of different drugs including 
MTX [73].  
rs35592 
This SNP is characterized by a substitution of a T to a C in an intron region 
of ABCC1. Its impact in transporter function is unknown and studies are 
needed to address this issue. Besides that, Warren et al. demonstrated a 
significant association of C carriers with non-response to MTX in psoriasis, 
but no significant association was observed for MTX-related toxicity [35]. 
Other studies did not show any association of this polymorphism with low-
dose MTX therapeutic outcome [30, 41]. 
rs246240 
The rs246240 polymorphism consists in a substitution of an A to a G in an 
intronic region of ABCC1 [19]. Similarly to the previous SNP, the impact of 
this SNP in ABCC1 function is unknown and further studies are necessary. 
Nevertheless, Warren et al. studied the influence of this SNP in MTX 
therapeutic outcome in psoriasis and associated G carriers with decreased 
MTX-related toxicity but no significant association was observed regarding 
clinical response [35]. 
rs2074087 
This SNP denotes a substitution of a C to a G in an intronic region (ABCC1 IVS 
18-30C>G) [19]. Similarly to the previous SNP, the functional impact is 
unknown. Nevertheless, Ranganathan et al. demonstrated no significant 
associations of this SNP with MTX-related toxicity [68]. 
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rs2230671 
The rs2230671 consists in a substitution at region 4002 of a G to an A that 
leads to a synonymous change of a Ser at codon 1334 (Ser1334Ser) [19]. 
Literature describes G homozygotes as having increased mRNA levels in 
peripheral blood cells and, thus, possibly increased MTX efflux [74]. 
However, no associations were observed in accordance to MTX-related 
toxicity [68]. 
rs3784864 
This SNP is characterized by a substitution of a G to an A in an intronic 
region [19]. To the best of our knowledge, its functional impact in ABCC1 is 
unknown. With concern to this SNP impact in therapeutic outcome, Warren et 
al. associated A carriers with decreased risk for MTX-related toxicity in 
psoriasis but no associations were observed in accordance to clinical 
response [35]. 
 
ABCC2  
The ABCC2, encoded by ABCC2 located on chromosome 10q24, is a well-
known canalicular multispecific organic anion transporter 1 or multidrug 
resistance-associated protein 2 (MRP2) [61]. It is present in apical (brush 
border) membranes of hepatocytes and epithelial cells of the small intestine 
and kidneys [48, 61]. This protein is an anionic conjugate efflux pump, 
constituted by seventeen transmembrane regions, that plays a role in the 
excretion of both endogenous and exogenous compounds, and influences 
the PK of many drugs such as MTX [75]. For the plasma PK of 7-OH-MTX after 
MTX administration, ABCC2 seem to be the main determinant in the 
elimination of MTX and its metabolite 7-OH-MTX [75].  
rs717620 
The rs717620 is a SNP characterized by a substitution of a G to an A in the 
5´UTR [19]. Studies reporting the influence of this SNP in transporter 
function have associated A homozygotes with increased clearance [76]. 
Nevertheless, studies evaluating the impact of this polymorphism in low-
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dose MTX therapeutic outcome have not shown any difference regarding 
clinical response [30, 40] or toxicity [68].  
rs2273697 
This SNP consists in a substitution of a G to an A at position 1249, which 
corresponds to a nonsynonymous change of a Val to an Ile at codon 417 [19]. 
Literature describes the effect of A homozygotes as conditioning an in vitro 
increased efflux [77]. Considering pharmacogenetic studies, Ranganathan et 
al. associated A homozygotes with increased risk for MTX-related GI 
disorders [68]. Nevertheless, other studies, both in RA and using DAS28 to 
define the clinical response to MTX, did not demonstrate associations of this 
SNP with low-dose MTX therapeutic outcome [40, 41]. Additionally, 
Ranganathan et al. collected toxicity information retrospectively and 
evaluated the influence in nine individual toxicities and in overall toxicity 
[68]; and, Stamp et al. applied a standardized questionnaire related to 
common MTX ADRs within the month preceding study entry was 
administered and, ADRs were grouped broadly into the follow categories: GI, 
CNS and others [41]. 
rs4148396 
This SNP is characterized by a change of a T to a C in an intronic region 
(ABCC2 IVS 23+56T>C) [19]. To the best of our knowledge there are not 
studies regarding the functional analysis of this polymorphism in ABCC2. 
However, studies analyzing its impact in low-dose MTX therapeutic outcome 
associated C homozygotes with increased risk for MTX-related skin and 
subcutaneous tissue disorders [68], GI disorders and overall toxicity [41]. 
Regarding clinical response, no associations were reported by Rotte et al. in 
JIA [30] and by Stamp et al in RA [41]. 
rs7080681 
The rs7080681 SNP is characterized by an alteration of a G to an A at 
position 1058 (ABCC2 G1058A) leading to a nonsynonymous amino acid 
substitution from Arg to His substitution at position 353 [19]. The impact of 
this SNP in ABCC2 function is currently unknown. Regarding 
pharmacogenetic studies, Ranganathan et al. observed that A homozygotes 
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were associated with an increased risk for MTX-related hepatobiliary 
disorders [68]. 
 
ABCC3 
The ABCC3, also known as canalicular multispecific organic anion 
transporter 2 or multidrug resistance-associated protein 3 (MRP3), is 
encoded by ABCC3 located on chromosome 17q22 [19]. It is constituted by 
seventeen transmembrane regions [61] and is found in basolateral plasma 
membranes of the liver and small intestine increasing MTX and 7-OH-MTX 
systemic levels and allowing an alternative route of elimination via the urine 
[78].  
rs4793665 
This SNP causes an alteration of a C to a T at 5´UTR region (ABCC3 C211T) 
[19]. Literature associated T homozygotes for this SNP with lower ABCC3 
transcript levels and a trend toward lower protein expression in human liver 
[79]. Considering pharmacogenetic studies, de Rotte et al. revealed that T 
homozygotes were associated with better response to MTX in JIA [30].  
 
ABCC4 
The ABCC4, also known as multidrug resistance protein 4 (MRP4), encoded 
by ABCC4 and located on chromosome 13q32.1 [19], is ubiquitously 
expressed, with a high expression in kidney proximal tubules and in liver 
[48]. This transporter membrane location is apical in most tissues, but in 
hepatocytes is basolateral [10] and, consequently, can lead to higher 
systemic levels and/or to increased renal clearance. The ABCC4 has been 
described as implicated in the transport of several drugs such MTX, as well 
as endogenous molecules including folates [80]. Because of this, and since 
there are no studies analyzing the contribution of SNPs in ABCC4 for low-
dose MTX therapeutic outcome, it seems important to conduct studies 
concerning this issue. 
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ABCG2 
The ABCG2, also known as multidrug resistance efflux transport ATP-binding 
or breast cancer resistance protein (BCRP), is expressed by ABCG2 located on 
chromosome 4q22 [61]. This transporter has six transmembrane regions and 
is present in apical membranes of several tissues, including hepatocytes, 
intestine and kidneys [41, 48, 61], also in synovial tissue macrophages, at the 
intimal lining layer and synovial sublining, and on endothelial cells in RA 
patients [72]. Higher ABCG2 expression levels were associated with the 
persistence of infiltrated synovial tissue macrophages after treatment with 
MTX and a diminished response to DMARD therapy [72]. It seems that, when 
ABCC2 is absent, ABCG2 plays a significant role in the elimination of MTX 
and 7-OH-MTX [116]. Moreover, ABCG2 seems to transport not only MTX but 
also MTXPGs, particularly those with two and three glutamic acid residues 
[81].  
rs2231142 
This SNP is characterized by a change of a C to an A at position 421 (C421A), 
which corresponds to a substitution of a glutamine (Gln) to a lysine (Lys) at 
codon 141 [19]. Functional studies have associated A homozygotes with 
reduced efflux capability [82] and pharmacogenetic studies reported A 
homozygotes as associated with increased risk for MTX-related overall 
toxicity, but no associations were observed regarding clinical response to 
MTX [40, 41]. 
rs13120400  
This polymorphism is characterized by a substitution of a T to a C in an 
intron region [19]. To the best of our knowledge there are no studies 
analyzing the functional impact of this SNP in ABCG2. Nevertheless, in a large 
population with psoriasis, Warren et al. associated C carriers with better 
response to MTX but no associations were observed regarding MTX-related 
toxicity [35].  
rs17731538 
This SNP is characterized by a change of a G to an A in an intronic region 
[19]. Similarly to the previous SNP, there are no studies regarding the 
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functional impact of this SNP in ABCG2. Nevertheless, Warren et al. 
associated A carriers with non-response to MTX [35], while Stamp et al. 
demonstrated no associations with either MTX clinical response or toxicity 
occurrence [41]. 
 
FUTURE PERSPECTIVES 
There are many inconsistent results regarding the associations of SNPs in 
genes encoding for MTX membrane transport proteins (influx and/or efflux) 
with low-dose MTX therapeutic outcome. These somehow discrepant results 
could be explained by differences observed in: study design, sample sizes, 
ethnicity, disease models, treatment regiments, as well as in therapeutic 
outcome endpoints definition, such clinical response and toxicity, leading to 
difficult comparisons and conclusions. In order to reduce the inconsistency 
of results and provide more solid evidences, ideal future studies should 
consider several factors that can lead to MTX PK and/or PD reduced 
variability as follow: 1) existence of different MTX transporters, granting 
different flux directions, expressed simultaneously, in same cells and/or in 
different tissues; 2) presence of endogenous substances (e.g. folates) or 
other drugs that could interact with MTX and/or with MTX transporters; 3) 
pH differences that could alter MTX solubility and, thus, dissolution (crucial 
for absorption when MTX is administered by per os route); 4) alterations in 
polyglutamation processes, and thus, in MTX cellular retention, possibly by 
changing the functionality of FPGS and GGH; 5) existence of other 
polymorphisms that could alter transporter levels, function or expression; 
and 6) presence of polymorphisms in genes encoding for proteins involved 
in MTX action mechanism pathways [83]. Genome-wide association 
approaches and/or next generation sequencing could be applied to reveal 
additional genes/polymorphisms associated with MTX treatment outcome. In 
fact, and to the best of our knowledge, there are several unknown SNPs 
concerning to functional impact in transporter (SLC16A7 rs10877333; 
SLC19A1 rs7499, rs2838956 and rs3788200; SLC22A11 rs11231809; 
SLC46A1 rs2239907; ABCC1 rs35592, rs246240, rs2074087 and rs3784864; 
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ABCC2 rs4148396 and rs7080681; and, ABCG2 rs13120400 and rs17731538), 
concerning to influence on low-dose MTX therapeutic outcome (SLC19A1 
rs3788200; SLC22A6 rs11568626; SLC22A8 rs45566039; SLC22A11 
rs11231809; SLCO1A2 rs10841795; and, SLCO1B1 rs56387224) and unknown 
importance of genes/possible SNPs (SLCO1B3, FOLR1 and ABCC4). Moreover, 
to improve the detection of more genetic factors responsible for interpatient 
variability in low-dose MTX therapeutic outcome, some important issues 
should be considered in future studies. Thus, studies should follow validated 
guidelines to define therapeutic outcomes, in order to homogenise 
definitions; study design should be prospective, due to the fewer potential 
sources of bias and confounding factors when compared to retrospective 
studies; studies should be larger and multicentric (a large sample size can 
greatly improve statistical power and multicentre international 
collaborations can rapidly generate large samples); and,  studies should 
undertake genotype and haplotype based approaches, in order to clarify the 
influence in PK parameters and in predicting MTX therapeutic outcome.  
 
CONCLUSIONS 
Candidate polymorphisms in genes encoding proteins involved in MTX 
carrier-mediated transport systems have been successfully identified. 
Therefore, over the past decade, numerous pharmacogenetic studies have 
been undertaken to establish possible associations between these 
polymorphisms and MTX therapeutic outcome. Despite different results 
among published studies, there are not many doubts that this area is very 
promising for tailoring therapeutic outcome. Additionally, and considering 
the intra and inter variability among patients, there is an increasing need to 
establish strong basis for personalized medicine. Yet, and despite the recent 
advances in pharmacogenomics, a fairly long path has to be covered to reach 
to personalized medicine and to find the optimal genetic biomarkers of low-
dose MTX therapeutic outcome. 
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EXECUTIVE SUMMARY 
Introduction 
 Low-dose methotrexate (MTX) is used in several rheumatic and 
dermatological diseases.  
 Significant intra and inter variability to MTX treatment is observed 
among patients.  
Methotrexate Pharmacogenomics: The Role of MTX-Transporters  
 Low-dose MTX membrane transport proteins (influx and/or efflux) can 
be major determinants of MTX therapeutic outcome. 
 Several pharmacogenetic studies have been undertaken to decipher 
associations between SNPs in genes encoding for MTX membrane 
transport proteins and MTX therapeutic outcome but, the majority of 
these findings are still inconclusive and inconsistent. 
 
Conclusions & Future Perspectives 
 Methotrexate therapeutic outcome prediction will offer a powerful tool 
for the translational role of into clinical practice and will be essential 
to sustain a breakthrough in the field of personalized medicine. 
 Developing effective biomarkers to help clinicians in the prediction of 
drug responses in routine clinical practice remains a big challenge. 
 
ABBREVIATIONS LIST 
A: adenine; aa: amino acid; ABCB1: ATP-binding cassette sub-family B member 1; 
ABCC1: ATP-binding cassette sub-family C member 1; ABCC2: ATP-binding cassette 
sub-family C member 2; ABCC3: ATP-binding cassette sub-family C member 3; ABCC4: 
ATP-binding cassette sub-family C member 4; ABCG2: ATP-binding cassette sub-
family G member 2; ACRped70: American College of Rheumatology 70 pediatric 
criteria; ADR: adverse drug reaction; Ala: alanine; ALT: alanine aminotransferase; Arg: 
arginine; AST: aspartate aminotransferase; AUC: area under the curve; BCRP: breast 
cancer resistance protein; C: cytosine; CD: cluster of differentiation; Chr: 
chromosome; CNS: central nervous system; CRP: C-reactive protein; CTCAE: Common 
Terminology Criteria for Adverse Events; DMARD: disease-modifying antirheumatic 
drug; ESR: erythrocyte sedimentation rate; EULAR: European League Against 
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Rheumatism; FBP: folate binding protein; FOLR1: folate receptor alpha; FOLT: folate 
transporter; FPGS: folylpolyglutamate synthetase; G: guanine; GI: gastrointestinal; 
GGH: gamma-glutamyl hydrolase; Gln: glutamine; Gly: glycine; HAQ: Health 
Assessment Questionnaire; HCP1: heme carrier protein 1; HCQ; hydroxychloroquine; 
His: histidine; ID: identification; Ile: isoleucine; IU: international units; JIA: Juvenile 
Idiopathic Arthritis; LD: linkage disequilibrium; Lys: lysine; LST: liver-specific 
transporter; MCT2: monocarboxylate transporter 2; MDR: multidrug resistance 
protein; MMP-3: matrix metallopeptidase 3; mRNA: messenger ribonucleic acid; MRP: 
multidrug resistance-associated protein; MTX: methotrexate; MTXPG: methotrexate 
polyglutamate; n.a.: not assigned; NA: not analyzed; NS: not-statistically significant; 
OAT: organic anion transporter; OATP: organic anion transporting polypeptide; PCFT: 
proton-coupled folate transporter; P-GP: P-glycoprotein; PD: pharmacodynamics; PK: 
pharmacokinetics; RA: rheumatoid arthritis; Ref: reference; RFC1: reduced folate 
carrier 1; S: statistically significant; Ser: serine; SLC16A7: solute carrier family 16 
member 7; SLC19A1: solute carrier family 19 member 1; SLC22A6: solute carrier 
family 22 member 6; SLC22A8: solute carrier family 22 member 8; SLC22A11: solute 
carrier family 22 member 11; SCL46A1: solute carrier family 46 member 1; SLCO1B1: 
solute carrier organic anion transporter family member 1B1; SLCO1B3: solute carrier 
organic anion transporter family member 1B3; SLCO1A2: solute carrier organic anion 
transporter family member 1A2; SNP: single nucleotide polymorphism; SOC: System 
Organ Class; SSZ: sulfasalazine; T: thymine; Thr: threonine; TNF-α : tumor necrosis 
factor-alpha; UTR: untranslated region; UK: United Kingdom; US: United States; Val: 
valine; VAS: visual analog scale. 
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Figure 1. Chemical structures of Methotrexate (A) and Folic Acid (B). Methotrexate is composed 
by a pteridine ring, p-aminobenzoic acid plus glutamic acid. Methotrexate and Folic Acid 
chemical structures are similar, differing in the pteridine ring (by substitution of a hydroxyl 
group for an amine) and on the 10(th) nitrogen of p-aminobenzoic acid (by addition of a 
methyl group).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Methotrexate mechanism of action. Left panel represents the intervention of MTX in 
de novo pyrimidine synthesis, folate and methionine pathways. Right panel shows the effect 
of MTX in de novo purine synthesis and adenosine pathway. These action mechanisms 
contribute to MTX antiproliferative and anti-inflammatory effects. 
ABC: adenosine triphosphate-binding cassette; FPGS: folylpolyglutamate synthetase; GGH: 
gamma-glutamyl hydrolase; MTX: methotrexate; MTXPG: methotrexate polyglutamate; SLC: 
solute carrier. 
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Figure 3. Methotrexate transporters cells location and representation of their influx and/or 
efflux function. 
ABCB1: ATP-binding cassette sub-family B member 1; ABCC1: ATP-binding cassette sub-family 
C member 1; ABCC2: ATP-binding cassette sub-family C member 2; ABCC3: ATP-binding 
cassette sub-family C member 3; ABCC4: ATP-binding cassette sub-family C member 4; ABCG2: 
ATP-binding cassette sub-family G member 2; FOLR1: folate receptor alpha; SLC16A7: solute 
carrier family 16 member 7; SLC19A1: solute carrier family 19 member 1; SLC22A6: solute 
carrier family 22 member 6; SLC22A8: solute carrier family 22 member 8; SLC22A11: solute 
carrier family 22 member 11; SCL46A1: solute carrier family 46 member 1; SLCO1B1: solute 
carrier organic anion transporter family member 1B1; SLCO1B3: solute carrier organic anion 
transporter family member 1B3; SLCO1A2: solute carrier organic anion transporter family 
member 1A2. 
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Table 1.  Characteristics and putative effects of SNPs in low-dose MTX transport function  
Genes Other 
names 
Location Chr rs ID Alleles Region  
(aa change) 
Putative effects  
in MTX transport 
function 
Ref. 
Solute carriers  
SLC16A7 MCT2 Kidney 12 rs3763980 A>T Exon (Thr445Ser) T carriers: ↓  influx  [17, 18] 
rs10877333 T>G Intron * [19] 
SLC19A1 
 
RFC1  
FOLT 
Ubiquitous 
 
21 rs7499 G>A 3´UTR * [20] 
 rs1051266 G>A Exon (Arg27His) AA: ↑  influx [24] 
 rs1131596 T>C 5´UTR CC: ↓  influx [39] 
 rs2838956 A>G Intron * [19] 
 rs3788200 G>A Intron *  [19] 
SLC22A6 OAT1 Kidney 11 rs11568626 C>T Exon (Arg50His) TT: ↓  influx [44, 46] 
SLC22A8 OAT3 Kidney 11 rs45566039 C>A Exon (Arg149Ser) AA: ↓  influx [47] 
SLC22A11 OAT4 Kidney 11 rs11231809 T>A Intron AA: ↑  clearance [49] 
SLC46A1 HCP1 
PCFT 
Intestine 17 rs2239907 G>A 3´UTR * [19] 
SLCO1A2 SLC21A3 Kidney 12 rs10841795 T>C Exon (Ile13Thr) CC: ↑  influx   [50, 51] 
SLCO1B1 LST1 
OATP1B1 
Liver 12 rs2306283 A>G Exon (Asn130Asp)  GG: ↑  influx [50, 54] 
rs4149056 T>C Exon (Val174Ala) CC: ↓  influx and 
clearance 
 
 
[52-54, 56] 
rs56387224 A>G Exon (Asn432Asp) GG: ↓  influx [52] 
SLCO1B3 LST3 
OATP1B3 
Liver 12 * n.a. n.a. n.a. [50] 
FOLR1 FBP 
FOLR 
Ubiquitous 11 * n.a. n.a. n.a. [58] 
ATP-binding cassette transporters   
ABCB1 MDR 
P-GP 
ABC20 
 CD243 
Intestine 7 rs1045642 C>T Exon (Ile1145Ile) TT: ↓  efflux [64] 
Liver Kidney rs1128503 C>T Exon (Gly412Gly) * [19] 
rs2032582 G>A/T Exon 
(Ala899Ser/Thr) 
A/T alleles: ↓  
efflux 
[70] 
 
ABCC1 MRP1 
ABC29 
Intestine 16 rs35592 T>C Intron * [71] 
rs246240 A>G Intron * [19] 
rs2074087 G>C Intron * [19] 
rs2230671 C>G Exon (Ser1334Ser) GG: ↑  efflux [74] 
rs3784864 G>A Intron * [19] 
ABCC2 MRP2 
ABC30 
Intestine  
Liver 
10 rs717620 G>A  5´UTR AA: ↑  clearance [76] 
 rs2273697 G>A Exon (Val417Ile) AA: ↑  efflux [77] 
Kidney  rs4148396 C>T  Intron * [19] 
  rs7080681 G>A Exon (Arg353His) * [19] 
ABCC3 MRP3 
ABC31 
Intestine 
Liver 
17 rs4793665 C>T 5´UTR TT: ↓  efflux [79] 
ABCC4 MRP4 
ABC32 
Liver 
Kidney 
13 * n.a. n.a. n.a. [48] 
ABCG2 BCRP 
 ABC15 
CD338 
Intestine 4 rs2231142 C>A Exon (Gln141Lys) AA: ↓  efflux [82] 
Liver  rs13120400 T>C Intron * [19] 
Kidney  rs17731538 G>A Intron * [19] 
↑ : increased; ↓ : decreased; *: unknown.  
A: adenine; aa: amino acid; Ala: alanine; Arg: arginine; ABC: ATP-binding cassette; BCRP: breast cancer resistance protein; C: 
cytosine; CD: cluster of differentiation; Chr: chromosome; FBP: folate binding protein; FOLR1: folate receptor alpha; FOLT: folate 
transporter; G: guanine; Gln: glutamine; Gly: glycine; HCP1: heme carrier protein 1; His: histidine; ID: identification; Ile: isoleucine; 
Lys: lysine; LST: liver-specific transporter; MCT2: monocarboxylate transporter 2; MDR: multidrug resistance protein; MRP: 
multidrug resistance-associated protein; MTX: methotrexate; n.a.: not assigned; OAT: organic anion transporter; OATP:  organic 
anion transporting polypeptide; PCFT: proton-coupled folate transporter; P-GP: P-glycoprotein;  Ref: reference; RFC1: reduced 
folate carrier 1; Ser: serine; SLC: solute carrier; SNP: single nucleotide polymorphism; T: thymine; Thr: threonine;  UTR: 
untranslated region; Val: valine. 
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CHAPTER V. SLC19A1 80G ALLELE AS A BIOMARKER OF 
METHOTREXATE-RELATED GASTROINTESTINAL TOXICITY IN 
PORTUGUESE RHEUMATOID ARTHRITIS PATIENTS 
This chapter  presents an original work that elucidates the clinical 
relevance of the solute carrier 19 family 1 G80A polymorphism and a set of 
clinicopathological variables as putative biomarkers of Methotrexate-related 
toxicity in Portuguese Rheumatoid Arthritis patients. As previously 
demonstrated, genetic polymorphisms, in genes encoding for Methotrexate 
membrane transport proteins with functional significance, can be partly 
responsible for pharmacokinetic and pharmacodynamics interpatient 
variability. One of the most important Methotrexate transporters is the 
solute carrier 19 family 1, a cell surface transmembrane protein which gene 
is polymorphic, being the rs1051266 described in literature as the most 
implicated in Methotrexate therapeutic outcome.  
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CHAPTER VI. SLC19A1, SLC46A1 AND SLCO1B1 
POLYMORPHISMS AS PREDICTORS OF METHOTREXATE-
RELATED TOXICITY IN PORTUGUESE RHEUMATOID 
ARTHRITIS PATIENTS 
 This chapter elucidates the influence of single nucleotide 
polymorphisms in genes encoding for Methotrexate membrane transporter 
proteins on the occurrence of Methotrexate-related toxicity in Portuguese 
Rheumatoid Arthritis patients. The work was performed in a relatively large 
number of single nucleotide polymorphisms (twenty-three) and in different 
genes (ten), because it was previously accepted that Methotrexate could enter 
cells by solute carrier 19 family 1 and, the presence of other influx and 
efflux transporters was not thoroughly explored concerning their functional 
polymorphisms impact in Methotrexate therapeutic outcome. In addition, 
many of the included single nucleotide polymorphisms had never been 
studied before, in both Rheumatoid Arthritis and Caucasian populations, 
concerning Methotrexate therapeutic outcome influence. 
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SLC19A1, SLC46A1 and SLCO1B1 polymorphisms as predictors of 
Methotrexate-related Toxicity in Portuguese Rheumatoid Arthritis 
patients 
 
RUNNING TITLE  
MTX transporters SNPs & MTX-related toxicity  
 
ABSTRACT 
Methotrexate (MTX) is used for rheumatoid arthritis (RA) treatment showing 
a wide toxicity profile. This study aims to evaluate the influence of single 
nucleotide polymorphisms (SNP) in genes that codify for MTX transporters 
with the occurrence of MTX-related toxicity (overall and gastrointestinal). A 
total of 233 Portuguese RA patients were genotyped for 23 SNPs. Haplotype 
analyses were performed and a toxicogenetic risk index (TRI) was created for 
those SNPs revealed to be statistically significant. Regarding MTX overall 
toxicity, an increased risk was associated to SLC19A1 rs7499 G carriers 
(P=0.017), SLC46A1 rs2239907 GG (P=0.030) and SLCO1B1 rs4149056 T 
carriers (P=0.040) and TT (P=0.019). TRI revealed that patients with index 3 
were 18-fold more likely to present an adverse drug reaction when compared 
to those with index 1 (P=0.001). For MTX gastrointestinal toxicity, results 
demonstrated an increased risk associated with SLC19A1 rs7499 G carriers 
(P=0.012) and GG (P=0.045), SLC19A1 rs1051266 G carriers (P=0.034), 
SLC19A1 rs2838956 A carriers (P=0.049) and, SLCO1B1 rs4149056 T carriers 
(P=0.042) and TT (P=0.025). Haplotype analysis showed association between 
GGAG haplotype for SLC19A1 rs7499, rs1051266, rs2838956 and rs3788200 
with MTX gastrointestinal toxicity (P=0.029). TRI revealed that patients with 
index 4 were 9-fold more likely to present a gastrointestinal disorder when 
compared to those with index 1 (P=0.020). This study revealed that SLC19A1, 
SLC46A1 and SLCO1B1 genotypes may help to identify patients with 
increased risk of MTX-related overall toxicity and that SLC19A1 
and SLCO1B1 genotypes, and SLC19A1 haplotypes may help to identify 
patients with increased risk of MTX-related gastrointestinal toxicity. 
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Keywords: Methotrexate; Polymorphisms; Rheumatoid arthritis; Transporters; 
Toxicity; Toxicogenetic risk index. 
 
INTRODUCTION 
Rheumatoid Arthritis (RA) is a complex, systemic autoimmune disease, 
characterized by a chronic inflammation of multiple peripheral joints (Smith 
et al., 2011), with a worldwide prevalence of 0.3% to 1.1% and incidence of 9 
to 60 cases per 100.000 inhabitants (Silman and Pearson, 2002). In Portugal, 
the prevalence of this disease is 0.36% and the incidence is between 20 and 
40 cases per 100 000 inhabitants (Branco and Canhao, 2011; Dias, 2001).  
Methotrexate (MTX) is currently the most widely used disease-modifying 
antirheumatic drug (DMARD) for RA treatment (Benucci et al., 2011) in doses 
up to 25mg per week. Nevertheless, treatment with MTX is not devoid of 
drawbacks and significant adverse drug reactions (ADRs) can occur due to 
interpatient variability (Benucci, et al., 2011;  Kremer, 2004). This variability 
can be consequence of MTX pharmacokinetics (PK) changes partly due to 
single nucleotide polymorphisms (SNPs) in genes that codify for MTX 
membrane transporter proteins - influx and/or efflux (Bohanec Grabar et al., 
2012;  Bohanec Grabar et al., 2008;  Chatzikyriakidou et al., 2007;  Moncrieffe 
et al., 2010;  Plaza-Plaza et al., 2012;  Trevino et al., 2009). MTX transporters 
are expressed in several tissues (International Transporter et al., 2010; 
Mikkelsen et al., 2011;  Qiu et al., 2006) which can affect absorption, 
distribution and/or elimination. In gastrointestinal tract, at apical membrane 
of enterocytes, MTX is absorbed through active transport mediated by solute 
carrier (SLC) family 19 member 1 (SLC19A1) and possibly by SLC family 46 
member 1 (SLC46A1) (Qiu, et al., 2006;  Swierkot and Szechinski, 2006;  Tian 
and Cronstein, 2007). As SLC19A1-mediated transport is saturable, MTX may 
also be transported by folate receptor alpha (FOLR1) (Spinella et al., 1995;  
Tian and Cronstein, 2007). Moreover, MTX effluxes from enterocytes to 
intestinal tract lumen can be mediated by ATP-binding cassette transporters 
(ABCs), i.e., by ABC sub-family C member 2 (ABCC2), ABC sub-family B 
member 1 (ABCB1) and ABC sub-family G member 2 (ABCG2), or to 
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bloodstream by ABC sub-family C member 1 (ABCC1) and ABC sub-family C 
member 3 (ABCC3) (Mikkelsen, et al., 2011). MTX hepatic uptake involves 
SLC19A1, SLC organic anion transporter family member 1B1 (SLCO1B1) and 
SLCO family member 1B3 (SLCO1B3) (Mikkelsen, et al., 2011); and, most of 
the MTX in hepatocytes reenters in bloodstream by ABCC3 and ABC sub-
family C member 4 (ABCC4) and only a small portion is excreted into the bile 
duct by ABCC2, ABCB1 and ABCG2 (International Transporter, et al., 2010;  
Mikkelsen, et al., 2011). MTX clearance is mainly through renal glomerular 
filtration and active secretion over the proximal tubular cells (Mikkelsen, et 
al., 2011). Several renal transporters have an affinity for MTX, allowing MTX 
influx into renal cells by SLC family 22 member 6 (SLC22A6) and SLC family 
22 member 8 (SLC22A8), in basolateral membrane, and by SLC family 22 
member 11 (SLC22A11) and SLCO family member 1A2 (SLCO1A2), in apical 
membrane (Inoue and Yuasa, 2014;  Mikkelsen, et al., 2011). Moreover, SLC 
family 16 member 7 (SLC16A7) has been described as having a moderate to 
low expression in plasma membrane of tubular cells, but its function on MTX 
transport remains unclear (Halestrap, 2013). Furthermore, MTX excretion 
through urinary tract can be mediated by ABCB1, ABCC2, ABCC4 and ABCG2 
(Benucci, et al., 2011;  Swierkot and Szechinski, 2006) (Figure 1). Since MTX 
therapeutic outcome can be conditioned by PK changes we aimed to 
elucidate the influence of SNPs in genes that codify for MTX membrane 
transporter proteins on the occurrence of MTX-related toxicity in Portuguese 
RA patients.   
 
MATERIALS AND METHODS 
Study design 
A retrospective study was performed between January 2009 and December 
2012 at São João Hospital Center (Porto, Portugal) in a cohort of consecutive 
Portuguese Caucasian patients with RA treated with MTX. All patients (≥ 18 
years) had to meet the 2010 revised classification criteria of American 
College of Rheumatology (ACR) and European League Against Rheumatism 
(EULAR) (Aletaha et al., 2010) and received MTX for at least one month. Other 
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concomitant drugs, such as corticosteroids, non-steroidal anti-inflammatory 
drugs (NSAIDs), and other DMARDs were allowed during the study. Patients 
were excluded from the study if had drug abuse history, recent pregnancy or 
desire to become pregnant during the study. The study was approved by the 
local research ethics committee (reference 33/2009) and informed written 
consent was obtained from all patients according to the standards of the 
Helsinki Declaration.  
 
Clinical assessments 
Patient demographics, clinicopathological and treatment characteristics were 
collected from clinical records. Clinical efficacy was assessed using the 
Disease Activity Score in 28 joints (DAS28) as described by Prevoo et al. 
(Prevoo et al., 1995). MTX-related toxicity was defined when patients 
presented any ADR related to MTX. At the time of each visit, physician 
directly asked the patient whether MTX-related ADRs were currently 
occurring and ADRs were recorded. The type of ADR was classified in System 
Organ Class (SOC) disorders, in accordance with the Common Terminology 
Criteria for Adverse Events (CTCAE) (U.S.department of health and human 
services, 2010). Due to the well-known protective effect of folic acid 
supplementation for the prevention of toxicity occurrence (Lima et al., 2013b;  
Ortiz et al., 2000), this drug was prescribed to all patients and their regular 
compliance was registered.  
 
Sample processing  
Whole blood samples were obtained with standard venipuncture technique in 
ethylenediaminetetraacetic acid (EDTA) containing tubes. Genomic 
deoxyribonucleic acid (DNA) was extracted with QIAamp

 DNA Blood Mini Kit 
(QIAGEN, Hilden, Germany), according to the manufacturer instructions, and 
quantified using the NanoDrop

 1000 Spectrophotometer v3.7 (Thermo 
Scientific, Wilmington DE, USA). 
 
 
 
 
178 
 
SNPs selection and genotyping procedures 
A total of twenty-three SNPs in ten genes that codify for MTX membrane 
transporter proteins were selected based on their putative effects on MTX 
transport function and/or MTX-related toxicity (Table 1). Sequenom® Assay 
Design 3.1 software was used to design the primers and genotyping was 
performed according to standard Sequenom® iPLEX protocol (Bradic et al., 
2011). Genomic sequence was amplified by multiplex polymerase chain 
reaction (PCR), the amplified product was treated with Shrimp alkaline 
phosphatase and used for allele specific primer extension (iPLEX) reaction 
(Sequenom®, Sand Diego, CA, USA). Reaction mixture was then spotted onto a 
SpectroCHIP microarray and subjected to the matrix-assisted laser 
desorption/ionization time-of-fight mass spectrometry (MALDI-TOF MS). 
Genotypes were assigned based on the presence of mass peaks by the 
MassARRAY Typer v4.0 software (Sequenom®, San Diego, CA, USA) (Bradic, et 
al., 2011). Results were manually inspected and verified, using the 
MassARRAY Typer Analyzer v4.0 software (Sequenom®, San Diego, CA, USA). 
For quality control, 10% of the samples were randomly selected for a second 
analysis and results were 100% concordant.  
 
Statistical analysis  
Statistical analyses were performed with either IBM
®
 SPSS
® 
Statistics for 
Windows, Version 20.0 (IBM Corp, Armonk, NY, USA) and SNPStats software 
(Sole et al., 2006). Genotype frequencies were assessed and tested for Hardy-
Weinberg equilibrium (HWE). SNPs were excluded from analysis when 
genotyping call rates were less than 95% and when minor allele frequency 
was less than 10.0%. Binary logistic regression analysis was used to identify 
which genotypes were associated with MTX-related toxicity. Analysis was 
performed adjusting to potential confounders, i.e. clinicopathological 
variables possibly influencing MTX-related toxicity, selected based on 
literature review and clinical significance (Halilova et al., 2012; Lima, et al., 
2013b;  Morel and Combe, 2005). These variables included: 1) patient-related: 
gender, age, smoking and renal function (estimated glomerular filtration rate 
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– eGFR – and serum creatinine – SCr); 2) disease-related: diagnosis age and 
disease duration; and, 3) treatment-related: folic acid, corticosteroids, 
NSAIDs, other DMARDs and MTX administration characteristics (dose, 
treatment duration and administration route). Haplotype analysis was 
performed to assess possible consequences on the phenotype by the co-
presence of several variants of the same gene. Linkage disequilibrium (LD) 
between SNPs in the same gene was estimated and expressed as D´ 
coefficients. The measure was interpretable as the proportion of the 
maximum possible level of association between two loci, given the allele 
frequencies, ranging from 0 (linkage equilibrium) to 1 (complete LD) (Schaid 
et al., 2002). Haplotype frequencies were estimated by SNPStats software. 
Possible haplotypes were tested for association with MTX-related toxicity by 
taking the most frequent haplotype as reference. Rare haplotypes (estimated 
haplotype frequency <2.0%) were excluded. A toxicogenetic risk index (TRI) 
was created for each patient by the sum of risk genotypes from the SNPs 
that revealed to be statistically significant when associated with MTX-related 
toxicity. Results were expressed as odds ratios (OR) with 95% confidence 
intervals (CI) and considering a probability (P) value of 5% or less as 
statistically significant. 
 
RESULTS 
Patients’ characteristics 
This study included follow-up data from 233 patients, 196 (84.1%) females 
and 37 (15.9%) males, with a median age of 52.0 (26.0-87.0) years old, of 
which 32 (13.7%) were smokers. In this population, the median of SCr was 
8.20 mg/L (4.00-19.80), the median of eGFR was 82.0 ml/min/1.73m
2
 (29.00-
186.00) and 30 patients (12.9%) presented chronic renal insufficiency (eGFR 
<60 ml/min/1.73m
2
).  Considering disease-related variables, the mean 
diagnosis age was 40.3 ± 13.2 years old and the median disease duration 
was 10.0 years (0.3-51.0). Only 136 patients (58.4%) used MTX as unique 
DMARD, while 97 patients (41.6%) were treated with MTX combined with 
other synthetic or biological DMARDs. MTX was administered by per os (PO) 
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in 210 (90.1%) and by subcutaneous route (SC) in 23 (9.9%) of the patients, 
and the median MTX treatment duration was 47.0 months (1.0-240.0) with a 
median dose of 15.0 mg/week (2.5-25.0). Regarding concomitant drugs, other 
than MTX, 188 (80.7%) patients were under corticosteroids therapy, 170 
patients (73.0%) used NSAIDs and 118 patients (50.6%) complied regularly 
with a folic acid supplementation.  MTX-related toxicity was registered in 77 
(33.0%) patients. Figure 2 represents the observed ADRs classified in SOCs 
disorders according to CTCAE. 
  
MTX transporters SNPs: Genotypes and Haplotypes characteristics 
Genotypes distribution of studied SNPs is represented in Table 2. SLC22A6 
rs11568626 and ABCG2 rs2231142 were excluded from analysis since minor 
allele frequency was less than 10.0% and ABCC1 rs2230671 was excluded 
from analysis because genotyping call rates were less than 95%. Taking this 
into account, twenty SNPs were considered. For ABCB1 rs2032582, 3 patients 
(1.3%) presented AG genotype and 3 patients (1.3%) presented AT genotype. 
Given the low frequency, these 6 patients were excluded from the analysis. 
Genotypes distribution was in HWE (P >0.050) except for the SLC19A1 G>A, 
rs1051266. Figure 3 demonstrates the estimated D´ coefficients of the 
studied SNPs for the possible haplotypes in the same gene. SLC16A7, 
SLC19A1, ABCB1, ABCC1, ABCC2 and ABCG2 SNPs were in LD, except for 
ABCC1 rs246240, and ABCC1 rs2074087. 
 
MTX transporters SNPs: Genotypes & MTX-related toxicity 
Table 3 and Table 4 represent the relation between MTX-related toxicity and 
SNPs in SLCs and ABCs, respectively. Regarding MTX overall toxicity, our 
results demonstrated that for SNPs in SLCs, SLC19A1 rs7499 G carriers 
(P=0.017, OR=3.72), SLC46A1 rs2239907 G homozygotes (P=0.030, OR=2.32) 
and SLCO1B1 rs4149056 T carriers and T homozygotes (P=0.040, OR=2.78; 
and P=0.019, OR=2.82; respectively) were associated with an increased risk 
for MTX-related overall toxicity. Considering the MTX gastrointestinal 
toxicity, similar results were shown for SNPs in SLCs. SLC19A1 rs7499 G 
carriers and G homozygotes (P=0.012, OR=5.64; and P=0.045, OR=2.39; 
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respectively), SLC19A1 rs1051266 G carriers (P=0.034, OR=3.07), SLC19A1 
rs2838956 (P=0.049, OR=3.21) and SLCO1B1 rs4149056 T carriers and T 
homozygotes (P=0.042, OR=3.09; and P=0.025, OR=2.92, respectively) were 
associated with MTX-related gastrointestinal toxicity. No statistically 
significant differences were observed in relation to the SNPs in ABCs for 
MTX-related overall and/or gastrointestinal toxicity.  
 
MTX transporters SNPs: Haplotypes & MTX-related toxicity 
Table 5 represents the relation between MTX transporters genes haplotypes 
and MTX-related toxicity. Since ABCC1 rs246240 and rs2074087 were not in 
LD, analyses were performed considering the following combinations: 1) 
ABCC1 rs35592, rs246240 and rs3784864; and 2) ABCC1 rs35592, rs2074087 
and rs3784864. Results showed that no statistically significant differences 
were observed in relation to MTX transporters genes haplotypes and MTX-
related overall toxicity. Nevertheless, for MTX gastrointestinal toxicity, our 
results demonstrated that GGAG haplotype (constituted by ancestral alleles) 
for SLC19A1 rs7499, rs1051266, rs2838956 and rs3788200, respectively, was 
associated with MTX-related gastrointestinal toxicity when compared to 
AAGA haplotype (constituted by minor alleles) (P=0.029). No statistically 
significant differences were observed for the remaining haplotypes.   
 
MTX transporters SNPs: Toxicogenetic risk index for MTX 
A TRI for MTX-related toxicity was created for each patient by the sum of risk 
genotypes from the SNPs that revealed to be statistically significant when 
associated with MTX-related toxicity (see Table 3 and Table 4). The TRI was 
adjusted for potential confounders as described in the Methods section. 
Regarding MTX overall toxicity, the risk genotypes were as follow: SLC19A1 
rs7499 G carriers, SLC46A1 rs2239907 G homozygotes and SLCO1B1 
rs4149056 T carriers. Figure 4 represents the contribution of the TRI to the 
occurrence of MTX-related overall toxicity in RA patients treated with MTX. 
The number (%) of patients is given for each incremental unit of the index. 
The TRI ranged from 0 to 3. An increased TRI value was associated with an 
 
 
182 
 
increased incidence of ADRs (P=0.020). Patients with index 2 were 3.06 times 
(95% CI: 1.04-8.99) more likely to present a ADR when compared to those 
with index 1 (P=0.042), patients with index 3 were 3.52 times (95% CI: 1.37-
9.03) more likely to present a ADR when compared to those with index 2 
(P=0.009) and patients with index 3 were 18.79 times (95% CI: 3.39-104.12) 
more likely to present a ADR when compared to those with index 1 (P=0.001). 
Regarding MTX gastrointestinal toxicity, the risk genotypes were as follow: 
SLC19A1 rs7499 G carriers, SLC19A1 rs1051266 G carriers, SLC19A1 
rs2838956 A carriers and SLCO1B1 rs4149056 T carriers. Figure 5 represents 
the contribution of the TRI to the occurrence of MTX-related gastrointestinal 
toxicity in RA patients under MTX. The number (%) of patients is given for 
each incremental unit of the index. The TRI ranged from 0 to 4 and an 
increased TRI value was associated with an increased incidence of 
gastrointestinal disorders (P=0.010). No statistically significant differences 
were observed between patients with index 1 and patients with index 2 
(P=1.000) and between patients with index 2 and patients exhibiting index 3 
(P=0.429). Patients with index 4 were 5.11 times (95% CI: 1.56-16.70) more 
likely to present gastrointestinal disorders compared to those with index 3 
(P=0.007) and patients with index 4 were 9.50 times (95% CI: 1.43-62.95) more 
likely to present gastrointestinal disorders when compared to those with 
index 1 (P=0.020). 
 
DISCUSSION 
MTX therapeutic outcome can be altered by several factors such as SNPs in 
genes that codify for MTX membrane transporter proteins. This study 
evaluated the influence of 23 SNPs in SLCs and ABCs MTX transporters as 
predictors of MTX-related toxicity in Portuguese RA patients. Hence, we have 
performed genotype and haplotype based approaches, considering a 
toxicogenetic risk index, with multivariate logistic regression analysis 
adjusted to potential confounders. Genotypes distribution of studied SNPs 
were in HWE and were similar to those previously described for Caucasian 
populations (de Rotte et al., 2012;  Moncrieffe, et al., 2010;  Owen et al., 
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2013) and in the National Center for Biotechnology Information (NCBI) 
database, except for the SLC19A1 rs1051266.  Regarding the observed ADRs, 
results were in accordance with literature and associated with weekly 
administration of MTX in low-dose, since the most frequent ADRs were 
gastrointestinal disorders (Bohanec Grabar, et al., 2012;  Kremer, 2004).  
 
Genotypes & MTX-related toxicity 
SLC19A1 is a bidirectional transporter, described as being expressed in the 
majority of tissues, with relevance in enterocytes and hepatocytes (Hinken, 
et al., 2011;  Qiu, et al., 2006). Accordingly to genotype analysis, our results 
demonstrated that SLC19A1 rs7499 G carriers were associated with an 
increased risk for MTX-related toxicity (overall and gastrointestinal). This 
SNP occurs in the 3´-untranslated region (UTR) in a region thought to be 
important for messenger ribonucleic acid (mRNA) stability, localization and 
translational efficiency (Lynch et al., 2005) and, therefore, important to 
membrane transporter expression. Nevertheless, its effect in this 
bidirectional transporter function is unknown. We propose that GG genotype 
could provide an increased influx capability leading to higher bioavailability, 
increased MTX tissues exposure and, consequently, to toxicity. In literature, 
only one study in Caucasian RA patients dealt with the influence of this SNP 
in MTX-related toxicity, but no association was found (Owen, et al., 2013). 
Regarding SLC19A1 rs1051266, our results showed that G carriers were 
associated with MTX-related gastrointestinal toxicity but no associations 
were observed in accordance to MTX overall toxicity. Bohanec Grabar et al. 
have previously reported that G homozygotes had a higher risk for MTX 
overall toxicity (Bohanec Grabar, et al., 2012;  Bohanec Grabar, et al., 2008) 
but did not clearly described the impact on gastrointestinal ADRs, and the 
majority of other studies did not have associations with toxicity 
(Chatzikyriakidou, et al., 2007;  Owen, et al., 2013;  Plaza-Plaza, et al., 2012). 
Thus, these controversial studies regarding to this SNP and MTX-related 
gastrointestinal toxicity need further clarification. We hypothesize that GG 
genotype could provide an increased influx capability leading to higher 
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bioavailability, increased MTX tissues exposure, mainly in tissues where 
SLC19A1 is highly expressed and, consequently, to gastrointestinal toxicity. 
Furthermore, is important to consider if enterohepatic recirculation 
contributes to major differences in bioavailability, reinforcing the importance 
of understanding the role of transporters in this pathway.  In addition, A 
carriers for SLC19A1 rs2838956, had a borderline trend towards significance 
for MTX-related toxicity (overall and gastrointestinal). This is possibly caused 
by an increased influx capability of A carriers, which consequently, leads to 
greater MTX tissues exposure and toxicity. Our results are in accordance 
with a previously report by Bohanec Grabar et al. that demonstrated a 
borderline significant trend towards MTX-related overall toxicity for A 
carriers, particularly for skin and subcutaneous tissue disorders (Bohanec 
Grabar, et al., 2012), yet other study reported no statistically significant 
association (Owen, et al., 2013). The impact of this variant in SLC19A1 is 
currently unknown and functional studies are essential since intronic SNPs 
can potentially influence RNA splicing, which may affect transporter 
structure and function (Wang and Cooper, 2007).  
In relation to SLC46A1 rs2239907, G homozygotes revealed association with 
MTX overall toxicity. This SNP is also located in a 3´UTR region, which is 
thought to be important in mRNA stability, localization and translational 
efficiency (Lynch, et al., 2005) and then considered as a potential functional 
SNP. However, the effect of this SNP in the transporter function is currently 
unknown. SLC46A1 is mostly expressed in apical membrane of enterocytes 
but also can be found in other cells (Qiu, et al., 2006). Thus, we hypothesized 
that GG genotype could provide an increased influx leading to higher 
bioavailability and, consequently, to higher MTX tissues exposure and 
toxicity. Nevertheless, the complexity of these mechanisms and the presence 
of other factors that could also play a role, such as the putative contribution 
of enterohepatic recirculation as well as its possible influence in renal 
function deserves further consideration. To our best knowledge this is the 
first report to analyze the effect of this SNP with MTX-related toxicity in RA. 
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Regarding SLCO1B1 rs4149056, T carriers were associated with MTX-related 
toxicity (overall and gastrointestinal). T carriers have been associated with 
an increased membrane expression of SLCO1B1 and higher MTX influx and 
clearance (Trevino, et al., 2009). Despite the SLCO1B1 transporter is mainly 
expressed on basolateral membrane of hepatocytes (Konig, et al., 2000), its 
mRNA also has been detected in other tissues, including small intestinal 
enterocytes (Glaeser et al., 2007), which can explain the MTX intracellular 
retention (gastrointestinal and hepatic) leading to cytotoxicity. The 
association of T allele with MTX-related toxicity has been previously 
described for high-dose MTX (Trevino, et al., 2009) but this is the first report 
to analyze the influence of SLCO1B1 rs4149056 with MTX-related toxicity in 
RA.  
Accordingly to ABCG2 rs13120400, C carriers had a borderline trend towards 
significance for MTX-related toxicity. ABCG2 transporter, located in apical 
membranes of enterocytes, hepatocytes and kidney tubular cells, is 
responsible for MTX efflux from the enterocytes to intestinal tract lumen and 
MTX excretion into bile and urine (Mikkelsen, et al., 2011). Then, it is 
plausible to explain our results as follows: C carriers should cause a reduced 
efflux capability, which is translated, in less MTX elimination and higher MTX 
bioavailability, thus leading to toxicity.  This is the first report to associate 
this SNP with MTX-related toxicity in RA patients.  
 
Haplotypes & MTX-related toxicity 
Haplotypes may have a particular significance in regard to functionality or as 
genetic markers for unknown functional variants, claiming for full haplotypic 
information to be encompassed into studies in order to better characterize 
the role of a candidate gene (Hodge et al., 1999;  Lima et al., 2013a). In fact, 
haplotypes constituted by SNPs with both unknown and known impact in 
transporter functions could provide a putative association of these, yet 
unknown variants, towards depicting the role of transporters function in 
toxicity development. Therefore, haplotype analysis was performed, to 
assess of possible consequences on the phenotype in the co-presence of 
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several variants of the same gene. From haplotypes analysis, our results 
showed that GGAG haplotype for SLC19A1 rs7499, rs1051266, rs2838956 
and rs3788200, was associated with MTX-related gastrointestinal toxicity 
when compared to AAGA haplotype. The association of GGAG haplotype with 
gastrointestinal toxicity was expected from the genotype analyses obtained 
results for those SNPs in SLC19A1. Considering this, we can hypothesize that 
GGAG haplotype could provide an increased MTX influx capability, leading to 
higher MTX intracellular levels, mainly in tissues where SLC19A1 is highly 
expressed (Qiu, et al., 2006) and, thus, have an increased risk for 
gastrointestinal toxicity development.  
 
Toxicogenetic risk index for MTX 
To an improved characterization of the impact of studied SNPs that were 
statistically significant associated with MTX-related toxicity, a TRI was 
created, both for overall and gastrointestinal toxicity. Accordingly to MTX 
overall toxicity, an increased TRI value was associated with an increased 
incidence of ADRs. Our results demonstrated that patients with index 3 were 
18-fold times more likely to present an ADR when compared to those with 
index 1. Regarding to the occurrence of gastrointestinal disorders, the TRI 
demonstrated that patients with index 4, when compared to those with index 
3 and 1, were 5-fold and 9-fold, respectively, more likely to present 
gastrointestinal disorders. This highlights the importance of genotyping 
patients and the urgency of developing the field of therapy personalization 
for the prediction of MTX-related toxicity development.  
Besides the potential importance of our results, we are aware of possible 
study limitations such the sample size and the study design. Despite this, 
our data are supported by the fact that: 1) our population is relatively 
homogenous regarding ethnic origin (all Caucasians from the North region of 
Portugal) with a prevalence of RA similar to other countries; 2) studied 
patient group characteristics were in accordance with other reported studies 
in regard to disease gender epidemiology (Gibofsky, 2012) and to diagnosis 
age range (Rindfleisch and Muller, 2005); 3) statistical analyses were 
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performed attending to potential confounder variables limiting the selection 
bias; and 4) having studied twenty-three SNPs in genes that codify for MTX 
membrane transporter proteins, many of which had never been studied 
before, in both RA and Caucasian populations. Moreover, and due the low 
frequency of SOC disorders, other than gastrointestinal disorders in our 
population, the influence of the studied SNPs in there occurrence could not 
be performed. Knowing that MTX transporters are expressed in different 
tissues, this line of investigation could be proved of remarkable relevance 
since it would enable the prediction of toxicity in each tissue and help to 
guide therapeutic choices. Moreover, the influence of SNPs in MTX 
transporters genes in MTX circulating levels should be performed in order to 
elucidate SNPs impact in transport function and toxicity development. 
Despite this, we have to consider that MTX retention is also dependent of 
MTX polyglutamation levels and, thus, genetic polymorphisms in enzymes 
involved in MTX polyglutamation process should also be evaluated.     
Other studies with similar approach demonstrated irrelevant results 
concerning the associations of discussed SNPs with MTX-related toxicity. 
Several explanations may be proposed to clarify these discrepancies as 
follow: differences in genotyping methodologies, ethnic origins, study 
population size and possible confounding variables not considered in 
studies; majority of authors do not define similarly the concept of toxicity; 
and, most of studies did not follow standard guidelines for ADRs 
classification. Those reasons concur to some erratic conclusions to be taken 
and render adequate comparison between studies difficult to pursuit. 
Therefore, and due to the lack of SNPs combined studies using both 
functional and/or associated with MTX-related toxicity, further evidence is 
necessary to support the interpretation of our results and elucidate previous 
inconsistent results.   
 
Final conclusions 
From this study, we can conclude that of all studied SNPs in ABCs, only 
ABCG2 rs13120400 seems to be associated with MTX-related toxicity 
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occurrence. Interestingly, it also reveals that SNPs in SLCs should be helpful 
to elucidate which patients will benefit from MTX treatment since SLC19A1 
rs7499, SLC46A1 rs2239907 and SLCO1B1 rs4149056, appeared to be 
associated with increased risk for MTX overall toxicity and SLC19A1 rs7499, 
SLC19A1 rs1051266, SLC19A1 rs2838956 and SLCO1B1 rs4149056, showed 
association with MTX gastrointestinal toxicity. Furthermore, SLC19A1 
haplotypes may help to identify patients with increased risk of developing 
MTX gastrointestinal toxicity. Additionally, the proposed toxicogenetic risk 
index highlights the importance of genotyping patients and the urgency of 
developing the field of therapy personalization for the prediction of MTX-
related toxicity development.  
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ABBREVIATIONS LIST 
A: adenine; aa: amino acid; Ala: alanine; Arg: arginine; ABC: ATP-binding cassette; ACR: 
American College of Rheumatology; ADR: adverse drug reaction; BCRP: breast cancer 
resistance protein; C: cytosine; Chr: chromosome; CI: confidence interval; CTCAE: Common 
Terminology Criteria for Adverse Events; DAS28: Disease Activity Score in 28 joints; DMARDs: 
disease modifying anti-rheumatic drugs; EDTA: ethylenediaminetetraacetic acid; eGFR: 
estimated glomerular filtration rate; EULAR: European League Against Rheumatism; FOLT: 
folate transporter; G: guanine; Gln: glutamine; Gly: glycine; HCP1: heme carrier protein 1; His: 
histidine; ID: identification; Ile: isoleucine; Lys: lysine; LST1: liver-specific transporter 1; MCT2: 
monocarboxylic acid – transporter 2; MDR: multidrug resistance protein; MRP: multidrug 
resistance-associated protein; MTX: methotrexate; NSAIDs: non-steroidal anti-inflammatory 
drugs; OAT: organic anion transporter; OR: odds ratio; P-GP: P-glycoprotein; PCFT: proton-
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coupled folate transporter; PK: pharmacokinetics; RA: rheumatoid arthritis; Ref: reference; 
RFC1: reduced folate carrier 1; SCr: serum creatinine; Ser: serine; SNP: single nucleotide 
polymorphisms; SLC: solute carrier; SOC: System Organ Class; T: thymine; Thr: threonine; TRI: 
toxicogenetic risk index; UTR: untranslated region; Val: valine. 
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FIGURES 
 
 
 
 
 
Figure 1. Methotrexate membrane transporter proteins location and representation of their influx and/or 
efflux function. 
ABCB1: ATP-binding cassette sub-family B member 1; ABCC1: ATP-binding cassette sub-family C member 1; ABCC2: ATP-binding 
cassette sub-family C member 2; ABCC3: ATP-binding cassette sub-family C member 3; ABCC4: ATP-binding cassette sub-family C 
member 4; ABCG2: ATP-binding cassette sub-family G member 2; FOLR1: folate receptor alpha; SLC16A7: solute carrier family 16 
member 7; SLC19A1: solute carrier family 19 member 1; SLC22A6: solute carrier family 22 member 6; SLC22A8: solute carrier family 
22 member 8; SLC22A11: solute carrier family 22 member 11; SCL46A1: solute carrier family 46 member 1; SLCO1A2: solute carrier 
organic anion transporter family member 1A2; SLCO1B1: solute carrier organic anion transporter family member 1B1; SLCO1B3: 
solute carrier organic anion transporter family member 1B3. 
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Figure 2. Observed MTX-related ADRs by SOCs disorders.   
Gastrointestinal disorders included anorexia, abdominal distension, diarrhea, dyspepsia, nauseas, stomach pain and/or vomiting. 
Skin and subcutaneous tissue disorders included alopecia, rash maculo-papular and rheumatoid nodulosis exacerbation. 
Hepatobiliary disorders included transaminases serum elevation. Respiratory, thoracic and mediastinal disorders included 
hypersensitivity pneumonitis. 
 
 
 
 
Figure 3. Estimated D´ coefficients and P values for possible haplotypes.  
Dark gray boxes represent the single nucleotide polymorphisms that were in linkage disequilibrium.  
A: adenine; ABCB1: ATP-binding cassette sub-family B member 1; ABCC1: ATP-binding cassette sub-family C member 1; ABCC2: ATP-
binding cassette sub-family C member 2; ABCG2: ATP-binding cassette sub-family G member 2; C: cytosine; G: guanine; SLC16A7: 
solute carrier family 16 member 7; SLC19A1: solute carrier family 19 member 1; T: thymine. 
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Figure 4. A. Contribution of the toxicogenetic risk index in MTX-related overall toxicity occurrence. B. 
Percentage of RA patients with MTX-related ADRs in relation to toxicogenetic risk index for overall 
toxicity.   
Index 0 included SLC19A1 rs7499 A homozygotes + SLC46A1 rs2239907 T carriers + SLCO1B1 rs4149056 C homozygotes. Index 1 
included SLC19A1 rs7499 G carriers, SLC46A1 rs2239907 G homozygotes or SLCO1B1 rs4149056 T carriers. Index 2 included 
SLC19A1 rs7499 G carriers + SLC46A1 rs2239907 G homozygotes; SLC19A1 rs7499 G carriers + SLCO1B1 rs4149056 T carriers; 
and, SLC46A1 rs2239907 G homozygotes + SLCO1B1 rs4149056 T carriers. Index 3 included SLC19A1 rs7499 G carriers + SLC46A1 
rs2239907 G homozygotes + SLCO1B1 rs4149056 T carriers. 
 
 
 
Figure 5. A. Contribution of the toxicogenetic risk index in MTX-related gastrointestinal toxicity 
occurrence. B. Percentage of RA patients with MTX-related gastrointestinal disorders in relation to 
toxicogenetic risk index for gastrointestinal toxicity.   
Index 0 included SLC19A1 rs7499 A homozygotes + SLC19A1 rs1051266 A homozygotes + SLC19A1 rs2838956 G homozygotes + 
SLCO1B1 rs4149056 C homozygotes. Index 1 included SLC19A1 rs7499 G carriers, SLC19A1 rs1051266 G carriers, SLC19A1 
rs2838956 A carriers or SLCO1B1 rs4149056 T carriers. Index 2 included SLC19A1 rs7499 G carriers + SLC19A1 rs1051266 G 
carriers; SLC19A1 rs7499 G carriers + SLC19A1 rs2838956 A carriers; SLC19A1 rs7499 G carriers + SLCO1B1 rs4149056 T carriers; 
SLC19A1 rs1051266 G carriers + SLC19A1 rs2838956 A carriers; SLC19A1 rs1051266 G carriers + SLCO1B1 rs4149056 T carriers; 
and, SLC19A1 rs2838956 A carriers + SLCO1B1 rs4149056 T carriers. Index 3 included SLC19A1 rs7499 G carriers + SLC19A1 
rs1051266 G carriers + SLC19A1 rs2838956 A carriers; SLC19A1 rs7499 G carriers + SLC19A1 rs1051266 G carriers + SLCO1B1 
rs4149056 T carriers; SLC19A1 rs7499 G carriers + SLC19A1 rs2838956 A carriers + SLCO1B1 rs4149056 T carriers; and, SLC19A1 
rs1051266 G carriers + SLC19A1 rs2838956 A carriers + SLCO1B1 rs4149056 T carriers. Index 4 included SLC19A1 rs7499 G 
carriers + SLC19A1 rs1051266 G carriers + SLC19A1 rs2838956 A carriers + SLCO1B1 rs4149056 T carriers. 
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Table 1.  Characteristics and putative effects of 23 SNPs in MTX transport function and related toxicity 
Genes Protein 
name 
Chr rs ID Allele
s 
Region  
(aa change) 
Putative effects  Ref. 
MTX Transport 
Function 
MTX-
related 
Toxicity 
Solute carriers        
SLC16A7 MCT2 12 rs3763980 A>T Exon 
(Thr445Ser) 
T allele: ↑ 
influx 
- (Halestrap, 2013) 
rs10877333 T>G Intron - - - 
SLC19A1 
 
RFC1  
FOLT 
21 rs7499 G>A 3´UTR - n.a. (Hinken et al., 2011;  
Owen et al., 2012) 
rs1051266 G>A Exon (Arg27His) AA: ↑ influx A carriers: 
↓ toxicity                
(Baslund et al., 
2008;  Bohanec 
Grabar, et al., 2012;  
Bohanec Grabar, et 
al., 2008;  
Chatzikyriakidou, et 
al., 2007;  Lima, et 
al., 2013b) 
rs2838956 A>G Intron - A carriers: 
↑ toxicity                
(Bohanec Grabar, et 
al., 2012) 
rs3788200 G>A Intron AA:  ↓ influx - (O'Byrne et al., 
2010) 
SLC22A6 OAT1 11 rs11568626 C>T Exon (Arg50His) TT: ↓ influx - (Bleasby et al., 2005;  
Sun et al., 2001) 
SLC22A1
1 
OAT4 11 rs11231809 T>A Intron AA: ↓ clearance - (Vormfelde et al., 
2006) 
SLC46A1 HCP1 
PCFT 
17 rs2239907 G>A 3´UTR - - - 
SLCO1B1 LST1 
OATP1B1 
12 rs4149056 T>C Exon (Val174Ala) CC: ↓ influx 
and clearance 
 
 
- (Konig et al., 2000;  
Trevino, et al., 2009) 
ATP-binding cassette transporters       
ABCB1 MDR 
P-GP 
 
7 rs1045642 C>T Exon (Ile1145Ile) TT: ↓ efflux TT: ↑ 
toxicity                
(Bohanec Grabar, et 
al., 2008;  Kooloos 
et al., 2010;  Wang 
et al., 2005) 
rs1128503 C>T Exon (Gly412Gly) - TT: ↑ 
toxicity 
(Ranganathan et al., 
2008) 
rs2032582 G>A/
T 
Exon 
(Ala899Ser/Thr) 
A/T alleles: ↓ 
efflux 
n.a. (Bohanec Grabar, et 
al., 2008) 
ABCC1 MRP1 
 
16 rs35592 T>C Intron - n.a.
 
(Berggren et al., 
2007;  Stamp et al., 
2010) 
rs246240 A>G Intron - - - 
rs2074087 G>C Intron - n.a. (Ranganathan, et al., 
2008) 
rs2230671 C>G Exon 
(Ser1334Ser) 
GG: ↑ efflux n.a. (Ranganathan, et al., 
2008) 
rs3784864 G>A Intron - - - 
ABCC2 MRP2 
 
10 rs717620 G>A  5´UTR AA: ↑ clearance n.a. (Ranganathan, et al., 
2008;  Simon et al., 
2013) 
rs4148396 C>T  Intron - CC: ↑ 
toxicity 
(Ranganathan, et al., 
2008;  Stamp, et al., 
2010) 
ABCG2 BCRP 
 
4 rs2231142 C>A Exon 
(Gln141Lys) 
AA: ↓ efflux AA: ↑ 
toxicity 
(Stamp, et al., 2010;  
Zhang et al., 2013) 
rs13120400 T>C Intron - - - 
rs17731538 G>A Intron - n.a. (Stamp, et al., 2010) 
-: Unknown; n.a.: not associated. 
A: adenine; aa: amino acid; Ala: alanine; Arg: arginine; ABC: ATP-binding cassette; BCRP: breast cancer resistance protein; C: cytosine; Chr: 
chromosome; FOLT: folate transporter; G: guanine; Gln: glutamine; Gly: glycine; HCP1: heme carrier protein 1; His: histidine; ID: identification; Ile: 
isoleucine; Lys: lysine; LST1: liver-specific transporter 1; MCT2: monocarboxylic acid – transporter 2; MDR: multidrug resistance protein; MRP: 
multidrug resistance-associated protein; MTX: methotrexate; OAT: organic anion transporter; PCFT: proton-coupled folate transporter; P-GP: P-
glycoprotein;  Ref: reference; RFC1: reduced folate carrier 1; Ser: serine; SNP: single nucleotide polymorphism; SLC: solute carrier T: thymine; Thr: 
threonine; UTR: untranslated region; Val: valine. 
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Table 2. Genotype distribution for the 23 studied SNPs 
Genes rs ID Alleles 
Genotype frequency  
Ancestral allele 
homozygotes 
Heterozygotes Minor  allele 
homozygotes 
Solute carriers    
SLC16A7 rs3763980 A>T  119 (51.1) 92 (39.5) 22 (9.4) 
 rs10877333 T>G  161 (69.1) 68 (29.2) 4 (1.7) 
SLC19A1 rs7499 G>A 91 (39.1) 104 (44.6) 38 (16.3) 
 rs1051266 G>A 80 (34.3) 91 (39.1) 62 (26.6) 
 rs2838956 A>G  82 (35.2) 109 (46.8) 42 (18.0) 
 rs3788200 G>A  82 (35.2) 109 (46.8) 42 (18.0) 
SLC22A6 rs11568626
#
 C>T  232 (99.6) 1 (0.4) 0 (0.0) 
SLC22A11 rs11231809 T>A 80 (34.3) 120 (51.5) 33 (14.2) 
SLC46A1 rs2239907 G>A  87 (37.3) 99 (42.5) 47 (20.2) 
SLCO1B1 rs4149056 T>C 169 (72.5) 16 (6.9) 48 (20.6) 
ATP-binding cassette transporters    
ABCB1 rs1045642 C>T 63 (27.0) 109 (46.8) 61 (26.2) 
 rs1128503 C>T  77 (33.0) 107 (46.0) 49 (21.0) 
 rs2032582* G>A/T 81 (34.8) 99 (42.5) 47 (20.1) 
ABCC1 rs35592 T>C 124 (53.2) 86 (36.9) 23 (9.9) 
 rs246240 A>G 159 (68.3) 66 (28.3) 8 (3.4) 
 rs2074087 G>C 146 (62.7) 76 (32.6) 11 (4.7) 
 rs2230671
#
 C>G 117 (92.9) 9 (7.1) 0 (0.0) 
 rs3784864 G>A 67 (28.8) 111 (47.6) 55 (23.6) 
ABCC2 rs717620 G>A 135 (57.9) 91 (39.1) 7 (3.0) 
 rs4148396 C>T 75 (32.2) 109 (46.8) 49 (21.0) 
ABCG2 rs2231142
#
 C>A  200 (85.8) 33 (14.2) 0 (0.0) 
 rs13120400 T>C 116 (49.8) 96 (41.2) 21 (9.0) 
 rs17731538 G>A 137 (58.8) 87 (37.3) 9 (3.9) 
#
 SNPs were excluded from analysis when genotyping call rates were less than 95% and when minor allele frequency was less than 
10.0%.  
* 6 patients were excluded from the analyses since 3 (1.3%) presented AG genotype and 3 (1.3%) presented AT genotype. 
A: adenine; ABC: ATP-binding cassette; C: cytosine; G: guanine; SLC: solute carrier; SLCO: solute carrier organic anion transporter; 
SNP: single nucleotide polymorphism; T: thymine. 
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Table 3. Relation between SNPs in solute carriers and MTX-related toxicity 
 Model Alleles MTX overall toxicity MTX gastrointestinal toxicity 
P  OR (95% CI) P  OR (95% CI) 
SLC16A7 A>T 
(rs3763980) 
Dominant  A carriers 
0.581 
Reference 
0.590 
Reference 
TT 0.72 (0.22-2.35) 0.70 (0.19-2.55) 
Recessive  AA 
0.447 
Reference 
0.539 
Reference 
T carriers 1.34 (0.63-2.85) 1.29 (0.57-2.91) 
SLC16A7 T>G 
(rs10877333) 
Dominant  T carriers 
0.636 
Reference 
0.843 
Reference 
GG 0.53 (0.04-7.31) 0.77 (0.06-10.00) 
Recessive  TT 
0.761 
Reference 
0.842 
Reference 
G carriers 1.23 (0.52-2.42) 1.09 (0.48-2.43) 
SLC19A1  G>A 
(rs7499) 
Dominant  G carriers 
0.017 
Reference 
0.012 
Reference 
AA 0.27 (0.09-0.79) 
a)
 0.18 (0.05-0.69) 
b)
 
Recessive  GG 
0.109 
Reference 
0.045 
Reference 
A carriers 0.54 (0.25-1.15) 0.43 (0.19-0.98) 
c)
 
SLC19A1 G>A 
(rs1051266) 
Dominant  G carriers 
0.150 
Reference 
0.034 
Reference 
AA 0.53 (0.23-1.26) 0.33 (0.12-0.92) 
d)
 
Recessive  GG 
0.690 
Reference 
0.512 
Reference 
A carriers 0.86 (0.40-1.82) 0.77 (0.35-1.70) 
SLC19A1  A>G 
(rs2838956) 
Dominant  A carriers 
0.055 
Reference 
0.049 
Reference 
GG 0.37 (0.14-1.02)  0.31 (0.10-1.00) 
e)
 
Recessive  AA 
0.170 
Reference 
0.126 
Reference 
G carriers 0.60 (0.28-1.25) 0.54 (0.24-1.19) 
SLC19A1 G>A 
(rs3788200) 
Dominant  G carriers 
0.140 
Reference 
0.078 
Reference 
AA 0.48 (0.18-1.27) 0.36 (0.12-1.12) 
Recessive  GG 
0.158 
Reference 
0.113 
Reference 
A carriers 0.58 (0.28-1.23) 0.53 (0.24-1.16) 
SLC22A11 T>A 
(rs11231809) 
Dominant  T carriers 
0.806 
Reference 
0.506 
Reference 
AA 0.89 (0.34-2.33) 0.70 (0.24-2.02) 
Recessive  TT 
0.906 
Reference 
0.716 
Reference 
A carriers 0.95 (0.43-2.09) 1.17 (0.50-2.78) 
SLC46A1  G>A 
(rs2239907) 
Dominant  G carriers 
0.605 
Reference 
0.859 
Reference 
AA 0.79 (0.32-1.94) 0.92 (0.36-2.33) 
Recessive  GG 
0.030 
Reference 
0.155 
Reference 
A carriers 0.43 (0.20-0.92) 
f)
 0.55 (0.24-1.25) 
SLCO1B1 T>C 
(rs4149056) 
Dominant  T carriers 
0.040 
Reference 
0.042 
Reference 
CC 0.36 (0.14-0.96) 
g)
 0.32 (0.11-0.96) 
h)
 
Recessive  TT 
0.019 
Reference 
0.025 
Reference 
C carriers 0.36 (0.15-0.84) 
i)
 0.34 (0.13-0.88) 
j)
 
P value <0.05 is considered to be of statistically significance (highlighted in bold). 
P value, odds ratio (OR) and 95% confidence intervals (CI) corresponds to multivariate logistic regression adjusted to patient-related 
variables (gender, age, smoking, eGFR and SCr), disease-related variables (diagnosis age and disease duration), and treatment-related 
variables (folic acid, corticosteroids, NSAIDs, other concomitant DMARDs and MTX administration characteristics such as dose, 
treatment duration and administration route). 
a)
When reference was AA genotype: OR=3.72, 95% CI: 1.26-10.93. 
b)
When reference was AA genotype: OR=5.64, 95% CI: 1.45-21.86. 
c)
When 
reference was A carriers: OR=2.39, 95% CI: 1.06-5.38. 
d)
When reference was AA genotype: OR=3.07, 95%CI: 1.09-8.65. 
e)
When reference 
was GG genotype: OR=3.21, 95%CI: 1.00-10.25. 
f)
When reference was A carriers: OR=2.32, 95% CI: 1.08-4.97.
 g)
When reference was CC 
genotype: OR=2.78, 95% CI: 1.05-7.39. 
h)
When reference was CC genotype: OR=3.09, 95% CI: 1.04-9.17. 
i)
When reference was C carriers: 
OR=2.82, 95% CI: 1.18-6.72.  
j)
When reference was C carriers: OR=2.92, 95% CI: 1.14-7.46. 
A: adenine; C: cytosine; CI: confidence interval; eGFR: estimated glomerular filtration rate; G: guanine; MTX: methotrexate; OR: odds 
ratio; SCr: serum creatinine; SLC: solute carrier; SLCO: solute carrier organic anion transporter; SNP: single nucleotide polymorphism; T: 
thymine. 
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Table 4. Relation between SNPs in ATP-binding cassette transporters and MTX-related toxicity  
 Model Alleles MTX overall toxicity MTX gastrointestinal toxicity 
P  OR (95% CI) P  OR (95% CI) 
ABCB1 C>T 
(rs1045642) 
Dominant  C carriers 
0.515 
Reference 
0.475 
Reference 
TT 0.76 (0.33-1.75) 0.72 (0.30-1.77) 
Recessive  CC 
0.794 
Reference 
0.540 
Reference 
T carriers 0.90 (0.41-1.98) 0.77 (0.34-1.77) 
ABCB1 C>T 
(rs1128503) 
Dominant  C carriers 
0.481 
Reference 
0.777 
Reference 
TT 1.36 (0.58-3.15) 1.14 (0.45-2.89) 
Recessive CC 
0.269 
Reference 
0.426 
Reference 
T carriers 1.55 (0.71-3.37) 1.39 (0.62-3.14) 
ABCB1 G>A/T 
(rs2032582) 
Dominant G carriers 
0.833 
Reference 
0.652 
Reference 
TT 0.91 (0.38-2.18) 0.80 (0.30-2.10) 
Recessive GG 
0.167 
Reference 
0.346 
Reference 
T carriers 1.71 (0.80-3.66) 1.47 (0.66-3.25) 
ABCC1 T>C 
(rs35592) 
Dominant T carriers 
0.734 
Reference 
0.367 
Reference 
CC 1.21 (0.40-3.73) 1.68 (0.55-5.15) 
Recessive TT 
0.349 
Reference 
0.141 
Reference 
C carriers 1.40 (0.69-2.85) 1.79 (0.82-3.88) 
ABCC1 A>G 
(rs246240) 
Dominant A carriers 
0.978 
Reference 
0.356 
Reference 
GG 0.97 (0.14-6.64) 0.28 (0.02-4.13) 
Recessive AA 
0.148 
Reference 
0.174 
Reference 
G carriers 1.78 (0.82-3.86) 1.78 (0.77-4.11) 
ABCC1 G>C 
(rs2074087) 
Dominant G carriers 
0.864 
Reference 
0.716 
Reference 
CC 1.15 (0.24-5.46) 1.34 (0.28-6.40) 
Recessive GG 
0.210 
Reference 
0.103 
Reference 
C carriers 0.62 (0.29-1.31) 0.50 (0.22-1.15) 
ABCC1 G>A 
(rs3784864) 
Dominant G carriers 
0.733 
Reference 
0.975 
Reference 
AA 1.16 (0.50-2.70) 0.99 (0.40-2.46) 
Recessive GG 
0.328 
Reference 
0.325 
Reference 
A carriers 0.67 (0.30-1.49) 0.66 (0.28-1.52) 
ABCC2 G>A 
(rs717620) 
Dominant  G carriers 
0.556 
Reference 
0.701 
Reference 
AA 1.74 (0.28-10.84) 1.50 (0.19-11.89) 
Recessive  GG 
0.722 
Reference 
0.672 
Reference 
A carriers 0.88 (0.42-1.81) 0.84 (0.38-1.85) 
ABCC2 C>T 
(rs4148396) 
Dominant  C carriers 
0.953 
Reference 
0.894 
Reference 
TT 1.03 (0.43-2.48) 1.07 (0.41-2.78) 
Recessive  CC 
0.995 
Reference 
0.562 
Reference 
T carriers 1.00 (0.45-2.21) 1.29 (0.54-3.05) 
ABCG2 T>C 
(rs13120400) 
Dominant T carriers 
0.457 
Reference 
0.354 
Reference 
CC 0.62 (0.18-2.18) 0.51 (0.12-2.12) 
Recessive  TT 
0.069 
Reference 
0.052 
Reference 
C carriers 1.99 (0.95-4.16) 2.21 (0.94-4.92) 
ABCG2 G>A 
(rs17731538) 
Dominant  G carriers 
0.459 
Reference 
0.455 
Reference 
AA 0.52 (0.10-2.89) 0.48 (0.07-3.31) 
Recessive  GG 
0.510 
Reference 
0.557 
Reference 
A carriers 0.78 (0.37-1.65) 0.78 (0.35-1.76) 
P value <0.05 is considered to be of statistically significance (highlighted in bold). 
P value, odds ratio (OR) and 95% confidence intervals (CI) corresponds to multivariate logistic regression adjusted to patient-related 
variables (gender, age, smoking, eGFR and SCr), disease-related variables (diagnosis age and disease duration), and treatment-related 
variables (folic acid, corticosteroids, NSAIDs, other concomitant DMARDs and MTX administration characteristics such as dose, 
treatment duration and administration route). 
A: adenine; ABC: ATP-binding cassette; C: cytosine; CI: confidence interval; eGFR: estimated glomerular filtration rate; G: guanine; MTX: 
methotrexate; OR: odds ratio; SCr: serum creatinine; SNP: single nucleotide polymorphism; T: thymine. 
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Table 5. Relation between MTX transporters genes haplotypes and MTX-related toxicity  
Haplotype Estimated 
frequency 
(%) 
MTX overall toxicity MTX gastrointestinal 
toxicity 
P OR (95% CI) P  OR (95% CI) 
SLC16A7 A>T 
(rs3763980) 
SLC16A7 T>G 
(rs10877333) 
   
  
 
 
A T   54.5  Reference  Reference 
T T   29.2 0.780 1.10 (0.58-2.08) 0.940 1.03 (0.51-2.05) 
A G   16.3 0.630 1.22 (0.55-2.70) 0.670 1.20 (0.53-2.72) 
SLC19A1  
G>A (rs7499) 
SLC19A1 G>A 
(rs1051266) 
SLC19A1  A>G 
(rs2838956) 
SLC19A1 G>A 
(rs3788200) 
 
  
 
 
G G A G 48.7  Reference  Reference 
A A G A 33.6 0.089 0.58 (0.31-1.08) 0.029 0.46 (0.23-0.92) 
G A A G 5.8 0.920 1.07 (0.25-4.52) 0.550 0.58 (0.09-3.55) 
G A G A 4.4 0.590 1.50 (0.34-6.56) 0.580 1.66 (0.28-10.02) 
A G A G 2.0 0.920 1.10 (0.19-6.27) 0.610 0.59 (0.07-4.64) 
ABCB1 C>T 
(rs1045642) 
ABCB1 C>T 
(rs1128503) 
ABCB1 G>A/T 
(rs2032582) 
  
  
 
 
C C G  43.7  Reference  Reference 
T T T  37.5 0.530 1.21 (0.66-2.23) 0.740 1.12 (0.58-2.15) 
T C G  10.7 0.084 0.33 (0.10-1.15) 0.100 0.35 (0.10-1.22) 
C T T  3.9 
0.670 
1.40 (0.30-6.62) 
0.720 
1.35 (0.27-6.75) 
C T G  2.7 
0.920 
0.91 (0.15-5.57) 
0.770 
0.75 (0.11-5.24) 
ABCC1 T>C 
(rs35592) 
ABCC1 G>C 
(rs2074087) 
ABCC1 G>A 
(rs3784864) 
  
 
 
 
 
T G A  42.6  Reference  Reference 
C G G  18.1 
0.640 
1.21 (0.54-2.69) 
0.300 
1.57 (0.68-3.62) 
T G G  17.7 
0.200 
1.83 (0.73-4.56) 
0.220 
1.85 (0.69-4.94) 
C C G  9.4 
0.370 
1.63 (0.56-4.74) 
0.320 
1.78 (0.57-5.48) 
T C G  7.4 
0.140 
0.23 (0.03-1.62) 
0.120 
0.18 (0.02-1.51) 
T C A  4.0 
0.560 
0.47 (0.04-6.06) 
0.700 
0.60 (0.05-7.75) 
ABCC1 T>C 
(rs35592) 
ABCC1 A>G 
(rs246240) 
ABCC1 G>A 
(rs3784864) 
  
 
 
 
 
T A A  46.3  Reference  Reference 
T A G  18.9 
0.890 
1.06 (0.44-2.54) 
0.710 
1.20 (0.46-3.09) 
C A G  16.4 
0.710 
1.18 (0.52-2.62) 
0.510 
1.34 (0.56-3.18) 
C G G  11.1 
0.200 
1.91 (0.71-5.16) 
0.140 
2.19 (0.78-6.12) 
T G G  6.2 
0.290 
2.00 (0.56-7.11) 
0.810 
1.21 (0.25-5.96) 
ABCC2 G>A 
(rs717620) 
ABCC2 C>T 
(rs4148396) 
   
 
 
 
 
G C   55.3  Reference  Reference 
A T   22.2 
0.240 
1.60 (0.74-3.48) 
0.110 
1.98 (0.85-4.59) 
G T   22.2 
0.700 
1.14 (0.60-2.17) 
0.800 
1.10 (0.55-2.20) 
ABCG2 T>C 
(rs13120400) 
ABCG2 G>A 
(rs17731538) 
   
 
 
 
 
T G   48.6  Reference  Reference 
C G   28.7 
0.900 
1.04 (0.52-2.11) 
0.840 
1.08 (0.52-2.22) 
T A   21.7 
0.210 
0.58 (0.25-1.35) 
0.290 
0.65 (0.29-1.44) 
P value < 0.05 is considered to be of statistically significance (highlighted in bold). 
P value, odds ratio (OR) and 95% confidence intervals (CI) corresponds to multivariate logistic regression adjusted to patient-related variables (gender, 
age, smoking, eGFR and SCr), disease-related variables (diagnosis age and disease duration), and treatment-related variables (folic acid, 
corticosteroids, NSAIDs, other concomitant DMARDs and MTX administration characteristics such as dose, treatment duration and administration 
route). 
A: adenine; ABC: ATP-binding cassette; C: cytosine; CI: confidence interval; DMARDs: disease modifying anti-rheumatic drugs; eGFR: estimated 
glomerular filtration rate; G: guanine; MTX: methotrexate; NSAIDs: non-steroidal anti-inflammatory drugs; OR: odds ratio; SCr: serum creatinine; SLC: 
solute carrier; T: thymine. 
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CHAPTER VII. PREDICTION OF METHOTREXATE CLINICAL 
RESPONSE IN PORTUGUESE RHEUMATOID ARTHRITIS 
PATIENTS: IMPLICATION OF MTHFR rs1801133 AND ATIC 
rs4673993 POLYMORPHISMS 
 Besides the influence of Methotrexate-carrier mediated system in 
therapeutic outcome, functional polymorphisms in genes encoding for target-
proteins involved on Methotrexate action mechanism (such as folate and de 
novo nucleotides synthesis pathways) could also determine Methotrexate 
pharmacodynamics. Thus, this chapter elucidates the influence of 
clinicopathological variables on clinical response to Methotrexate, as well of 
methylenetetrahydrofolate reductase C677T and aminoimidazole 
carboxamide adenosine ribonucleotide transformylase T675C 
polymorphisms, in Portuguese Rheumatoid Arthritis patients. 
Methylenetetrahydrofolate reductase, an enzyme involved in folate pathway, 
despite not directly inhibited by Methotrexate or by its polyglutamate forms, 
its expression levels seemed play a role in Methotrexate effect by modifying 
the folate status. Additionally, it is known that aminoimidazole carboxamide 
adenosine ribonucleotide transformylase, an enzyme involved in the de novo 
purine synthesis pathway, is directly inhibited by Methotrexate 
polyglutamate forms, leading to the release of adenosine, a potent anti-
inflammatory agent. Therefore, these enzymes seem to be key targets for 
analyzing potential functional polymorphisms impact in Methotrexate 
therapeutic outcome. 
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CHAPTER VIII. CURRENT APPROACHES ON THYMIDYLATE 
SYNTHASE POLYMORPHISMS AND ITS IMPORTANCE ON 
MOLECULAR EPIDEMIOLOGY AND PHARMACOGENETICS 
This chapter presents a review about thymidylate synthase biological 
and pharmacological role and its genetic polymorphisms association with 
disease susceptibility, Methotrexate therapeutic outcome (clinical response 
and toxicity occurrence) and patients’ survival. This work was motivated by 
thymidylate synthase potential as an important target for several drugs, 
such as Methotrexate, and also to be a critical target for providing the 
needed nucleotide precursors to maintain deoxyribonucleic acid synthesis 
and repair. Since thymidylate synthase is involved in folate modulation, and 
several diseases have frequent genetic alterations in folate metabolism 
associated genes, it seems important to analyze the association between 
thymidylate synthase genetic polymorphisms and the diseases susceptibility 
and prognosis. The most studied thymidylate synthase polymorphisms 
(rs34743033, rs2853542 and rs34489327) are located on untranslated 
regions and seem to influence thymidylate synthase protein expression 
levels.  
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CHAPTER IX. ROLE OF KEY TYMS POLYMORPHISMS ON 
METHOTREXATE THERAPEUTIC OUTCOME IN RHEUMATOID 
ARTHRITIS PORTUGUESE PATIENTS 
This chapter elucidates the clinical relevance of the most studied 
thymidylate synthase polymorphisms (rs34743033, rs2853542 and 
rs34489327), using genotype and haplotype-based approaches, in 
Methotrexate therapeutic outcome (clinical response and toxicity occurrence) 
of Portuguese Rheumatoid Arthritis patients. The focus on thymidylate 
synthase stems from conclusions obtained in the review article that it is 
worth analyzing thymidylate synthase genetic polymorphisms association 
with Methotrexate therapeutic outcome. 
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Role of key TYMS polymorphisms on Methotrexate therapeutic 
outcome in Rheumatoid Arthritis Portuguese patients 
 
SHORT TITLE  
TYMS polymorphisms & MTX therapeutic outcome in RA 
 
ABSTRACT 
Background: Therapeutic outcome of rheumatoid arthritis (RA) patients 
treated with methotrexate (MTX) can be modulated by thymidylate synthase 
(TS) levels, which may be altered by genetic polymorphisms in TS gene 
(TYMS). This study aims to elucidate the influence of TYMS polymorphisms in 
MTX therapeutic outcome (regarding both clinical response and toxicity) in 
Portuguese RA patients. Methods: Clinicopathological data from 233 
Caucasian RA patients treated with MTX were collected, outcomes were 
defined and patients were genotyped for the following TYMS polymorphisms: 
1) 28 base pairs (bp) variable number tandem repeat (rs34743033); 2) single 
nucleotide polymorphism C>G (rs2853542); and 3) 6bp sequence deletion 
(1494del6, rs34489327). Chi-square and binary logistic regression analyses 
were performed, using genotype and haplotype-based approaches. Results: 
Considering TYMS genotypes, 3R3R (p=0.005, OR=2.34), 3RC3RG (p=0.016, 
OR=3.52) and 6bp- carriers (p=0.011, OR=1.96) were associated with non-
response to MTX. Multivariate analysis confirmed the increased risk for non-
response to MTX in 6bp- carriers (p=0.016, OR=2.74). Data demonstrated that 
TYMS polymorphisms were in linkage disequilibrium (p<0.00001). Haplotype 
multivariate analysis revealed that haplotypes harboring both 3R and 6bp- 
alleles were associated with non-response to MTX. Regarding MTX-related 
toxicity, no statistically significant differences were observed in relation to 
TYMS genotypes and haplotypes. Conclusion: Our study reveals that TYMS 
polymorphisms could be important to help predicting clinical response to 
MTX in RA patients. Despite the potential of these findings, translation into 
clinical practice needs larger studies to confirm these evidences.   
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Key Words: Genotypes; Haplotypes; Methotrexate; Polymorphisms; 
Rheumatoid Arthritis; Therapeutic Outcome; Thymidylate Synthase; TS; TYMS. 
 
INTRODUCTION  
Methotrexate (MTX) is the cornerstone for rheumatoid arthritis (RA) 
treatment and is the most widely used disease-modifying antirheumatic drug 
(DMARD) in newly diagnosed patients [1,2]. Despite its cost-effectiveness, 
therapeutic outcome is variable mainly concerning to MTX clinical response 
and/or development of MTX-related toxicity [3-7]. MTX is an antifolate drug 
with important anti-inflammatory and antiproliferative effects, partly 
achieved by the intracellular inhibition of thymidylate synthase (TS) [8-10]. 
TS is a key protein for the de novo pyrimidine synthesis and is responsible 
for the simultaneous conversion of deoxyuridine monophosphate (dUMP) 
and 5,10-methylenetetrahydrofolate (5,10-MTHF) to deoxythymidine 
monophosphate (dTMP) and dihydrofolate (DHF). Subsequently, the dTMP is 
phosphorylated to deoxythymidine triphosphate (dTTP) and used for the 
deoxyribonucleic acid (DNA) synthesis and repair [6,11,12] (Figure 1A). Since 
TS levels were found to be predictive of MTX therapeutic outcome [13,14] 
and genetic polymorphisms in TS gene (TYMS) have been associated with TS 
levels [15,16], pharmacogenomics has raised great interest and, in fact, some 
studies have attempted to clarify the influence of genetic variations on 
clinical response to MTX in RA [17]. The most studied polymorphisms 
(rs34743033, rs2853542 and rs34489327) are represented on Figure 1B. 
Polymorphism rs34743033 is a 28 base pairs (bp) variable number tandem 
repeat (VNTR), located on 5’ untranslated region (UTR) [18]. Is characterized 
by exhibiting a putative Enhancer box (E-box) sequence on the first 28bp 
repeat of 2R allele and on the two first repeats of 3R allele [15,19]. Therefore, 
a higher number of repeats should increase the amount of E-box binding 
sites for the upstream stimulating factors (USF), leading to an increased 
transcription of TYMS and, consequently, to higher TS levels [20]. In addition, 
a single nucleotide polymorphism (SNP) characterized by a cytosine to 
guanine (C>G) transition on the twelfth nucleotide of the second repeat of 
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VNTR 3R allele (rs2853542) has been described [15]. In the presence of 
cytosine (3RC) the E-box seems to be disrupted, reducing the stimulation of 
transcription in comparison to 3RG, thereby decreasing TS levels [15]. Since 
this SNP occurs within the TYMS 28bp VNTR polymorphism, several studies 
have been performed combining the information from both TYMS enhancer 
region (TSER) polymorphisms [6,21]. Another important polymorphism is a 
6bp sequence (TTAAAG) deletion (1494del6, rs34489327) at 3´UTR, which 
seems to affect a region of TS pre-messenger ribonucleic acid (mRNA) that 
contains cis adenylate-uridylate-rich elements (AREs) [22,23]. These elements 
bind to a trans AU-rich factor 1 (AUF1), preferentially in the presence of 
deletion allele (6bp-), diminishing mRNA stability and, consequently, 
decreasing TS levels [16,22,23]. Therefore, the aim of this study was to 
elucidate the clinical relevance of these TYMS polymorphisms, by genotype 
and haplotype-based approaches, in MTX therapeutic outcome of Portuguese 
RA patients. 
 
METHODS 
Patients and study design 
A retrospective study was performed between January 2009 and December 
2012 at São João Hospital Center (Porto, Portugal) in a cohort of consecutive 
Caucasian patients (≥ 18 years) with RA treated with MTX. Patients were 
excluded from the study if there was history of drug abuse, recent pregnancy 
or desire to become pregnant. The study was approved by the Ethical 
Committee of São João Hospital Center (reference 33/2009), procedures were 
considered to be according to the standards of the Helsinki Declaration and 
all patients provided an informed written consent.  
After diagnosis, patients were classified according the 1987 criteria of the 
American College of Rheumatology (ACR) and reclassified according the 
2010 criteria of the ACR and the European League Against Rheumatism 
(EULAR) [24]. All patients were initially treated with 10mg per os (PO)/week 
of MTX in monotherapy. This dose was increased 5mg at each three weeks if 
the patients did not meet the EULAR criteria for response, i.e., if presented a 
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Disease Activity Score in 28 joints (DAS28) >3.2. Every 3 months treatment 
response was evaluated and, on the: 1) first evaluation, if patients have no 
response or show gastrointestinal toxicity, administration route was 
changed to subcutaneous (SC); 2) second evaluation, if maximum tolerable 
dose was used without response, MTX therapy was discontinued or 
associated with other synthetic DMARD; and 3) third evaluation, in patients 
without response and other contraindication, therapy was changed by 
associating a biological DMARD. The occurrence of MTX-related toxicity was 
registered at each visit and, according to severity, MTX dose was adjusted or 
discontinued. Folic acid supplementation was prescribed to all patients for 
the prevention of toxicity occurrence and their regular compliance was 
registered [7,25,26]. Other concomitant drugs, such as corticosteroids and 
non-steroidal anti-inflammatories (NSAIDs) were allowed during the study. 
 
Outcome definition 
Non-response. MTX clinical response was recorded at time of each visit. Non-
response was defined when patients presented a DAS28 >3.2, calculated and 
defined as described by Prevoo et al. [27], in two consecutive evaluations. 
Therefore, non-response to MTX had a minimum period of MTX therapy, at 
least, of six months.  
 
Toxicity. The occurrence of MTX-related toxicity, defined when patients 
presented any adverse drug reaction (ADR) related to MTX, was recorded 
upon each visit. The type of ADR was classified in System Organ Class (SOC) 
disorders, in accordance with Common Terminology Criteria for Adverse 
Events (CTCAE) [28].  
 
Samples handling and TYMS genotyping 
Whole blood samples from each patient were obtained with standard 
venipuncture technique in ethylenediaminetetraacetic acid (EDTA) containing 
tubes. Genomic DNA was extracted with QIAamp
® 
DNA Blood Mini Kit 
(QIAGEN, Hilden, Germany) according to manufacturer instructions and total 
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genomic DNA was quantified, and its purity analyzed, using the NanoDrop

 
1000 Spectrophotometer v3.7 (Thermo Scientific, Wilmington DE, USA). 
 
TSER polymorphisms. 28bp VNTR polymorphism (rs34743033) and SNP C>G 
(rs2853542) at the twelfth nucleotide of the second repeat of 3R allele were 
genotyped as described by Lima et al. [29].  For quality control, 10% of the 
samples were randomly selected for a second analysis and 10% percent of 
cases were confirmed by automated sequencing in a 3130xl Genetic Analyzer 
using the Kit BigDye Terminator v3.1 (Life Technologies, Foster City, CA, 
USA). Results were 100% concordant.  
 
TYMS 1494del6 polymorphism. 1494del6 polymorphism (rs34489327) was 
genotyped as described by Lima et al. [29] with slight modifications. PCR 
products were purified with USB ExoSAP-IT (Affymetrix, Santa Clara, CA, 
USA) before cycle sequencing. Sequence reactions were carried out using the 
sequencing Kit BigDye Terminator v.3.1 (Life Technologies, Foster City, CA, 
USA) according to manufacturer’s specifications. The sequencing profile was 
30 cycles at 96°C for 10 seconds, 55°C for 10 seconds and 60° for 60 seconds, 
followed by an extension cycle at 60°C for 10 minutes. The sequence 
products were purified with illustra Sephadex G-50 Fine DNA Grade (GE 
Healthcare, Fairfield, CT, EUA) columns, denatured with Hi-Di™ Formamide 
and run in an 3130xl Genetic Analyzer (Life Technologies, Foster City, CA, 
USA). For quality control, 10% of the samples were randomly selected for a 
second analysis and results were 100% concordant.  
 
Polymorphisms classification and linkage disequilibrium measure 
TSER polymorphisms were classified according to their theoretical TS 
functional status as previously described [6] and grouped by predicted 
expression levels, as follow: low expression genotypes (2R2R, 2R3RC and 
3RC3RC), median expression genotypes (2R3RG and 3RC3RG) and high 
expression genotype (3RG3RG). Haplotype analysis was performed using a 
two-stage iterative method named expectation maximization algorithm 
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(SNPStats software) [30]. In order to estimate LD between pairs of alleles at 
TSER and TYMS 1494del6 loci, D’ coefficients were calculated in Arlequin for 
Windows, Version 3.11 (University of Berne, Bern, Switzerland) [31]
 
with 
100,000 number of steps in Markov chain. The measure was interpretable as 
the proportion of maximum possible level of association between two loci, 
given the allele frequencies, ranging from 0 (linkage equilibrium) to 1 
(complete LD) [32]. Possible haplotypes were tested for association with risk 
for non-response to MTX and for MTX-related toxicity by taking the most 
frequent haplotype as reference.  
 
Statistical analysis 
Statistical analyses were performed with either IBM
®
 SPSS
® 
Statistics for 
Windows, Version 20.0 (IBM Corp, Armonk, NY, USA), OpenEpi for Windows, 
Version 2.3.1 [33] and SNPStats software [30]. Genotype and allele 
frequencies were assessed and tested for Hardy-Weinberg equilibrium (HWE). 
All statistical tests were two-sided and a probability (p) value of 5% or less 
was considered as statistically significant. The Pearson Chi-square test or 
Fisher’s exact test were used to compare the outcome variables and TYMS 
polymorphisms. The odds ratio (OR) and the correspondent 95% confidence 
intervals (CI) were calculated as a measure of the association between the 
categorical variables. To correct for multiple comparisons, Bonferroni’s 
method was applied in order to control the false positive rate, and a 
significance level of α=0.05/(n comparisons) was used [34]. Forest plot was 
performed using MedCalc
®
 software for Windows, Version 13.1.2 [35]. 
Multivariate analysis with binary logistic regression was used to identify 
which TYMS genotypes or haplotypes could predict the occurrence of non-
response to MTX and MTX-related toxicity. This analysis was performed 
adjusting to potential confounding clinicopathological variables in three 
steps. In the first step patient-related variables (age, gender and smoking) 
were considered; in a second step, beyond patient-related variables, disease-
related variables (diagnosis age and disease duration) were added; and in a 
third step, beyond patient and disease-related variables, treatment-related 
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variables (folic acid supplementation, corticosteroids therapy, use of NSAIDs, 
other concomitant DMARDs used and MTX administration characteristics - 
dose, treatment duration and administration route) were also considered.  
 
RESULTS 
Population description  
This study included follow-up data of 233 patients, 196 (84.1%) females and 
37 (15.9%) males, with a mean age of 51±11.6 years old, of which 32 (13.7%) 
were smokers. Considering the disease-related variables, the mean age at 
diagnosis was 40.3 ± 13.2 years old and the median disease duration was 7.0 
years (0.3-51.0). All 233 (100.0%) patients were treated with MTX with a 
median dose of 15.0 mg/week (2.5-25.0), 118 (50.6%) complied regularly to 
folic acid supplementation, 188 (80.7%) were under corticosteroid therapy 
and 170 (73.0%) used NSAIDs. 
Non-response to MTX (DAS28 >3.2 in two consecutive evaluations) was 
observed in 128 (54.9%) patients. Regarding disease activity, the mean for 
DAS28 was 4.2 ± 1.3.  MTX-related toxicity was registered in 77 (33.0%) 
patients. The observed ADRs were classified in SOCs disorders as follow: 58 
(75.3%) gastrointestinal disorders (abdominal distension, diarrhea, 
dyspepsia, nauseas, stomach pain and/or vomiting); 9 (11.7%) skin and 
subcutaneous tissue disorders (alopecia, rash maculo-papular and 
rheumatoid nodulosis exacerbation); 5 (6.5%) hepatobiliary disorders 
(determined by transaminases serum elevation); and 5 (6.5%) respiratory, 
thoracic and mediastinal disorders (hypersensitivity pneumonitis). Since the 
number of cases in each SOCs disorders were small, the evaluation of TYMS 
polymorphisms with clinical relevance as possible biomarkers of MTX-related 
toxicity was performed for MTX-related overall toxicity.  
 
TYMS genotype and haplotype analyses  
Genotypes distribution of TYMS polymorphisms was in HWE (p>0.050) in the 
studied population. Frequencies of 28bp VNTR alleles and genotypes were: 
2R allele 41.8%; 3R allele 57.3%; 4R allele 0.9%; 2R2R 15.0% (n=35); 2R3R 
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53.7% (n=125); 3R3R 29.6% (n=69); and 3R4R 1.7% (n=4). Due to the low 
frequency of 3R4R genotype, it was excluded from the analyses. Considering 
TSER polymorphisms, genotypes distribution was: 2R allele 42.6%; 3RC allele 
33.0%; 3RG allele 24.4%; 2R2R 15.3% (n=35); 2R3RC 29.7% (n=68); 2R3RG 
24.9% (n=57); 3RC3RC 12.6% (n=29); 3RC3RG 10.9% (n=25); and 3RG3RG 6.6% 
(n=15). According to TS theoretical functional status, genotypes frequencies 
were: low expression 57.6% (n=132); median expression 35.8% (n=82); and 
high expression 6.6% (n=15). Frequencies of 1494del6 alleles and genotypes 
were: 6pb+ allele 70.0%; 6bp- allele 30.0%; 6bp+6bp+ 48.9% (n=114); 6bp+6bp- 
41.6% (n=97); and 6bp-6bp- 9.5% (n=22). 
Haplotype analysis revealed that 28bp VNTR and 1494del6 polymorphisms 
were in LD (p<0.00001). Alleles 2R and 6bp+, and alleles 3R and 6bp- were 
the most linked ones (D’=0.67 for both). The analysis demonstrated four 
haplotypes: 2R6bp+ 38.4%; 2R6bp- 4.1%; 3R6bp+ 31.7% and 3R6bp- 25.8%. 
TSER and 1494del6 polymorphisms were also in LD (p<0.00001). Alleles 2R 
and 6bp+ (D’=0.67) and 3RG and 6bp- (D’=0.48) demonstrated to be the most 
linked ones. This analysis showed six haplotypes: 2R6bp+ 38.4%; 2R6bp- 
4.1%; 3RC6bp+ 22.7%; 3RG6bp+ 9.0%; 3RC6bp- 10.3%; and 3RG6bp- 15.5%.  
 
TYMS genotypes and MTX therapeutic outcome  
Table 1 reports the relation between TYMS polymorphisms and MTX 
therapeutic outcome both regarding MTX non-response and toxicity.  
 
Non-response. In relation to 28bp VNTR polymorphism, 3R allele was 
significantly associated with non-response to MTX when compared to 2R 
allele (p=0.012, OR=1.61). In addition, 3R homozygotes were associated with 
more than 2-fold increased risk for non-response to MTX when compared to 
2R homozygotes (p=0.018, OR=2.71) and 2R carriers (p=0.005, OR=2.34) and 
remained significant after corrected for multiple comparisons. For TSER 
polymorphisms, 3RC allele shown to be associated with non-response to MTX 
when compared to 2R allele (p=0.008, OR=1.79). Furthermore, and attending 
to functional 3R, 3RC3RG was related with more than 3-fold increased risk 
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for non-response to MTX when compared to 2R3RG (p=0.016, OR=3.52), which 
remained significant after multiple comparisons correction. Considering the 
1494del6 polymorphism, 6bp- allele was significantly associated with non-
response to MTX when compared to 6bp+ allele (p=0.006, OR=1.76). 
Moreover, and compared to 6bp+ homozygotes, 6bp+6bp- (p=0.038, 
OR=1.79), 6bp-6bp- (p=0.024, OR=3.07) and 6bp- carriers (p=0.011, OR=1.96) 
presented a statistically significant increased risk for non-response to MTX 
and, excepting for 6bp+6bp-, continued significant after correcting for 
multiple comparisons.  
 
Toxicity. No statistically significant differences were observed in relation to 
TYMS genotypes and MTX-related overall toxicity.   
 
TYMS haplotypes and MTX therapeutic outcome  
Table 2 represents the relationship between TYMS haplotypes and MTX 
therapeutic outcome both regarding MTX non-response and toxicity.  
 
Non-response. 3R6bp- haplotype was found significantly associated with non-
response to MTX when compared to 2R6bp+ haplotype (p=0.001, OR=2.54). 
Moreover, 3RC6bp+, 3RC6bp- and 3RG6bp- haplotypes were statistically 
significant associated with non-response to MTX when compared to 2R6bp+ 
haplotype (p=0.041, OR=1.79; p=0.013, OR=2.80; and p=0.009, OR=2.39, 
respectively). 
 
Toxicity. No statistically significant differences were observed in relation to 
TYMS haplotypes and MTX-related overall toxicity.   
 
Multivariate analysis 
Multivariate analysis was performed in three steps adjusting to potential 
confounding variables. Table 3 shows multivariate analysis results of TYMS 
genotypes and haplotypes and clinical response to MTX. Figure 2 resumes 
the impact of all potential confounding variables in the association of TYMS 
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genotypes and haplotypes with clinical response to MTX. Regarding TYMS 
genotypes, results demonstrated that 6bp- carriers were statistically 
significant associated with more than 2-fold increased risk for non-response 
to MTX when compared to 6bp+ homozygotes (p=0.016, OR=2.74). According 
to TYMS haplotypes, our results shown that haplotypes harboring 
simultaneously 3R and 6bp- alleles were statistically significant associated 
with almost 3-fold increased risk for non-response to MTX when compared to 
2R6bp+ haplotype.  
 
DISCUSSION 
Thymidylate synthase is a key enzyme for DNA synthesis and repair [11,12] 
inhibited by MTXPGs and, therefore, contributes for MTX antiproliferative 
and anti-inflammatory effects [10]. In fact, TS levels were found to be 
predictive of MTX therapeutic outcome [13,14]. Since genetic polymorphisms 
in TYMS have been associated with TS levels [6], in this study we aimed to 
elucidate the influence of TYMS polymorphisms (28bp VNTR, SNP C>G and 
1494del6) in MTX therapeutic outcome of Portuguese RA patients. 
All patients enrolled in this study were recruited within a well-defined 
geographical area and were of Caucasian ethnicity, with gender and age at 
time of diagnosis distributions similar to other reported populations [36,37]. 
Genotypes distribution of TYMS polymorphisms was in HWE and was similar 
to those found for other Caucasian populations [21,38,39]. Nevertheless, and 
despite the potential of our results, possible study limitations include: 1) 
relatively reduced population size; 2) presence of other TYMS polymorphisms 
that possibly could alter TS expression or functionality; 3) limited screen of 
some important genes that codify other enzymes involved in MTX action 
mechanism. 
 
TYMS genotypes and MTX therapeutic outcome  
 
Non-response. Among our population and regarding 28bp VNTR 
polymorphism, 3R allele was associated with risk for non-response to MTX, 
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which increases in the presence of both 3R alleles, in accordance to previous 
studies [13,40]. Literature describes 3R allele as associated with higher TS 
levels [19,20] and TS levels as predictive of clinical response to MTX [13,40]. 
Moreover, 3R allele has been associated with higher MTX doses required [13] 
and higher RA disease activity [40]. Despite the significant univariate 
analysis results, multivariate analysis did not confirm them. Additionally, 
other studies demonstrated associations between 3R homozygotes and 
response to MTX [39] or showed no association [21,41-43]. It has been 
suggested by some authors that it is of greater importance to consider the 
SNP C>G on 3R allele and analyze the TSER polymorphisms instead of 
studying 28bp VNTR polymorphism alone. 3RG allele was associated with 
higher transcriptional activity and translation efficiency due to its increased 
ability to complex with the USF protein [15,44]. Accordingly, the number of 
functional E-box in both 2R and 3RC alleles should be the same [6,15], which 
should reveal that patients with these genotypes would have similar TS 
expression and, consequently, a resembling clinical response. However, our 
results seem to demonstrate that 2R and 3RC alleles are different since 
3RC3RG genotype was associated with over 3-fold increased risk for non-
response to MTX when compared to 2R3RG. In addition, our results showed 
that 3RC allele was associated with non-response to MTX, when compared to 
2R allele, and 3RC3RC genotype has a non-significant trend for non-response 
to MTX when compared to 2R2R genotype. Nevertheless, no statistically 
significant differences were observed attending to TSER polymorphisms 
grouped according to theoretically TS expression levels and to multivariate 
analysis. Moreover, a previous study demonstrated that non-response to MTX 
was associated to 3RG3RG patients [21]. Therefore, the putative relationship 
between TSER polymorphisms and clinical response to MTX outcome needs 
further clarification.  
In relation to 1494del6 polymorphism, our results demonstrated that 6bp- 
allele was associated with non-response to MTX. Additionally, multivariate 
analysis showed that 6bp- carriers were associated with about 3-fold 
increased risk for non-response to MTX. In vitro studies have demonstrated 
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that 6bp- allele has decreased mRNA stability and, thereby reduced TS 
expression [22,23], however, in other previously reported studies in RA 
Caucasian patients no association was observed [41]. Moreover, one study in 
Psoriasis, a disease where MTX is used in similar doses than RA, 6bp- allele 
demonstrated a trend for non-response, however, this study included 
Caucasian and non-Caucasian patients [45]. Studies in Asiatic patients have 
reported different results, some of them reported an association between 
6bp- allele and response [13,43], while others reported no associations 
[42,46]. From all of these results it seems that ethnicity could be an 
important factor to predict the clinical response to MTX. 
 
Toxicity. Regarding the occurrence of MTX-related overall toxicity, our results 
did not reach significance pertaining to TSER and 1494del6 polymorphisms, 
in accordance with previously reported studies [21,41,42,46,47]. 
Nevertheless, other studies reported significant associations of 28bp VNTR 
polymorphism with MTX-related toxicity [38,48]. To the best of our 
knowledge this is the first report evaluating the influence of TSER 
polymorphisms in MTX-related toxicity in RA.  
 
TYMS haplotypes and MTX therapeutic outcome  
 
Non-response. Haplotypes may have a particular significance in regard to 
functionality or as genetic markers for unknown functional variants. 
Therefore, haplotype analysis was performed, to assess of possible 
consequences on the phenotype in the copresence of several variants of the 
same gene. As reported by others [6,39,49,50], TYMS polymorphisms were in 
LD, especially 2R6bp+ and 3RG6bp- haplotypes. Univariate haplotype analysis 
demonstrated that 3R6bp-, 3RC6bp+, 3RC6bp- and 3RG6bp- haplotypes 
(haplotypes harboring 3R allele for 28bp VNTR, 3RC allele for TSER and 6bp- 
allele for 1494del6) were associated with almost 3-fold increased risk for 
non-response to MTX. Nevertheless, multivariate analysis showed that 
haplotypes harboring simultaneously 3R and 6bp- alleles (3R6bp-, 3RC6bp- 
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and 3RG6bp-) were associated with non-response to MTX. This suggests a 
prominent role of the 3'-UTR polymorphism in predicting the clinical 
response to MTX and it seems that 6bp- allele can interact differently with 2R 
and 3R alleles, in agreement with Lurje et al. [51]. Additionally, our results 
suggested that the haplotype revealing more risk for non-response to MTX 
was 3RC6bp-, which combines the major risk alleles from the 5´UTR (3RC) 
and from the 3´UTR (6bp-). Only one study in RA has performed haplotype 
analysis, where an association between 3R6bp- haplotype and response to 
MTX was demonstrated [39]. Nevertheless, there are some important 
differences: no reference to SNP C>G; studied population included patients 
with early RA; and the study evaluated the impact in clinical response to MTX 
combined therapy with sulfasalazine. Thus, we propose that TYMS haplotype 
analysis should be used in future studies to elucidate the influence of TYMS 
in MTX therapeutic outcome, which could help to interpret these preliminary 
conflicting data.  
 
Toxicity. Regarding MTX-related toxicity, no differences were observed 
attending to TYMS haplotypes. Despite it was expected that TYMS haplotypes 
follow the same tendency as TYMS genotypes, to the best of our knowledge 
no studies analyzed the TYMS haplotypes and the development of toxicity 
arising from MTX in RA. 
 
The observed discrepancies among different studies could be explained by 
inter-study variability, ethnicity variability, samples sizes, variety of methods 
used to measure the MTX therapeutic outcome, different treatment regimens, 
and different genotyping protocols with limited quality of results. Therefore, 
functional TS studies in RA should be conducted to better understanding TS 
expression regulation mechanism and its putative importance in establishing 
more effective clinical therapeutic strategies when MTX is used in RA 
patients. To the best of our knowledge, this is the first report regarding the 
study of the association of TYMS polymorphisms with MTX therapeutic 
outcome in Portuguese RA patients. This study concluded that TYMS 
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polymorphisms seem to be important to predict clinical response to MTX in 
RA patients; TYMS genotypes and haplotypes harboring 6bp- allele were 
associated with non-response to MTX; TYMS haplotypes harboring 
simultaneously 3R and 6bp- alleles seem to be predictors of non-response to 
MTX; and, to elucidate the role of TYMS on MTX therapeutic outcome full 
haplotypic information should be exploited. Despite the potential of our 
findings, translation into clinical practice requires larger and multicentric 
studies in order to clearly endorse the utility of these polymorphisms. 
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FIGURES 
 
 
 
Figure 1. A. Part of MTX action mechanism in which thymidylate synthase (TS) is involved. MTX 
enters the cell after binding to folate transporters, mainly by solute carriers (SLC), and can be exported by 
members of the ATP-binding cassette (ABC) transporters family. To prevent MTX rapid efflux from cells 
and enhance its intracellular retention, MTX is polyglutamated by the enzyme folylpolyglutamyl synthase 
into MTX polyglutamates (MTXPGs) which inhibit TS activity. TS is a key protein for the de novo pyrimidine 
synthesis and is responsible for the simultaneous conversion of deoxyuridine monophosphate (dUMP) 
and 5,10-methylenetetrahydrofolate (5,10-MTHF) to deoxythymidine monophosphate (dTMP) and 
dihydrofolate (DHF). Subsequently, the dTMP is phosphorylated to deoxythymidine triphosphate (dTTP) 
and used for the DNA synthesis and repair. B. TYMS structure and location of VNTR 28bp 
(rs34743033), SNP C>G (rs2853542) and 1494del6 (rs34489327) polymorphisms. 5,10-MTHF: 
5,10-methylenetetrahydrofolate; A: adenine; ABC: ATP-binding cassette; bp: base pairs; C: cytosine; del: 
deletion; DHF: dihydrofolate; dTMP: deoxythymidine monophosphate; dTTP: deoxythymidine triphosphate; 
dUMP: deoxyuridine monophosphate; E-box: enhancer box; G: guanine; MTXPG: methotrexate 
polyglutamates; R: repeat; SLC: solute carrier; SNP: single nucleotide polymorphism; TS: thymidylate 
synthase (protein); TSER: thymidylate synthase enhancer region; T: thymine; TYMS: thymidylate synthase 
(gene); UTR: untranslated region; VNTR: variable number tandem repeat. 
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Figure 2. Forest plot of multivariate analysis in the association of thymidylate synthase 
genotypes and haplotypes with clinical response to methotrexate. Odds ratio and 95% confidence 
intervals are reported for clinical response to methotrexate. bp: base pairs; C: cytosine; CI: confidence 
interval; del: deletion; G: guanine; R: repeat; TYMS: thymidylate synthase (gene).  
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TABLES 
 
Table 1. Thymidylate synthase polymorphisms and methotrexate therapeutic outcome  
 MTX Response MTX Toxicity 
 Response 
 
Non-
Response 
p  OR (95% CI) Non-
Toxicity 
Toxicity p OR (95% CI) 
TYMS 28bp VNTR (rs34743033) #  
2R2R 19 (54.3) 16 (45.7)  Reference 25 (71.4) 10 (28.6)  Reference 
2R3R 62 (49.6) 63 (50.4) 0.624 1.21 (0.57-2.56) 78 (62.4) 47 (37.6) 0.324 1.51 (0.67-3.41) 
3R3R  21 (30.4) 48 (69.6) 0.018 
¥
 2.71 (1.17-6.29) 50 (72.5) 19 (27.5) 0.911 0.95 (0.39-2.35) 
         
2R carriers  81 (50.6) 79 (49.4)  Reference 103 (64.4) 57 (35.6)  Reference 
3R3R 21 (30.4) 48 (69.6) 0.005 
¥
 2.34 (1.29-4.27) 50 (72.5) 19 (27.5) 0.233 0.69 (0.37-1.28) 
         
2R2R  19 (54.3) 16 (45.7)  Reference 25 (71.4) 10 (28.6)  Reference 
3R carriers 83 (42.8) 111 (57.2) 0.208 1.59 (0.77-3.27) 128 (66.0) 66 (34.0) 0.529 1.29 (0.58-2.84) 
         
2R allele 100 (51.3) 95 (48.7)  Reference 128 (65.6) 67 (34.4)  Reference 
3R allele 104 (39.5) 159 (60.5) 0.012 
¥
 1.61 (1.09-2.38) 178 (67.7) 85 (32.3) 0.647 0.91 (0.60-1.38) 
TSER polymorphisms (rs2853542* and rs34743033) 
Functional 2R         
2R2R 19 (54.3) 16 (45.7)  Reference 25 (71.4) 10 (28.6)  Reference 
2R3RC 32 (47.1) 36 (52.9) 0.487 1.34 (0.59-3.03) 44 (64.7) 24 (35.3) 0.492 1.36 (0.56-3.31) 
3RC3RC 9 (31.0) 20 (69.0) 0.062 2.64 (0.94-7.39) 23 (79.3) 6 (20.7) 0.469 0.65 (0.20-2.08) 
         
Functional 3R         
2R3RG    30 (52.6) 27 (47.4)  Reference 34 (59.6) 23 (40.4)  Reference 
3RC3RG 6 (24.0) 19 (76.0) 0.016 
¥
 3.52 (1.23-10.10) 16 (64.0) 9 (36.0) 0.710 0.83 (0.31-2.20) 
3RG3RG 6 (40.0) 9 (60.0) 0.384 1.67 (0.52-5.30) 11 (73.3) 4 (26.7) 0.384§ 0.54 (0.15-1.90) 
         
2R allele 100 (51.3) 95 (48.7)  Reference 128 (65.6) 67 (34.4)  Reference 
3RC allele 56 (37.1) 95 (62.9) 0.008 
¥
 1.79 (1.13-2.82) 106 (70.2) 45 (29.8) 0.369 0.81 (0.50-1.31) 
3RG allele 48 (42.9) 64 (57.1) 0.155  1.40 (0.86-2.30) 72 (64.3) 40 (35.7) 0.810 1.06 (0.63-1.78) 
TSER polymorphisms grouped according to theoretically TS expression levels** 
Low expression 60 (45.5) 72 (54.5)  Reference 92 (69.7) 40 (30.3)  Reference 
Median 
expression 
36 (43.9) 46 (56.1) 0.824 1.07 (0.61-1.85) 50 (61.0) 32 (39.0) 0.189 1.47 (0.83-2.63) 
High 
expression 
6 (40.0) 9 (60.0) 0.687 1.25 (0.42-3.71) 11 (73.3) 4 (26.7) 1.000§ 0.84 (0.25-2.79) 
         
Low + Median 
expression 
96 (44.9) 118 (55.1)  Reference 142 (66.4) 72 (33.6)  Reference 
High 
expression 
6 (40.0) 9 (60.0) 0.714 1.22 (0.42-3.55) 11 (73.3) 4 (26.7) 0.778§ 0.72 (0.22-2.33) 
         
Low expression 60 (45.5.) 72 (54.5)  Reference 92 (69.7) 40 (30.3)  Reference 
Median + High 
expression 
42 (43.4) 55 (56.7) 0.746 1.09 (0.64-1.85) 61 (62.9) 36 (37.1) 0.279 1.36 (0.78-2.36) 
TYMS 1494del6 (rs34489327) 
6bp+6bp+ 61 (53.5) 53 (46.5)  Reference 78 (68.4) 36 (31.6)  Reference 
6bp+6bp- 38 (39.2) 59 (60.8) 0.038  1.79 (1.03-3.10) 59 (60.8) 38 (39.2) 0.249 1.40 (0.79-2.46) 
6bp-6bp- 6 (27.3) 16 (72.7) 0.024 
¥
 3.07 (1.12-8.41) 19 (86.4) 3 (13.6) 0.122§ 0.34 (0.10-1.23) 
         
6bp+6bp+  61 (53.5) 53 (46.5)  Reference 78 (68.4) 36 (31.6)  Reference 
6bp- carriers  44 (37.0) 75 (63.0) 0.011 
¥
 1.96 (1.16-3.31) 78 (65.5) 41 (34.5) 0.641 1.14 (0.66-1.97) 
         
6bp+ carriers  99 (46.9) 112 (53.1)  Reference 137 (64.9) 74 (35.1)  Reference 
6bp-6bp-  6 (27.3) 16 (72.7) 0.078 2.36 (0.89-6.26) 19 (86.4) 3 (13.6) 0.055§ 0.29 (0.08-1.02) 
         
6bp+ allele  160 (49.2) 165 (50.8)  Reference 215 (66.2) 110 (33.8)  Reference 
6bp- allele  50 (35.5) 91 (64.5) 0.006 
¥
 1.76 (1.15-2.71) 97 (68.8) 44 (31.2) 0.578 0.89 (0.57-1.38) 
Results are expressed in n (%). p value <0.05 was considered to be of statistical significance (highlighted in bold). §Fisher’s exact test 
used when number of cases of one cell was less than 5.   
¥
Statistically significant when p values were adjusted for multiple comparisons correction using Bonferroni’s method (α=0.05/n 
comparisons). 
#3R4R genotype (n=4) was excluded from analyses due to the low frequency. *rs2853542 - TYMS SNP C>G on 3R allele. **Genotypes 
theoretically associated with TS expression: a) high: 3RG3RG; b) median: 2R3RG and 3RC3RG; c) low: 2R2R, 2R3RC and 3RC3RC. 
bp: base pairs; C: cytosine; del: deletion; G: guanine; OR: odds ratio; R: repeat; SNP: single nucleotide polymorphism; TS: thymidylate 
synthase (protein); TSER: TYMS enhancer region; TYMS: thymidylate synthase (gene); VNTR: variable number tandem repeat. 
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Table 2. Thymidylate synthase haplotypes and methotrexate therapeutic outcome 
 MTX Response MTX Toxicity 
TYMS 
Haplotypes 
Response Non-
Response  
p  OR (95% CI) Non-
Toxicity 
Toxicity p  OR (95% CI) 
Based on TYMS 28bp VNTR and TYMS 1494del6 polymorphisms 
2R6bp+ 43.0 30.0  Reference 36.2 33.9  Reference 
2R6bp- 6.0 7.4 0.360 1.70 (0.54-5.32) 5.7 10.2 0.190 2.20 (0.69-7.03) 
3R6bp+ 33.9 34.5 0.100 1.55 (0.92-2.60) 33.1 37.8 0.490 1.23 (0.69-2.20) 
3R6bp- 17.1 28.1 0.001 2.54 (1.46-4.43) 25.0 18.1 0.320 0.74 (0.41-1.34) 
Based on TSER and TYMS 1494del6 polymorphisms 
2R6bp+ 43.2 30.2  Reference 36.2 34.8  Reference 
2R6bp- 5.8 7.2 0.360 1.70 (0.55-5.24) 5.6 9.3 0.220 2.02 (0.66-6.20) 
3RC6bp+ 21.2 25.6 0.041 1.79 (1.03-3.12) 23.8 23.6 0.820 1.07 (0.59-1.95) 
3RC6bp- 6.2 11.8 0.013 2.80 (1.25-6.25) 10.9 6.0 0.240 0.55(0.21-1.47) 
3RG6bp+ 12.5 8.7 0.880 1.06 (0.50-2.24) 9.3 13.3 0.300 1.53 (0.69-3.38) 
3RG6bp-  11.1 16.5 0.009 2.39 (1.24-4.59) 14.2 13.0 0.810 0.92 (0.46-1.82) 
Results are expressed in estimated frequencies (%) under linkage disequilibrium. p value <0.05 was considered to be of 
statistical significance (highlighted in bold). 
bp: base pairs; C: cytosine; del: deletion; G: guanine; OR: odds ratio; R: repeat; TSER: TYMS enhancer region; TYMS: 
thymidylate synthase (gene); VNTR: variable number tandem repeat.  
 
 
 
Table 3. Multivariate analysis of thymidylate synthase polymorphisms and clinical response to 
methotrexate 
                Adjusted 
Genetic            variables 
variables 
Patient-related Patient-related + Disease-
related 
Patient-related + Disease-
related + Treatment-related 
 P OR (95% CI) P OR (95% CI) P OR (95% CI) 
TYMS genotypes       
TYMS 28bp VNTR (rs34743033)      
2R carriers   Reference  Reference  Reference 
3R3R 0.013 2.23 (1.19-4.17) 0.013 2.24 (1.19-4.21) 0.135 1.99 (0.81-4.91) 
TSER polymorphisms        
Functional 3R       
2R3RG     Reference  Reference  Reference 
3RC3RG 0.069 2.90 (0.92-9.13) 0.071 2.91 (0.91-9.25) 0.203 2.70 (0.59-12.47) 
TYMS 1494del6 (rs34489327)      
6bp+6bp+   Reference  Reference  Reference 
6bp- carriers  0.003 2.33 (1.32-4.10) 0.003 2.38 (1.34-4.23) 0.016 2.74 (1.21-6.23) 
TYMS haplotypes       
Based on TYMS 28bp VNTR and TYMS 1494del6 polymorphisms   
    2R6bp+  Reference  Reference  Reference 
    3R6bp- <0.001 2.87 (1.59-5.19) <0.001 2.92 (1.60-5.32) 0.012 2.68 (1.25-5.75) 
Based on TSER and TYMS 1494del6 polymorphisms     
    2R6bp+  Reference  Reference  Reference 
    3RC6bp+ 0.041 1.81 (1.03-3.20) 0.035 1.86 (1.05-3.31) 0.090 1.85 (0.91-3.76) 
    3RC6bp- 0.012 2.97 (1.28-6.93) 0.018 2.75 (1.19-6.32) 0.048 2.89 (1.01-8.21) 
    3RG6bp- 0.004 2.78 (1.39-5.56) 0.003 3.06 (1.49-6.31) 0.043 2.60 (1.04-6.49) 
P value <0.05 is considered to be of statistical significance (highlighted in bold). 
Adjusted variables include: 1) patient-related variables (age, gender and smoking); 2) disease-related variables (diagnosis 
age and disease duration); and 3) treatment-related variables (folic acid supplementation, corticosteroids, non-steroidal 
anti-inflammatories, other concomitant disease-modifying antirheumatic drugs and methotrexate administration 
characteristics - dose, treatment duration and administration route). Genetic variables include: TYMS genotypes and TYMS 
haplotypes. 
bp: base pairs; C: cytosine; del: deletion; G: guanine; OR: odds ratio; R: repeat; TSER: TYMS enhancer region; TYMS: 
thymidylate synthase (gene); VNTR: variable number tandem repeat. 
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CHAPTER X - GENERAL DISCUSSION 
This chapter discusses the overall study’s results regarding the 
association of clinicopathological and genetic variables with Methotrexate 
therapeutic outcome, as also explores its limitations. 
 
 
Despite MTX is extensively used in RA treatment, there is a great 
interpatient variability to MTX therapeutic outcome, which can be partly 
determined by clinicopathological and genetic factors. Therefore, this work 
evaluated the influence of clinicopathological variables and several genetic 
polymorphisms in genes encoding for MTX membrane transport proteins as 
also for proteins involved in MTX action mechanism pathways, as predictors 
of clinical response to MTX and/or MTX-related adverse drug reactions 
occurrence in Portuguese RA patients.  
 
 
1. POPULATION 
 
The patients enrolled in this work were recruited based on inclusion 
criteria applied in the study (adults, Caucasian, without drug abuse history, 
recent pregnancy or desire to become pregnant during the study, diagnosed 
with RA, treated with MTX, with well characterized clinicopathological 
variables). The size of population was in accordance to the prevalence of the 
disease in the Portuguese population with reported disease gender 
epidemiology (22), suggesting an occurrence of two to four times higher in 
females, and age of diagnosis range, occurring between the third and the 
fifth decades of life, similar to other reported populations (24, 321). In 
addition, the studied population was a representative clinical practice cohort 
of established and well-defined RA patients (224, 320).  
Additionally, the evaluated outcomes (non-response to MTX and MTX-
related ADRs occurrence) were in accordance with literature. Non-response to 
MTX was registered for 128 (54.9%) patients and, literature reports that 40% 
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to 60% of patients fail to achieve a good response profile (322). Non-
response was measured only after six months of treatment with MTX 
because the maximum improvement tends to occur only after approximately 
six months of starting with MTX (166), even it is dependent of other factors 
such, for example, comorbidities and patients’ age. Considering MTX-related 
toxicity, 77 (33.0%) patients presented ADRs, which is in accordance with 
literature that reports about 15% to 30% of patients experience ADRs (322). 
Similarly to literature descriptions, the most frequent observed ADRs were 
minor GI disorders (75.3%), including abdominal distension, diarrhea, 
dyspepsia, nauseas, stomach pain and/or vomiting, and none has led to MTX 
discontinuation (191, 200, 206, 225). Other observed ADRs included skin and 
subcutaneous tissue disorders (alopecia, rash maculo-papular and 
rheumatoid nodulosis exacerbation); hepatobiliary disorders (determined by 
transaminases serum elevation); and, respiratory, thoracic and mediastinal 
disorders (hypersensitivity pneumonitis), which are in agreement with the 
descriptions in literature (323).  
 
 
2. CLINICOPATHOLOGICAL VARIABLES & MTX THERAPEUTIC OUTCOME 
 
Several clinicopathological variables were reported as associated with 
MTX therapeutic outcome variability among RA patients.  
 
 
2.1. Clinical Response to MTX 
In accordance to MTX clinical response, results demonstrated that non-
current smokers were associated with non-response to MTX. Although some 
studies have pointed out that smokers had a worst response to MTX, 
presenting a higher disease activity and severity (329, 330), others were able 
to demonstrate that tobacco exposure reduced radiographic progression and 
favored a better functional score (331, 332). In fact, literature describes the 
association between smoking and decreased folate levels which enhance the 
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antifolate effect of MTX and, therefore, improve the response to MTX (324-
326). Furthermore, cigarette nicotine seems to potentiate the 
immunosuppressive and anti-inflammatory effects by acting on the 
immunological system (327, 328).  
Results also demonstrated that anti-CCP and ANAs positivity were 
associated with more than 2-fold increased risk of non-response to MTX. 
These autoantibodies are presented in RA patients and are strongly 
correlated with erosive disease, worse functional status, higher disease 
activity and with non-response to MTX (2, 333-337). Nevertheless, other 
studies have shown a correlation between anti-CCP positivity and a better 
response to MTX or absence of associations in early RA populations (338, 
339). The discrepancy with prior studies may be explained by the fact that 
our population had established disease.  To the best of my knowledge there 
are no studies in RA associating ANAs and MTX response.  
Additionally, this study revealed that an increased score in HAQ was 
associated with an increased risk for non-response to MTX. As reported by 
others, the higher HAQ score corresponds to an increased disease activity, 
thus it was expected that these patients would have a worst response to 
MTX (338, 340). 
The concomitant use of NSAIDs was correlated with non-response to 
MTX. These results could be explained by the existence of drug-drug 
interactions, since NSAIDS are known to alter MTX and 7-OH-MTX binding to 
plasmatic proteins and to impair MTX hepatic metabolism (161). This 
translates into low amount of free MTX and reduced formation of active MTX 
metabolites in hepatocytes. Due to the importance of NSAIDs as symptomatic 
therapy in RA, and to contradictory results, further studies are required to 
clarify this association (316, 338).  
In addition, SC administration route was significantly associated with 
better response to MTX. This result can be explained by the higher MTX 
bioavailability associated with this route of administration (341), which 
consequently leads tissues to a greater exposure to MTX, higher cellular 
polyglutamation and retention and, therefore, to better response to MTX. 
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2.2. Toxicity to MTX 
According to MTX-related toxicity, results demonstrated statistically 
significant associations between lower MTX treatment duration and MTX-
related toxicity occurrence (overall and GI) in univariate analysis and with 
MTX-related GI toxicity in multivariate analysis. These results are in 
accordance with published literature, where the median time for MTX-related 
ADRs occurrence was 36.5 months (323). Moreover, results confirmed the 
protective effect afforded by folic acid supplementation. Since it is expected 
that folic acid supplements reduce the toxicity of low-dose MTX therapy (143, 
342-345), the concomitant use of folic acid with MTX is considered the 
standard treatment (142, 143). Even though folic acid supplementation was 
prescribed to all patients, only 118 (50.6%) complied with the treatment. 
Becker et al. reported an association between MTX-related toxicity 
occurrence and lower intracellular folates (346). Furthermore, two meta-
analyses support the obtained findings by concluding that the low-doses of 
folate supplementation have protective effects for MTX-related GI toxicity 
(142, 143). Also, one study demonstrated that GI toxicity was the main 
reason for MTX withdrawal when related with the absence of folate 
supplementation (316). In fact, studies reported that MTX treatment leads to 
a folate deficiency status, given that mammalian cells cannot synthesize 
folates de novo (347). Moreover, RA itself also conditioned a decrease in 
folate levels (348) and, consequently, without the appropriate reposition of 
folates, several metabolic pathways, such as the biosynthesis of purines, 
pyrimidines and some amino acids (such serine and methionine), processes 
which maintain normal cell growth and replication, will be compromised 
(347). For this reason, rapidly dividing tissues, such as of the GI tract, are 
more susceptible to folate depletion and, therefore, the supplementation 
with folic acid will help to protect from GI toxicity (347). Other reason 
contributing for the protective mechanism resulting from folic acid 
supplementation may be the interaction of folic acid with MTX (161). This 
interaction causes the block of MTX reabsorption in the renal distal tubule 
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leading to a decrease of MTX circulating levels, and consequently to lower 
toxicity (161).  
Additionally, results demonstrated an association between increased 
levels of ESR and MTX-related overall toxicity but not with GI toxicity. The 
DAS28 is widely used for the assessment of RA patients in the clinic to 
monitor disease activity (349-353) and is calculated from four components: 
TJC, SJC, VAS and ESR or CRP. Reasons for using CRP include not only its 
potential to be a more direct measure of inflammation, but also the 
increasing usage of B-cell directed therapies that may have differential 
effects on these inflammatory markers (354). However, recent data from two 
large observational studies suggested that DAS28(CRP) scores tended to be 
lower than DAS28(ESR) scores and Inoue et al. suggested potential new 
thresholds for disease activity categories for DAS28(CRP) (116, 117). Since no 
threshold has been defined, we have used the ESR for DAS28 calculation. The 
ESR measure is a simple and inexpensive laboratory test for assessing the 
inflammatory or acute response (353) with reduced sensitivity and 
specificity. Consequently, the obtained results can be explained by the 
greater impact of the other observed ADRs in the inflammatory process, such 
skin and subcutaneous tissue disorders; hepatobiliary disorders; and, 
respiratory, thoracic and mediastinal disorders, when compared to GI 
toxicity. In fact, other studies have reported an increase of acute phase 
reactants in rheumatoid nodulosis (355, 356), hepatotoxicity (357), and 
hypersensitivity pneumonitis (358), that were also observed as ADRs in 
studied population, which can explain the reason why higher ESR levels were 
associated with MTX-related overall toxicity and not with MTX-related GI 
toxicity. 
 
 
3. GENETIC VARIABLES & MTX THERAPEUTIC OUTCOME 
 
The genotypes of studied polymorphisms were in HWE and the 
distribution was similar to the published literature for other Caucasian 
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populations (183, 223, 224, 227, 232, 259, 264, 273, 286, 320, 322, 359-361) 
and with the National Center for Biotechnology Information (NCBI) database, 
except for SLC19A1 G80A polymorphism (rs1051266). Nevertheless, it is well 
known that NCBI database does not contemplate all the populations and, 
there are no studies available for this polymorphism regarding the 
Portuguese population to allow comparisons of the obtained genotypes 
distribution. 
 
 
3.1. MTX Carrier-Mediated Transport Pathway & MTX-Related Toxicity 
The SLC19A1 is a bidirectional transporter, described as being 
expressed in the majority of tissues, with relevance in enterocytes and 
hepatocytes (177, 215). Genotype analysis, pertaining the influence of 
SLC19A1 G80A polymorphism (rs1051266) on overall toxicity, demonstrated 
no statistically significant differences but, G carriers were at a significant 
increased risk of MTX-related GI toxicity when compared to A homozygotes. 
Bohanec Grabar et al. have previously reported that G homozygotes had an 
increased risk for MTX-related overall toxicity (224, 225) but did not clearly 
described the impact on GI disorders, and, the majority of other studies did 
not shown associations with MTX-related toxicity (228, 232, 233). 
Considering the obtained data and literature, it can be hypothesized that GG 
genotype could provide an increased influx capacity. Here, we can 
hypothesize that GG genotype could provide an increased influx capacity 
leading to higher bioavailability, increased MTX tissues exposure, mainly in 
tissues where SLC19A1 is highly expressed and, consequently, resulting in GI 
toxicity. Moreover, results demonstrated that SLC19A1 rs7499 G carriers 
were associated with an increased risk for MTX-related toxicity (overall and 
GI). This SNP occurs in a portion of 3’-UTR believed to be important for mRNA 
stability, localization and translational efficiency (216) and, thus, important 
to membrane transporter expression. Although, its effect in this bidirectional 
transporter function is unknown, it can be  proposed that GG genotype could 
provide an increased influx capacity leading to higher bioavailability, 
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increased MTX tissues exposure and, consequently, to toxicity. In the 
literature, only one study in Caucasian patients addressed the influence of 
this SNP in MTX-related toxicity, but no associations were observed (232). In 
addition, A carriers for SLC19A1 rs2838956, presented a borderline trend 
towards significance for MTX-related toxicity (overall and GI). This is possibly 
due to an increased influx capability of A carriers, which consequently, leads 
to greater MTX tissues exposure and toxicity. Results are in agreement with 
a previously report by Bohanec Grabar et al. that demonstrated a borderline 
significant trend towards MTX-related overall toxicity for A carriers, 
particularly for skin and subcutaneous tissue disorders (225), yet another 
study reported no statistically significant association (232). The impact of 
this variant in SLC19A1 is currently unknown and functional studies are 
essential since intronic SNPs can potentially influence RNA splicing, which 
may affect transporter structure and function (234).  
As for SLC46A1 rs2239907, G homozygotes revealed association with 
MTX-related overall toxicity. This SNP is also located in a 3´UTR region, 
which is considered as important in mRNA stability, localization and 
translational efficiency (216). Despite the effect of this SNP in transporter 
function is currently unknown, it is regarded as a potential functional SNP. 
The SLC46A1 is mostly expressed in apical membrane of enterocytes but 
also can be found in other cells (177). Thus, it can be proposed that GG 
genotype could provide an increased influx capacity leading to higher 
bioavailability and, consequently, to higher MTX tissues exposure and 
toxicity. To the best of my knowledge this is the first report to analyze the 
effect of this SNP with MTX-related toxicity in RA. 
Regarding SLCO1B1 rs4149056, results demonstrated that T carriers 
were associated with MTX-related toxicity (overall and GI). Literature reports 
that T carriers are associated with an increased membrane expression of 
SLCO1B1 and higher MTX influx and clearance (362). Despite the SLCO1B1 
transporter is mainly expressed on basolateral membrane of hepatocytes 
(236), its mRNA also has been detected in other tissues, including 
enterocytes (238), which can explain the MTX intracellular retention (GI and 
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hepatic) leading to cytotoxicity. The association of T allele with MTX-related 
toxicity has been previously described for high-dose MTX (362) but this is 
the first report to analyze the influence of this SNP with MTX-related toxicity 
in RA.  
In ABCG2, rs13120400 C carriers showed a trend towards for MTX-
related toxicity. The ABCG2 transporter, located in apical membranes of 
enterocytes, hepatocytes and kidney tubular cells, is responsible for MTX 
efflux from the enterocytes to intestinal tract lumen and MTX excretion into 
bile and urine (173). Then, it is plausible that C carriers would cause a 
reduced efflux capability, which is translated in less MTX elimination and 
higher MTX bioavailability, leading to toxicity. This is the first report to 
associate this SNP with MTX-related toxicity in RA patients.  
From haplotype analyses, this work showed that GGAG haplotype for 
SLC19A1 rs7499, rs1051266, rs2838956 and rs3788200 was associated with 
MTX-related GI toxicity when compared to AAGA haplotype. The association 
of GGAG haplotype with GI toxicity was expected from the genotype analyses 
obtained results for those SNPs in SLC19A1. Hence, it can be hypothesize 
that GGAG haplotype could provide an increased MTX influx capability, 
leading to higher MTX intracellular levels, mainly in tissues where SLC19A1 
is highly expressed (177) and, thus, have an increased risk for GI toxicity 
development. In fact, it appears more evident that, to better characterize the 
role of a candidate gene, the full haplotypic information should be exploited 
in order to assess the possible consequences on the phenotype in the 
copresence of several variants of the same gene (317, 318).   
Accordingly to TRI for MTX-related overall toxicity, an increased TRI 
value was associated with an increased incidence of ADRs. From this work, 
results demonstrated that patients with Index 3 were 18-fold more likely to 
present an ADR when compared to those with Index 1. Regarding to the 
occurrence of MTX-related GI disorders, the TRI demonstrated that patients 
with Index 4, when compared to those with Index 3 and 1, were 5-fold and 9-
fold, respectively, more likely to present GI disorders. This highlights the 
importance of genotyping patients and the urgency of developing the field of 
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therapy personalization for the prediction of MTX-related toxicity 
development.  
 
 
3.2 . MTX Cellular Pathway & MTX-Related Toxicity 
To evaluate the influence of pyrimidine pathway in the MTX-related 
toxicity, the influence of TYMS polymorphisms was studied. Similarly to other 
reported studies, presented data showed no association of MTX-related 
toxicity with TYMS TSER and 1494del6 polymorphisms (226, 232, 246, 264, 
363), while other studies reported significant associations of 28bp VNTR 
polymorphism with MTX-related toxicity occurrence (224, 269). Regarding 
TYMS haplotypes, no differences were observed too. Despite it was expected 
that TYMS haplotypes follow the same tendency as TYMS genotypes, to the 
best of my knowledge this is the first report evaluating the influence of TSER 
polymorphisms in MTX-related toxicity and no previously studies analyzed 
TYMS haplotypes and the development of toxicity arising from MTX in RA 
patients. 
 
 
3.3. MTX Cellular Pathway & Clinical Response to MTX 
To evaluate the influence in MTX clinical response of genetic 
polymorphisms in genes encoding to proteins involved in MTX cellular 
pathways, four genetic polymorphisms were analyzed, which are related with 
folate and de novo nucleotides synthesis pathways.  
 
3.3.1. Folate pathway 
Methylenetetrahydrofolate reductase is not directly inhibited by MTX or 
MTXPG but its expression levels seemed to influence MTX action by 
modifying the folate status (221). The obtained results demonstrated a 
significant association between MTHFR C677T polymorphism (rs1801133) T 
homozygotes and non-response to MTX. Despite the lack of consistency of 
some studies (259, 273), the results presented in this work are in accordance 
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with others previously reported (183, 227). Literature describes that TT 
genotype is responsible for a reduction of MTHFR activity (267), leading to 
reduced 5-MTHF and another folate cofactors levels, affecting both folate and 
methionine pathways (190, 191). This will lead to a decreased release of the 
anti-inflammatory adenosine (192) and, consequently, to MTX non-response. 
 
3.3.2. De novo pyrimidine synthesis pathway 
Regarding the de novo pyrimidine synthesis pathway, 3R allele for TYMS 
28bp VNTR polymorphism (rs34743033) was associated with increased risk 
for non-response to MTX, which increased in the presence of both 3R alleles, 
as suggested by other authors (221, 291). In fact, literature describes 3R 
allele as associated with higher TS levels (288, 290) and TS levels as 
predictive of clinical response to MTX (221, 291). Moreover, 3R allele has 
been associated with higher MTX doses required (291) and of higher RA 
disease activity (221). Despite the statistically significance for the univariate 
analysis results, multivariate analysis did not confirm them. Additionally, 
other studies demonstrated associations between 3R homozygotes and 
better response to MTX (223) or showed no association (232, 264, 292, 363). 
It has been suggested that it is of great importance to consider the C>G 
modification on 3R allele of TYMS (rs2853542) and analyze the TSER 
polymorphisms instead of studying the 28bp VNTR polymorphism isolated 
(286). The 3RG allele was associated with higher transcriptional activity and 
translation efficiency due to its increased ability to complex with the USF 
protein (289, 364). Nevertheless, the number of functional E-box in both 2R 
and 3RC alleles should be the same (289), which should reveal that patients 
with these genotypes would have similar TS expression and, consequently, a 
resembling clinical response. Results seemed to point out that 2R and 3RC 
alleles are different, as previously suggested by Lima et al. (286),  since 
3RC3RG genotype was associated with over 3-fold increased risk for non-
response to MTX when compared to 2R3RG. In addition, the obtained results 
showed that 3RC allele was associated with non-response to MTX, when 
compared to 2R allele, and 3RC3RC genotype has a non-significant trend for 
 
 
273 
 
non-response to MTX when compared to 2R2R genotype. Nevertheless, no 
statistically significant differences were observed regarding to TSER 
polymorphisms grouped according to theoretically TS expression levels, as 
suggested by Lima et al. (286). A previously study demonstrated that non-
response to MTX was associated to 3RG3RG patients (264). Therefore, the 
putative relationship between TSER polymorphisms and clinical response to 
MTX outcome needs further clarification.  
For TYMS 1494del6 polymorphism (rs34489327), the obtained results 
demonstrated that 6bp- allele was associated with non-response to MTX. 
Additionally, multivariate analysis showed that 6bp- carriers were associated 
with about 3-fold increased risk for non-response to MTX. In vitro studies 
have demonstrated that 6bp- allele has decreased mRNA stability and, 
thereby reduced TS expression (293, 294); however, in other previously 
reported study in RA Caucasian patients no associations were observed 
(232). Studies including Asiatic patients have reported different results, some 
of them reported an association between 6bp- allele and better response to 
MTX (291, 292), while others reported no associations (226, 363). From all of 
these results it seems that ethnicity could be an important factor to predict 
the clinical response to MTX attending to TYMS 1494del6 polymorphism.  
As reported by other authors, TYMS polymorphisms were in LD, 
especially 2R6bp+ and 3RG6bp- haplotypes (223, 286, 366). Univariate 
haplotype analysis demonstrated that 3R6bp-, 3RC6bp+, 3RC6bp- and 
3RG6bp- haplotypes (haplotypes harboring 3R allele for 28bp VNTR, 3RC 
allele for TSER and 6bp- allele for 1494del6) were associated with almost 3-
fold increased risk for non-response to MTX. Nevertheless, multivariate 
analysis showed that haplotypes harboring simultaneously 3R and 6bp- 
alleles (3R6bp-, 3RC6bp- and 3RG6bp-) were associated with non-response to 
MTX. This suggests a prominent role of the 3'-UTR polymorphism in 
predicting the clinical response to MTX and it seems that 6bp- allele can 
interact differently with 2R and 3R alleles, in agreement with Lima et al. 
(286) and with Lurje et al. (367). Additionally, results suggested that the 
haplotype revealing increased risk for non-response to MTX was 3RC6bp-, 
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which combines the major risk alleles from the 5´UTR (3RC) and from the 
3´UTR (6bp-). The only study in RA were haplotype analysis was performed 
demonstrated an association between 3R6bp- haplotype and better response 
to MTX (223); nevertheless, there are some important differences in relation 
to the obtained results from this thesis work: no reference to SNP C>G; 
studied population included patients with early RA; and the study evaluated 
the impact in clinical response to MTX combined therapy with SSZ.  
 
3.3.3. De novo purine synthesis pathway 
Regarding the de novo purine synthesis pathway, results indicated that 
T carriers for ATIC T675C polymorphism (rs4673993) are at increased risk 
for non-response to MTX, as previously suggested (273, 322). Since ATIC is 
directly inhibited by MTXPG, the intracellular accumulation of AICAR and its 
metabolites causes the inhibition of ADA and AMPD1, thus leading to 
increased intracellular concentrations of adenosine and its consequent 
release for the extracellular space, contributing for the anti-inflammatory 
effects of MTX (184). To the best of my knowledge, there are no functional 
studies reporting the effect of this polymorphism in ATIC activity. 
Nevertheless, it can be hypothesize that in the presence of T allele it might 
lead to MTX non-response due to increased conversion of AICAR to FAICAR, 
causing the degradation of adenosine and its non-liberation, thus leading to 
less MTX anti-inflammatory effects. In addition, T allele seems to contribute 
for the increase of the de novo purine synthesis and for the decrease of MTX 
anti-proliferative effect (161), leading to non-response to MTX. Therefore, 
more studies are required to elucidate the impact of this polymorphism in 
the ATIC activity and clinical response to MTX. Moreover, this polymorphism 
seems to be in LD with ATIC C347G (rs2372536), a SNP of which the G allele 
carriers (minor allele) have been reported as related with better response 
(221, 273, 368, 369). Hence, results are consistent with the obtained, 
reporting an association between ATIC 675C homozygotes (minor allele) and 
clinical response to MTX.   
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4. STUDY LIMITATIONS 
 
Albeit the potential importance of the results presented in this thesis, 
the limitations of this study should be considered. The sample size of 
studied population could be one of the limitations, although it is in 
accordance to the epidemiology data of the disease in the Portuguese 
population (22). Moreover, and due to the low frequency of SOC disorders, 
other than GI disorders, the influence of the studied polymorphisms in the 
occurrence of these other SOC disorders were not possible to test.  
Despite the pharmacogenetic potential of the obtained data, it is 
important to consider that MTX transporters are expressed in different 
tissues and, therefore, this line of investigation could be proved of 
remarkable relevance since it would enable the prediction of toxicity for each 
tissue and help to guide therapeutic choices. Moreover, it is important to 
analyze the influence of polymorphisms in folate and MTX intracellular and 
circulating levels in order to better elucidate the impact on MTX PK and PD. 
Furthermore, and due to complexity of MTX action mechanism, as 
previously reported by other studies (163, 189, 232, 259, 320, 370), multiple 
factors, such as the clinicopathological and other genetic variables, can 
influence and/or be associated with the MTX non-response and/or related 
toxicity occurrence. Although in this work a relative great portion of 
potentially implicated polymorphisms were studied, many of which had 
never been studied before in both RA and Caucasian populations, the 
presence of other genetic polymorphisms in genes encoding for MTX 
transporters and for proteins involved in folate, de novo purine and 
pyrimidine synthesis, adenosine and methionine pathways, deserves further 
evaluation. Thus, combined genetic and functional studies are needed to 
address the impact of polymorphisms in protein levels and function. 
As referred previously, controversial results regarding 
clinicopathological variables and the studied genetic polymorphisms 
association with clinical response to MTX and MTX-related toxicity 
development have been published, motivating the need for more and larger 
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studies, necessary to clarify raised questions and support the obtained 
results.  
The reported variations on different studies should be discussed 
regarding the possible misleading drawn conclusion for each study, either 
bias related to study design and settings, sample size/power, ethnicity, the 
population disease duration (early or established RA), changes in folate 
status and gene-gene interactions. Additionally, one of the major issues 
found was the different definition of concepts such as toxicity and clinical 
response to MTX, thus influencing conclusions drawn and rendering 
comparisons difficult. In this work,  non-response to MTX was defined when 
patients presented a DAS28 >3.2 in two consecutive evaluations after at least 
six months of MTX therapy (114) and ADR was defined according to the 
International Committee on Harmonization as “a response - mild, moderate 
or severe - to a drug that is noxious and unintended and occurs at doses 
normally used in humans for the prophylaxis, diagnosis and treatment of 
disease or for modification of physiological function” (371), with ADRs 
classified in SOC disorders according to CTCAE (301).  
Furthermore, another factor that must be highlighted is that, reported 
studies relating MTX-related overall toxicity association for the studied 
polymorphisms are not entirely clear regarding the incidence of other ADRs 
results. Since membrane transport proteins expression level is different 
depending the tissue (215), different impacts on tissue toxicity are expected 
and so, considering only the concept of overall toxicity will increase the 
difficulty for establish comparisons. Moreover, membrane transport proteins 
mechanisms have been referred as different depending on MTX dose (low-
dose implicates the transporters and high-dose implicates both transporters 
and passive diffusion (372)). Consequently, this point is of great importance 
when previous studies are scrutinized to evaluate the influence of 
polymorphisms on MTX PK and PD. In fact, in this field, when studying MTX 
action in individuals, it is crucial to focus on these two major determinants: 
(1) PK, how much of a drug is needed to reach its target in the body, and (2) 
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PD, how well the target cells respond to the drug, which are both critical for 
consideration in the field of Pharmacogenomics (179).  
Therefore, when analyzing the Pharmacogenomics of a specific disease 
it is important to investigate and discuss all the possible interactions and 
the integration of the different mechanisms of disease development and 
treatment response (Figure 27). 
 
 
 
Figure 27. The interplay of disease, treatment and patient for therapeutic outcome prediction.  
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CHAPTER XI – CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
This chapter presents the main conclusions and highlights the future 
work that is required and its importance. 
 
 
Methotrexate therapeutic outcome is variable among RA patients both 
regarding clinical response and toxicity occurrence. This interpatient 
variability can be caused by different clinicopathological variables, patient-, 
disease- and treatment-related variables, as well as genetic polymorphism in 
genes encoding for proteins involved in MTX action mechanism.  
Due to the inconsistent results reported in the literature about the 
putative predictors of MTX therapeutic outcome in RA patients, in order to 
reduce these discrepancies and provide more robust evidences, ideal future 
studies should consider as crucial several factors as follow: 1) the existence 
of distinct transporters, granting MTX different flux directions, expressed 
simultaneously, in the same cells and/or in different tissues; 2) the presence 
of endogenous substances (e.g. folates) or other drugs that could interact 
with MTX and/or with MTX transporters; 3) pH differences that could alter 
MTX solubility and, thus, dissolution (crucial for absorption when MTX is 
administered by PO route); 4) alterations in polyglutamation turnover, and 
thus, in MTX cellular retention, possibly by changing the functionality of 
FPGS and GGH; 5) the existence of other polymorphisms that could alter 
transporter levels, function or expression; and, 6) the presence of genetic 
polymorphisms in genes encoding for proteins involved in MTX action 
pathways than that under study in this work. The analysis of polymorphisms 
in genes encoding for MTX-carrier mediated transport pathway and its 
association with clinical response, and in MTHFR and ATIC with MTX-related 
toxicity should be analysed in future studies. Moreover, in order to improve 
the detection of further genetic factors responsible for variability in low-
dose MTX therapeutic outcome, future studies should follow validated 
guidelines defining therapeutic outcomes, in order to harmonize definitions; 
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study design should be prospective, due to the fewer potential sources of 
bias and confounding factors when compared to retrospective studies; 
studies should be larger and multicentric (a large sample size can greatly 
improve statistical power and multicentre national and/or international 
collaborations can rapidly generate large samples); and, studies should 
undertake genotype and haplotype based approaches, in order to clarify the 
influence in PK parameters and in predicting MTX therapeutic outcome. 
From the obtained results, it is possible to conclude that several genetic 
polymorphisms (rs7499, rs1051266, rs1801133, rs2239907, rs2838956, 
rs2853542, rs34489327, rs34743033, rs3788200, rs4149056 and rs4673993) 
encoding for MTX membrane transporters, as also for proteins involved in 
MTX intracellular pathways (specifically for SLCs, ABCs, TS, MTHFR and ATIC 
proteins) are useful predictors for MTX clinical response and/or of MTX-
related toxicity development. Methotrexate is the cornerstone disease-
modifying antirheumatic drug for RA treatment and, with the ageing of 
population and longer working life span, RA represents an expanding social 
and economic problem. Rheumatoid arthritis appears now to be a 
“syndrome”, with different mechanisms underlying different clinical subsets, 
and is a major cause of morbidity and reduction in life expectancy, due to its 
systemic involvement, affecting patients, in particular, and the society, in 
general.  
These results are clearly important for RA patients, since they can be 
helpful as biomarkers of MTX therapeutic outcome to elucidate which 
patients will not benefit from MTX treatment, both because of non-response 
and/or because the ADRs occurrence. Hence, it is of great importance to 
improve the knowledge of personalized treatment with MTX in RA patients. 
The obtained results indicate that genotyping of patients with RA 
clearly will contribute to the development of a personalized medicine 
approach for MTX therapeutic strategies. Nevertheless, it is imperative to 
validate these results in prospective studies, that will reduce potential 
sources of bias and confounding factors when compared to retrospective 
studies; with a large number of cases that can greatly improve statistical 
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power; with a multicentre design that could rapidly generate large samples 
and better comparison of results); with better definition of outcome 
variables; preferably using both genotype and haplotype based approaches, 
in order to clarify the influence in PK parameters and in predicting MTX 
therapeutic outcome. Hence, these polymorphisms could be validated as 
biomarkers of MTX therapeutic outcome, helping clinicians to select patients 
that will not benefit from MTX treatment contributing for the personalization 
of treatment for each patient. 
In conclusion, several polymorphisms were demonstrated to be 
associated with MTX therapeutic outcome. After further validation, the 
studied polymorphisms can be useful as biomarkers of MTX therapeutic 
outcome, helping to elucidate which patients will not benefit from MTX 
treatment. All together, these results indicate that genotyping of patients 
with RA clearly will contribute to the development of a personalized 
medicine approach for MTX therapeutic strategies. 
However, scientists also recognize that even as the knowledge 
continues to expand, its translation into clinics still requires evidences, 
needed to be generated for a particular disease and drug combination, 
before treatment can be customized to a patient's genotype. Thus, much 
work remains to be done before personalized medicine can reach its fullest 
potential. 
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CHAPTER XII – EXECUTIVE SUMMARY 
 
INTRODUCTION 
Rheumatoid Arthritis 
 Rheumatoid Arthritis is a complex, systemic autoimmune disease, 
characterized by a chronic inflammation of multiple peripheral joints. 
 The incidence and prevalence of RA, a “New World disease”, vary 
across populations and it’s higher in North America and Northern 
Europe and in certain native American-Indian populations. 
 Rheumatoid Arthritis is a multifactorial disease, involving both genetic 
and environmental factors, which pathophysiology mechanisms are 
currently not fully established.  
 The 2010 ACR/EULAR classification criteria provide diagnostic support 
for recognition of early RA. 
 Rheumatoid Arthritis monitoring is performed taking into account the 
quantification of joint damage, disease activity and health-related 
quality of life impact. 
 Earlier detection of RA and a rapid, effective and aggressive 
therapeutic institution are the key factors to achieve the disease 
remission and improve survival rates. 
 
Methotrexate 
 Methotrexate is the most used and cost-effective disease-modifying 
antirheumatic drug for RA treatment. 
 Low-dose MTX passes through several biological membranes by 
mediation of membrane transporters, which may be classified as 
influx (SLCs) and efflux (ABCs). 
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 Once inside the cells, MTX and/or MTXPGs inhibit multiple enzymes 
involved in folate pathway and de novo nucleotides synthesis. This 
inhibition capacity is then reflected in other pathways, such as 
methionine and adenosine pathways, which will along contribute to 
MTX Pharmacodynamics (antiproliferative and anti-inflammatory 
effects). 
 
Pharmacogenomics and Predictors of Therapeutic Outcome 
 Patients’ clinicopathological variables, as also as genetic 
polymorphisms in genes encoding for proteins involved in MTX carrier-
mediated transport systems and/or in intracellular pathways, have 
been described as contributors to the observed therapeutic outcome 
variability among RA patients. 
 
OBJECTIVES 
 The main aim of this study was to evaluate the influence of 
clinicopathological variables and genetic polymorphisms in genes 
encoding for proteins involved in MTX action mechanism as predictors 
of clinical response to MTX and/or of MTX-related toxicity occurrence 
in Portuguese RA patients. 
 
MATERIALS AND METHODS 
 A retrospective study, in a cohort of 233 consecutive Caucasian 
patients with RA treated with MTX was conducted.  
 Clinicopathological data were collected from individual clinical records 
by physicians and include variables possibly influencing disease state 
and clinical response to MTX, selected based either in literature review 
and/or clinical significance. Whole blood samples for genotyping 
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techniques were obtained in the time of the patient inclusion in the 
study.  
 Therapeutic outcome endpoints, non-response to MTX and MTX-related 
toxicity occurrence, were defined, as a DAS28 >3.2 in two consecutive 
evaluations after at least six months of MTX therapy and as the 
presence of any ADR related to MTX, respectively.  
 Statistical analyses were performed whenever relevant and included: 
univariate and multivariate analyses by genotypes and haplotypes and 
toxicogenetic risk indexes, Forest plot and correction for multiple 
comparisons. 
 
RESULTS 
Clinicopathological variables & clinical response to MTX 
 Non-current smokers, positivity to anti-CCP and to ANA antibodies, 
higher HAQ score and NSAIDs users were associated with non-response 
to MTX.  
 Subcutaneous administration route was associated with better 
response to MTX.   
 
Clinicopathological variables & MTX-related toxicity occurrence 
 Lower MTX treatment duration and non-folic acid supplementation 
were associated with MTX-related GI toxicity occurrence.  
 Higher ESR levels were associated with MTX-related overall toxicity. 
 
MTX-carrier mediated transport pathway & MTX-related toxicity occurrence 
 Increased risk for MTX-related overall toxicity was associated with 
SLC19A1 rs7499 G carriers, SLC46A1 rs2239907 G homozygotes and 
SLCO1B1 rs4149056 T carriers and T homozygotes.  
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 Toxicogenetic risk index analysis revealed that patients with Index 3 
were 18-fold more likely to present an ADR when compared to those 
with Index 1.  
 An increased risk for MTX-related GI toxicity was associated with 
SLC19A1 rs7499 G carriers and G homozygotes, SLC19A1 rs1051266 
G carriers, SLC19A1 rs2838956 A carriers and, SLCO1B1 rs4149056 T 
carriers and T homozygotes. 
 A higher risk of earlier MTX-related GI toxicity was registered for 
SLC19A1 rs1051266 G carriers.  
 Haplotype GGAG for SLC19A1 rs7499, rs1051266, rs2838956 and 
rs3788200 was associated with increased risk for MTX-related GI 
toxicity. 
 Toxicogenetic risk index analysis revealed that patients with Index 4 
were 9-fold more likely to present a GI disorder when compared to 
those with Index 1. 
 
Folate pathway & clinical response to MTX 
 The T homozygotes for MTHFR rs1801133 were associated with over 
4-fold increased risk for non-response to MTX. 
 
De novo pyrimidine synthesis pathway & clinical response to MTX 
 Genotypes 3R3R, 3RC3RG and 6bp- carriers for TYMS rs34743033, 
rs34743033+rs2853542 and rs34489327, respectively, were 
associated with non-response to MTX. 
 Haplotypes harboring both 3R and 6bp- alleles were associated with 
increased risk for non-response to MTX. 
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De novo pyrimidine synthesis pathway & MTX-related toxicity occurrence 
 No statistically significant differences were observed regarding MTX-
related toxicity and TYMS polymorphisms. 
 
De novo purine synthesis pathway & clinical response to MTX 
 The T carriers for ATIC rs4673993 were associated with over 4-fold 
increased risk for non-response to MTX. 
 
CONCLUDING REMARKS & FUTURE PERSPECTIVES 
 This work suggests that genetic polymorphisms combined with 
clinicopathological data may help to identify patients whom will not 
benefit from MTX treatment but validation from other studies is 
essential. 
 Consideration of clinicopathological data and genotyping of patients 
with RA clearly will contribute to the development of a personalized 
medicine approach for MTX therapeutic strategies but much work 
remains to be done before personalized medicine can reach its fullest 
potential. 
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